Document:

<PAGE>

                                                                    Exhibit 10.9

                        Edwards Lifesciences Corporation

                                      and

                        First Chicago Trust Company of
                       New York, a division of Equiserve

                                       as

                                  Rights Agent

                                Rights Agreement

                         Dated as of March __, 2000
<PAGE>

                               Table of Contents

<TABLE>
<CAPTION>

        Section                                                                                                                 Page
        -------                                                                                                                 ----
<S>                                                                                                                             <C>

Section 1.     Certain Definitions.............................................................................................   1
Section 2.     Appointment of Rights Agent.....................................................................................   4
Section 3.     Issue of Rights Certificates....................................................................................   4
Section 4.     Form of Rights Certificates.....................................................................................   6
Section 5.     Countersignature and Registration...............................................................................   7
Section 6.     Transfer, Split Up, Combination and Exchange of Rights Certificates; Mutilated, Destroyed, Lost or Stolen Rights
               Certificates....................................................................................................   7
Section 7.     Exercise of Rights; Purchase Price; Expiration Date of Rights...................................................   8
Section 8.     Cancellation of Rights Certificates.............................................................................  10
Section 9.     Reservation and Availability of Capital Stock...................................................................  10
Section 10.    Preferred Stock Record Date.....................................................................................  11
Section 11.    Adjustment of Purchase Price, Number and Kind of Shares or Number of Rights.....................................  12
Section 12.    Certificate of Adjusted Purchase Price or Number of Shares......................................................  19
Section 13.    Consolidation, Merger or Sale or Transfer of Assets, Cash Flow or Earning Power.................................  19
Section 14.    Fractional Rights and Fractional Shares.........................................................................  21
Section 15.    Rights of Action................................................................................................  23
Section 16.    Agreement of Rights Holders.....................................................................................  23
Section 17.    Rights Certificate Holder Not Deemed a Stockholder..............................................................  24
Section 18.    Concerning the Rights Agent.....................................................................................  24
Section 19.    Merger or Consolidation or Change of Name of Rights Agent.......................................................  24
Section 20.    Duties of Rights Agent..........................................................................................  25
Section 21.    Change of Rights Agent..........................................................................................  27
Section 22.    Issuance of New Rights Certificates.............................................................................  27
Section 23.    Redemption and Termination......................................................................................  28
</TABLE>

                                       i
<PAGE>

<TABLE>
<S>                                                                                                                              <C>
Section 24.    Exchange........................................................................................................  28
Section 25.    Notice of Certain Events........................................................................................  29
Section 26.    Notices.........................................................................................................  30
Section 27.    Supplements and Amendments......................................................................................  31
Section 28.    Successors......................................................................................................  31
Section 29.    Determination and Actions by the Board of Directors, etc........................................................  31
Section 30.    Benefits of this Agreement......................................................................................  32
Section 31.    Severability....................................................................................................  32
Section 32.    Governing Law...................................................................................................  32
Section 33.    Counterparts....................................................................................................  33
Section 34.    Descriptive Headings............................................................................................  33
</TABLE>

                                      ii
<PAGE>

                                RIGHTS AGREEMENT

          RIGHTS AGREEMENT, dated as of March __, 2000 (the "Agreement"),
between Edwards Lifesciences Corporation, a Delaware corporation (the
"Company"), and First Chicago Trust Company of New York, a division of
Equiserve, a ______________ corporation (the "Rights Agent").

                              W I T N E S S E T H:

          WHEREAS, on ____________, 2000 (the "Rights Dividend Declaration
Date"), the Board of Directors of the Company authorized and declared a dividend
distribution of one Right (as hereinafter defined) for each share of Common
Stock (as hereinafter defined) of the Company outstanding at the Close of
Business on March __, 2000, after giving effect to the distribution of
shares of Common Stock by Baxter International Inc. to its stockholders (the
"Record Date"), each Right initially representing the right to purchase one one-
hundredth of a share of Series A Junior Participating Preferred Stock of the
Company having the rights, powers and preferences set forth in the form of
Certificate of Designations attached hereto as Exhibit A, upon the terms and
subject to the conditions hereinafter set forth (the "Rights"), and has further
authorized the issuance of one Right (as such number may hereinafter be adjusted
pursuant to the provisions of Section 11(p) hereof) for each share of Common
Stock of the Company issued between the Record Date and the earlier of the
Distribution Date or the Expiration Date (as such terms are hereinafter defined)
or, in certain circumstances provided in Section 22 hereof, after the
Distribution Date (as hereinafter defined);

          NOW, THEREFORE, in consideration of the premises and the mutual
agreements herein set forth, the parties hereby agree as follows:

          Section 1. Certain Definitions. For purposes of this Agreement, the
                     -------------------
following terms have the meanings indicated:

          (a)  "Acquiring Person" shall mean any Person who or which, together
     with all Affiliates and Associates of such Person, shall be the Beneficial
     Owner of 15% or more of the shares of Common Stock then outstanding, but
     shall not include the Company, any Subsidiary of the Company, any employee
     benefit plan of the Company or of any Subsidiary of the Company, or any
     Person organized, appointed and acting in such appointed capacity, or
     established by the Company for or pursuant to the terms of any such plan.
     Notwithstanding the foregoing, no Person shall become an "Acquiring Person"
     as the result of an acquisition of shares of Common Stock by the Company
     which, by reducing the number of shares outstanding, increases the
     proportionate number of shares beneficially owned by such Person to 15% or
     more of the shares of Common Stock then outstanding; provided, however,
                                                          --------  -------
     that if a Person shall become the Beneficial Owner of 15% or more of the
     shares of Common Stock then outstanding by reason of share purchases by the
     Company and shall, after such share purchases by the Company, become the
     Beneficial Owner of any additional shares of Common Stock, then such Person
     shall be deemed to be an "Acquiring Person".  Notwithstanding the
     foregoing, no Person shall become an "Acquiring Person" if  (i) such Person
     has reported or is required to report such ownership on Schedule 13G under
     the Securities Exchange Act of 1934, as amended and in effect on the date
     of this Agreement (the "Exchange Act") (or any comparable or successor
     report) or on Schedule 13D under the Exchange Act (or any comparable or
     successor report) which Schedule 13D does not state any intention to or
     reserve the right to control or influence the management or policies of the
     Company or engage in any of the actions specified in Item 4 of such
     schedule (other than the
<PAGE>

     disposition of the Common Stock), (ii) such Person, together with all
     Affiliates and Associates of such Person, does not beneficially own 20% or
     more of the outstanding shares of Common Stock then outstanding and (iii)
     within ten (10) Business Days of being requested by the Company to advise
     it regarding the same, such Person properly certifies to the Company that
     such Person acquired shares of Common Stock in excess of 14.9%
     inadvertently or without knowledge of the terms of the Rights and who,
     together with all Affiliates and Associates, thereafter does not acquire
     any additional shares of Common Stock while the Beneficial Owner of 15% or
     more of the shares of Common Stock then outstanding; provided, however,
                                                          --------  -------
     that (i) if the Person requested to so certify fails to do so within ten
     (10) Business Days, then such Person shall become an Acquiring Person
     immediately after such ten-Business-Day period, (ii) if the Person
     requested to so certify, so certifies but the Board of Directors determines
     that such Person so certified falsely, then such Person shall become an
     Acquiring Person immediately upon such determination and (iii) if the
     Person acquires additional shares of Common Stock while the Beneficial
     Owner of 15% or more of the shares of Common Stock then outstanding, then
     such Person shall immediately become an Acquiring Person.

          (b) "Act" shall mean the Securities Act of 1933, as amended.

          (c) "Affiliate" and "Associate" shall have the respective meanings
ascribed to such terms in Rule 12b-2 of the General Rules and Regulations under
the Exchange Act.

          (d) A Person shall be deemed the "Beneficial Owner" of, and shall be
deemed to "beneficially own," any securities:

              (i)  which such Person or any of such Person's Affiliates
          or Associates, directly or indirectly, has the right to acquire
          (whether such right is exercisable immediately or only after the
          passage of time) pursuant to any agreement, arrangement or
          understanding (whether or not in writing) or upon the exercise of
          conversion rights, exchange rights, rights, warrants or options,
          or otherwise; provided, however, that a Person shall not be
                        --------  -------
          deemed the "Beneficial Owner" of, or to "beneficially own," (A)
          securities tendered pursuant to a tender or exchange offer made by
          such Person or any of such Person's Affiliates or Associates until
          such tendered securities are accepted for purchase or exchange, or (B)
          securities issuable upon exercise of Rights at any time prior to the
          occurrence of a Triggering Event, or (C) securities issuable upon
          exercise of Rights from and after the occurrence of a Triggering Event
          which Rights were acquired by such Person or any such Person's
          Affiliates or Associates prior to the Distribution Date or pursuant to
          Section 3(a) or Section 22 hereof (the "Original Rights") or pursuant
          to Section 11(i) hereof in connection with an adjustment made with
          respect to any Original Rights;

              (ii) which such Person or any of such Person's Affiliates
     or Associates, directly or indirectly, has the right to vote or
     dispose of or has "beneficial ownership" of (as determined
     pursuant to Rule 13d-3 of the General Rules and Regulations
     under the Exchange Act), including pursuant to any agreement,
     arrangement or understanding, whether or not in writing;

                                       2
<PAGE>

          provided, however, that a Person shall not be deemed the
          --------  -------
          "Beneficial Owner" of, or to "beneficially own," any
          security under this subparagraph (ii) as a result of an
          agreement, arrangement or understanding to vote such
          security if such agreement, arrangement or understanding:
          (A) arises solely from a revocable proxy given in response
          to a public proxy or consent solicitation made pursuant to,
          and in accordance with, the applicable provisions of the
          General Rules and Regulations under the Exchange Act, and
          (B) is not also then reportable by such Person on Schedule
          13D under the Exchange Act (or any comparable or successor
          report); or

               (iii) which are beneficially owned, directly or
          indirectly, by any other Person (or any Affiliate or
          Associate thereof) with which such Person (or any of such
          Person's Affiliates or Associates) has any agreement,
          arrangement or understanding (whether or not in writing),
          for the purpose of acquiring, holding, voting (except
          pursuant to a revocable proxy as described in the proviso to
          subparagraph (ii) of this paragraph (d)) or disposing of any
          voting securities of the Company;

     provided, however, that nothing in this paragraph (d) shall cause a
     --------  -------
     Person engaged in business as an underwriter of securities to be
     the "Beneficial Owner" of, or to "beneficially own," any
     securities acquired through such Person's participation in good
     faith in a firm commitment underwriting until the expiration of
     forty days after the date of such acquisition.

          (e) "Business Day" shall mean any day other than a Saturday,
     Sunday or a day on which banking institutions in the State of New
     York are authorized or obligated by law or executive order to
     close.

          (f) "Close of Business" on any given date shall mean 5:00
     P.M., New York time, on such date, provided, however, that if
                                        --------  -------
     such date is not a Business Day it shall mean 5:00 P.M., New York
     time, on the next succeeding Business Day.

          (g) "Common Stock" shall mean the common stock, par value
     $1.00 per share, of the Company, except that "Common Stock" when
     used with reference to any Person other than the Company shall
     mean the capital stock of such Person with the greatest voting
     power, or the equity securities or other equity interest having
     power to control or direct the management, of such Person.

          (h) "Person" shall mean any individual, firm, limited
     liability company, corporation, partnership or other entity and
     shall include any successor (by merger or otherwise) of such
     entity.

          (i) "Preferred Stock" shall mean shares of Series A Junior
     Participating Preferred Stock, par value $.01 per share, of the
     Company, and, to the extent that there is not a sufficient number
     of shares of Series A Junior Participating Preferred Stock
     authorized to permit the full exercise of the Rights, any other
     series of preferred stock, par value $.01 per share, of the
     Company designated for such purpose containing terms
     substantially similar to the terms of the Series A Junior
     Participating Preferred Stock.

                                       3
<PAGE>

          (j) "Section 11(a)(ii) Event" shall mean the event described
     in Section 11(a)(ii) hereof.

          (k) "Section 13 Event" shall have the meaning set forth in
     Section 13(a) hereof.

          (l) "Stock Acquisition Date" shall mean the first date of
     public announcement (which, for purposes of this definition,
     shall include, without limitation, a report filed pursuant to
     Section 13(d) under the Exchange Act) by the Company or an
     Acquiring Person that an Acquiring Person has become such.

          (m) "Subsidiary" shall mean, with reference to any Person,
     any corporation or other entity of which an amount of voting
     securities sufficient to elect at least a majority of the
     directors, or other Persons acting in a capacity similar to
     directors, of such corporation or other entity is beneficially
     owned, directly or indirectly, by such Person, or otherwise
     controlled by such Person.

          (n) "Triggering Event" shall mean any Section 11(a)(ii)
     Event or any Section 13 Event.

          In addition, for purposes of this Agreement, the following terms have
the meanings indicated in specified sections of this Agreement:  (i) "Adjustment
Shares" shall have the meaning set forth in Section 11(a)(ii) hereof; (ii)
"common stock equivalents" shall have the meaning set forth in Section
11(a)(iii) hereof; (iii) "current market price" shall have the meaning set forth
in Section 11(d) hereof; (iv) "Current Value" shall have the meaning set forth
in Section 11(a)(iii) hereof; (v) "Distribution Date" shall have the meaning set
forth in Section 3(a) hereof; (vi) "equivalent preferred stock" shall have the
meaning set forth in Section 11(b) hereof; (vii) "Exchange Ratio" shall have the
meaning set forth in Section 24(a) hereof; (viii) "Expiration Date" shall have
the meaning set forth in Section 7(a) hereof; (ix) "Final Expiration Date" shall
have the meaning set forth in Section 7(a) hereof; (x) "Nasdaq" shall have the
meaning set forth in Section 11(d)(i) hereof; (xi) "Principal Party" shall have
the meaning set forth in Section 13(b) hereof; (xii) "Purchase Price" shall have
the meaning set forth in Section 4(a); (xiii) "Record Date" shall have the
meaning set forth in the recitals hereof; (xiv) "Redemption Price" shall have
the meaning set forth in Section 23(a) hereof; (xv) "Rights" shall have the
meaning set forth in the recitals hereof; (xvi) "Rights Certificates" shall have
the meaning set forth in Section 3(a) hereof; (xvii) "Section 11(a)(ii) Trigger
Date" shall have the meaning set forth in Section 11(a)(iii) hereof; (xviii)
"Spread" shall have the meaning set forth in Section 11(a)(iii) hereof; (xix)
"Substitution Period" shall have the meaning set forth in Section 11(a)(iii)
hereof; (xx) "Summary of Rights" shall have the meaning set forth in Section
3(b) hereof; and (xxi) "Trading Day" shall have the meaning set forth in Section
11(d)(i) hereof.

          Section 2. Appointment of Rights Agent. The Company hereby appoints
                     ---------------------------
the Rights Agent to act as agent for the Company in accordance with the terms
and conditions hereof, and the Rights Agent hereby accepts such appointment. The
Company may from time to time appoint such co-Rights Agents as it may deem
necessary or desirable upon ten (10) days' prior written notice to the Rights
Agent.

          Section 3. Issue of Rights Certificates.
                     ----------------------------

          (a) Until the earlier of (i) the Close of Business on the tenth day
after the Stock Acquisition Date (or, if the tenth day after the Stock
Acquisition Date occurs before the Record Date,

                                       4
<PAGE>

the Close of Business on the Record Date) or (ii) the Close of Business on the
tenth Business Day (or such later date as may be determined by action of the
Board of Directors of the Company prior to such time as any Person becomes an
Acquiring Person) after the date that a tender or exchange offer by any Person
(other than the Company, any Subsidiary of the Company, any employee benefit
plan of the Company or of any Subsidiary of the Company, or any Person
organized, appointed or established by the Company for or pursuant to the terms
of any such plan) is first published or sent or given within the meaning of Rule
14d-2(a) of the General Rules and Regulations under the Exchange Act, if upon
consummation thereof, such Person would be the Beneficial Owner of 15% or more
of the shares of Common Stock then outstanding, (the earlier of (i) and (ii)
being herein referred to as the "Distribution Date"), (x) the Rights will be
evidenced (subject to the provisions of paragraph (b) of this Section 3) by the
certificates for the Common Stock registered in the names of the holders of the
Common Stock (which certificates for Common Stock shall be deemed also to be
certificates for Rights) and not by separate certificates and (y) the Rights
will be transferable only in connection with the transfer of the underlying
shares of Common Stock (including a transfer to the Company). The Company shall
give the Rights Agent prompt written notice of the Distribution Date. As soon as
practicable after the Distribution Date, and receipt of written notice of the
Distribution Date from the Company, the Rights Agent will, at the Company's
expense, send by first-class, insured, postage prepaid mail, to each record
holder of the Common Stock as of the Close of Business on the Distribution Date,
at the address of such holder shown on the records of the Company, one or more
Rights certificates, in substantially the form of Exhibit B hereto (the "Rights
Certificates"), evidencing one Right for each share of Common Stock so held,
subject to adjustment as provided herein. In the event that an adjustment in the
number of Rights per share of Common Stock has been made pursuant to Section
11(p) hereof, at the time of distribution of the Rights Certificates, the
Company shall make the necessary and appropriate rounding adjustments (in
accordance with Section 14(a) hereof) so that Rights Certificates representing
only whole numbers of Rights are distributed and cash is paid in lieu of any
fractional Rights. As of and after the Distribution Date, the Rights will be
evidenced solely by such Rights Certificates.

          (b)  As promptly as practicable following the Record Date, the Company
will send a copy of a Summary of Rights to Purchase Preferred Stock, in
substantially the form attached hereto as Exhibit C (the "Summary of Rights"),
by first-class, postage prepaid mail, to each record holder of the Common Stock
as of the Close of Business on the Record Date, at the address of such holder
shown on the records of the Company.  With respect to certificates for the
Common Stock outstanding as of the Record Date, until the Distribution Date, the
Rights will be evidenced by such certificates registered in the names of the
holders thereof together with a copy of the Summary of Rights attached thereto.
Until the earlier of the Distribution Date or the Expiration Date, the surrender
for transfer of any certificate representing shares of Common Stock in respect
of which Rights have been issued, with or without a copy of the Summary of
Rights attached thereto, shall also constitute the transfer of the Rights
associated with such shares of Common Stock.

          (c)  Rights shall be issued in respect of all shares of Common Stock
which are issued after the Record Date but prior to the earlier of the
Distribution Date or the Expiration Date or, in certain circumstances provided
in Section 22 hereof, after the Distribution Date.  Certificates representing
such shares of Common Stock shall also be deemed to be certificates for Rights,
and shall bear a legend substantially in the following form:

          This certificate also evidences and entitles the holder
     hereof to certain rights as set forth in the Rights Agreement
     between Edwards Lifesciences Corporation (the "Company") and
     First Chicago Trust Company of New York, a division of Equiserve (the
     "Rights Agent") dated as of March __, 2000 (the "Rights Agreement"),
     the terms of
                                       5
<PAGE>

     which are hereby incorporated herein by reference and a copy of
     which is on file at the principal offices of the Company. Under
     certain circumstances, as set forth in the Rights Agreement, such
     Rights will be evidenced by separate certificates and will no
     longer be evidenced by this certificate. The Company will mail to
     the holder of this certificate a copy of the Rights Agreement, as
     in effect on the date of mailing, without charge promptly after
     receipt of a written request therefor. Under certain
     circumstances set forth in the Rights Agreement, Rights issued
     to, or held by, any Person who is, was or becomes an Acquiring
     Person or any Affiliate or Associate thereof (as such terms are
     defined in the Rights Agreement), whether currently held by or on
     behalf of such Person or by any subsequent holder, may become
     null and void.

With respect to such certificates containing the foregoing legend, until the
earlier of the Distribution Date or the Expiration Date, the Rights associated
with the Common Stock represented by such certificates shall be evidenced by
such certificates alone and registered holders of Common Stock shall also be the
registered holders of the associated Rights, and the surrender for transfer of
any of such certificates shall also constitute the transfer of the Rights
associated with the Common Stock represented by such certificates.  In the event
the Company purchases or acquires any shares of its Common Stock after the
Record Date but prior to the Distribution Date, any Rights associated with such
shares shall be deemed cancelled and retired so that the Company shall not be
entitled to exercise any Rights associated with shares of Common Stock that are
not outstanding.

          Section 4.    Form of Rights Certificates.
                        ---------------------------

          (a)  The Rights Certificates (and the forms of election to purchase
and of assignment to be printed on the reverse thereof) shall each be
substantially in the form set forth in Exhibit B hereto and may have such marks
of identification or designation and such legends, summaries or endorsements
printed thereon as the Company may deem appropriate and as are not inconsistent
with the provisions of this Agreement, or as may be required to comply with any
applicable law or with any rule or regulation made pursuant thereto or with any
rule or regulation of any stock exchange on which the Rights may from time to
time be listed, or to conform to usage.  The Rights Certificates shall be in a
machine printable format reasonably satisfactory to the Rights Agent.  Subject
to the provisions of Section 11 and Section 22 hereof, the Rights Certificates,
whenever distributed, shall be dated as of the Record Date or, in the case of
Rights with respect to shares of Common Stock issued or becoming outstanding
after the Record Date, the same date as the stock certificate evidencing such
shares, shall show the date of countersignature, and on their face shall entitle
the holders thereof to purchase such number of one one-hundredths of a share of
Preferred Stock as shall be set forth therein at the price set forth therein
(such exercise price per one one-hundredth of a share, the "Purchase Price"),
but the amount and type of securities purchasable upon the exercise of each
Right and the Purchase Price thereof shall be subject to adjustment from time to
time as provided in Sections 11 and 13(a) hereof.

          (b)  Any Rights Certificate issued pursuant to Section 3(a) or Section
22 hereof that represents Rights beneficially owned by any Person known to be:
(i) an Acquiring Person or any Associate or Affiliate of an Acquiring Person,
(ii) a transferee of an Acquiring Person (or of any such Associate or Affiliate)
who becomes a transferee after the Acquiring Person becomes such, or (iii) a
transferee of an Acquiring Person (or of any such Associate or Affiliate) who
becomes a transferee prior to or concurrently with the Acquiring Person becoming
such and receives such Rights pursuant to either (A) a transfer (whether or not
for consideration) from the Acquiring Person to holders of equity interests in
such Acquiring Person or to any Person with whom such Acquiring Person has any

                                       6
<PAGE>

continuing agreement, arrangement or understanding regarding the transferred
Rights or (B) a transfer which the Board of Directors of the Company has
determined is part of a plan, arrangement or understanding which has as a
primary purpose or effect avoidance of Section 7(e) hereof, and any Rights
Certificate issued pursuant to Section 6 or Section 11 hereof upon transfer,
exchange, replacement or adjustment of any other Rights Certificate referred to
in this sentence, shall contain (to the extent feasible) the following legend:

     The Rights represented by this Rights Certificate are or were
     beneficially owned by a Person who was or became an Acquiring
     Person or an Affiliate or Associate of an Acquiring Person (as
     such terms are defined in the Rights Agreement). Accordingly,
     this Rights Certificate and the Rights represented hereby may
     become null and void in the circumstances specified in Section
     7(e) of such Agreement.

     The Company shall instruct the Rights Agent in writing of the Rights which
should be so legended.

          Section 5.    Countersignature and Registration.
                        ---------------------------------

          (a)  The Rights Certificates shall be executed on behalf of the
Company by its Chairman of the Board, its Chief Executive Officer, its President
or any Vice President, either manually or by facsimile signature, and shall have
affixed thereto the Company's seal or a facsimile thereof which shall be
attested by the Secretary or an Assistant Secretary of the Company, either
manually or by facsimile signature.  The Rights Certificates shall be
countersigned manually by the Rights Agent and shall not be valid for any
purpose unless so countersigned.  In case any officer of the Company who shall
have signed any of the Rights Certificates shall cease to be such officer of the
Company before countersignature by the Rights Agent and issuance and delivery by
the Company, such Rights Certificates, nevertheless, may be countersigned by the
Rights Agent and issued and delivered by the Company with the same force and
effect as though the person who signed such Rights Certificates had not ceased
to be such officer of the Company; and any Rights Certificates may be signed on
behalf of the Company by any person who, at the actual date of the execution of
such Rights Certificate, shall be a proper officer of the Company to sign such
Rights Certificate, although at the date of the execution of this Rights
Agreement any such person was not such an officer.

          (b)  Following the Distribution Date, the Rights Agent will keep or
cause to be kept, at its principal office or offices designated as the
appropriate place for surrender of Rights Certificates upon exercise or
transfer, books for registration and transfer of the Rights Certificates issued
hereunder.  Such books shall show the names and addresses of the respective
holders of the Rights Certificates, the number of Rights evidenced on its face
by each of the Rights Certificates and the certificate number and the date of
each of the Rights Certificates.

          Section 6.    Transfer, Split Up, Combination and Exchange of Rights
                        ------------------------------------------------------
Certificates; Mutilated, Destroyed, Lost or Stolen Rights Certificates.
----------------------------------------------------------------------

          (a)  Subject to the provisions of Section 4(b), Section 7(e) and
Section 14 hereof, at any time after the Close of Business on the Distribution
Date, and at or prior to the Close of Business on the Expiration Date, any
Rights Certificate or Certificates (other than Rights Certificates representing
Rights that have become null and void pursuant to Section 7(e) or that have been
exchanged pursuant to Section 24 hereof) may be transferred, split up, combined
or exchanged for another Rights Certificate or Certificates, entitling the
registered holder to purchase a like number of

                                       7
<PAGE>

one one-hundredths of a share of Preferred Stock (or, following a Triggering
Event, Common Stock, other securities, cash or other assets, as the case may be)
as the Rights Certificate or Certificates surrendered then entitled such holder
(or former holder in the case of a transfer) to purchase. Any registered holder
desiring to transfer, split up, combine or exchange any Rights Certificate or
Certificates shall make such request in writing delivered to the Rights Agent,
and shall surrender the Rights Certificate or Certificates to be transferred,
split up, combined or exchanged at the principal office or offices of the Rights
Agent designated for such purpose. Neither the Rights Agent nor the Company
shall be obligated to take any action whatsoever with respect to the transfer of
any such surrendered Rights Certificate until the registered holder shall have
completed and signed the certificate contained in the form of assignment on the
reverse side of such Rights Certificate and shall have provided such additional
evidence of the identity of the Beneficial Owner (or former Beneficial Owner) or
Affiliates or Associates thereof as the Company or the Rights Agent shall
reasonably request. Thereupon the Rights Agent shall, subject to Section 4(b),
Section 7(e), Section 14 and Section 24 hereof, countersign and deliver to the
Person entitled thereto a Rights Certificate or Rights Certificates, as the case
may be, as so requested. The Company may require payment by the holders of
Rights of a sum sufficient to cover any tax or governmental charge that may be
imposed in connection with any transfer, split up, combination or exchange of
Rights Certificates.

          (b)  Upon receipt by the Company and the Rights Agent of evidence
reasonably satisfactory to them of the loss, theft, destruction or mutilation of
a Rights Certificate, and, in case of loss, theft or destruction, of indemnity
or security reasonably satisfactory to them, and reimbursement to the Company
and the Rights Agent of all reasonable expenses incidental thereto, and upon
surrender to the Rights Agent and cancellation of the Rights Certificates if
mutilated, the Company will execute and deliver a new Rights Certificate of like
tenor to the Rights Agent for countersignature and delivery to the registered
owner in lieu of the Rights Certificate so lost, stolen, destroyed or mutilated.

          Section 7.    Exercise of Rights; Purchase Price; Expiration Date of
                        ------------------------------------------------------
Rights.
------

          (a)  Subject to Section 7(e) hereof, the registered holder of any
Rights Certificate may exercise the Rights evidenced thereby (except as
otherwise provided herein including, without limitation, the restrictions on
exercisability set forth in Section 9(c), Section 11(a)(iii) and Section 23(a)
hereof) in whole or in part at any time after the Distribution Date upon
surrender of the Rights Certificate, with the form of election to purchase and
the certificate on the reverse side thereof duly executed, to the Rights Agent
at the principal office or offices of the Rights Agent designated for such
purpose, together with payment of the aggregate Purchase Price with respect to
the total number of one one-hundredths of a share of Preferred Stock (or other
securities, cash or other assets, as the case may be) as to which such
surrendered Rights are then exercisable, at or prior to the earliest of (i) the
Close of Business on March __, 2010 (the "Final Expiration Date"), (ii) the time
at which the Rights are redeemed as provided in Section 23 hereof or (iii) the
time at which such Rights are exchanged pursuant to Section 24 hereof (the
earliest of (i), (ii) and (iii) being herein referred to as the "Expiration
Date").  Notwithstanding anything in this Agreement to the contrary, the Rights
shall not be exercisable prior to the Distribution Date.

          (b)  The Purchase Price for each one one-hundredth of a share of
Preferred Stock pursuant to the exercise of a Right shall initially be $___,
and shall be subject to adjustment from time to time as provided in Sections 11
and 13(a) hereof and shall be payable in accordance with paragraph (c) below.

                                       8
<PAGE>

          (c)  Upon receipt of a Rights Certificate representing exercisable
Rights, with the form of election to purchase and the certificate duly executed,
accompanied by payment, with respect to each Right so exercised, of the Purchase
Price per one one-hundredth of a share of Preferred Stock (or other securities,
cash or other assets, as the case may be) to be purchased as set forth below and
an amount equal to any applicable transfer tax required to be paid by the holder
of the Rights Certificate in accordance with Section 9(e) hereof, the Rights
Agent shall, subject to Section 20(k) hereof, thereupon promptly (i) (A)
requisition from any transfer agent of the shares of Preferred Stock (or make
available, if the Rights Agent is the transfer agent for such shares)
certificates for the total number of one one-hundredths of a share of Preferred
Stock to be purchased and the Company hereby irrevocably authorizes its transfer
agent to comply with all such requests, or (B) if the Company shall have elected
to deposit the total number of shares of Preferred Stock issuable upon exercise
of the Rights hereunder with a depositary agent, requisition from the depositary
agent depositary receipts representing such number of one one-hundredths of a
share of Preferred Stock as are to be purchased (in which case certificates for
the shares of Preferred Stock represented by such receipts shall be deposited by
the transfer agent with the depositary agent) and the Company will direct the
depositary agent to comply with such request, (ii) requisition from the Company
the amount of cash, if any, to be paid in lieu of fractional shares in
accordance with Section 14 hereof, (iii) after receipt of such certificates or
depositary receipts, cause the same to be delivered to or upon the order of the
registered holder of such Rights Certificate, registered in such name or names
as may be designated by such holder, and (iv) after receipt thereof, deliver
such cash, if any, to or upon the order of the registered holder of such Rights
Certificate.  The payment of the Purchase Price (as such amount may be reduced
pursuant to Section 11(a)(iii) hereof) shall be made in cash or by certified
bank check or bank draft payable to the order of the Company.  In the event that
the Company is obligated to issue other securities (including Common Stock) of
the Company, pay cash and/or distribute other property pursuant to Section 11(a)
hereof, the Company will make all arrangements necessary so that such other
securities, cash and/or other property are available for distribution by the
Rights Agent, if and when necessary to comply with the terms of this Agreement.
The Company reserves the right to require prior to the occurrence of a
Triggering Event that, upon any exercise of Rights, a number of Rights be
exercised so that only whole shares of Preferred Stock would be issued.

          (d)  In case the registered holder of any Rights Certificate shall
exercise less than all the Rights evidenced thereby, a new Rights Certificate
evidencing Rights equivalent to the Rights remaining unexercised shall be issued
by the Rights Agent and delivered to, or upon the order of, the registered
holder of such Rights Certificate, registered in such name or names as may be
designated by such holder, subject to the provisions of Section 14 hereof.

          (e)  Notwithstanding anything in this Agreement to the contrary, from
and after the first occurrence of a Section 11(a) (ii) Event, any Rights
beneficially owned by (i) an Acquiring Person or an Associate or Affiliate of an
Acquiring Person, (ii) a transferee of an Acquiring Person (or of any such
Associate or Affiliate) who becomes a transferee after the Acquiring Person
becomes such, or (iii) a transferee of an Acquiring Person (or of any such
Associate or Affiliate) who becomes a transferee prior to or concurrently with
the Acquiring Person becoming such and receives such Rights pursuant to either
(A) a transfer (whether or not for consideration) from the Acquiring Person (or
any Affiliate or Associate thereof) to holders of equity interests in such
Acquiring Person (or any Affiliate or Associate thereof) or to any Person with
whom the Acquiring Person (or any Affiliate or Associate thereof) has any
continuing agreement, arrangement or understanding regarding the transferred
Rights or (B) a transfer which the Board of Directors of the Company has
determined is part of a plan, arrangement or understanding which has as a
primary purpose or effect the avoidance

                                       9
<PAGE>

of this Section 7(e), shall become null and void without any further action and
no holder of such Rights shall have any rights whatsoever with respect to such
Rights, whether under any provision of this Agreement or otherwise. The Company
shall use all reasonable efforts to ensure that the provisions of this Section
7(e) and Section 4(b) hereof are complied with, but neither the Company nor the
Rights Agent shall have any liability to any holder of Rights Certificates or
other Person as a result of the Company's failure to make any determinations
with respect to an Acquiring Person or any of its Affiliates, Associates or
transferees hereunder. The Rights Agent will endeavor to comply with the
provisions of this Section 7(e) to the extent it has received instructions from
the Company concerning such matters.

          (f)  Notwithstanding anything in this Agreement to the contrary,
neither the Rights Agent nor the Company shall be obligated to undertake any
action with respect to a registered holder upon the occurrence of any purported
exercise as set forth in this Section 7 unless such registered holder shall have
(i) properly completed and signed the certificate contained in the form of
election to purchase set forth on the reverse side of the Rights Certificate
surrendered for such exercise, and (ii) provided such additional evidence of the
identity of the Beneficial Owner (or former Beneficial Owner) or Affiliates or
Associates thereof as the Company or the Rights Agent shall reasonably request.

          Section 8.    Cancellation and Destruction of Rights Certificates.
                        ---------------------------------------------------

          All Rights Certificates surrendered for the purpose of exercise,
transfer, split up, combination or exchange shall, if surrendered to the Company
or any of its agents, be delivered to the Rights Agent for cancellation or in
cancelled form, or, if surrendered to the Rights Agent, shall be cancelled by
it, and no Rights Certificates shall be issued in lieu thereof, except as
expressly permitted by any of the provisions of this Agreement.  The Company
shall deliver to the Rights Agent for cancellation and retirement, and the
Rights Agent shall so cancel and retire, any other Rights Certificates purchased
or acquired by the Company otherwise than upon the exercise thereof.  The Rights
Agent shall deliver all cancelled Rights Certificates to the Company, or shall,
at the written request of the Company, destroy such cancelled Rights
Certificates, and in such case shall deliver a certificate of destruction
thereof to the Company.

          Section 9.    Reservation and Availability of Capital Stock.
                        ---------------------------------------------

          (a)  The Company covenants and agrees that it will cause to be
reserved and kept available out of its authorized and unissued shares of
Preferred Stock (and, following the occurrence of a Triggering Event, out of its
authorized and unissued shares of Common Stock and/or other securities) the
number of shares of Preferred Stock (and, following the occurrence of a
Triggering Event, Common Stock and/or other securities) that, as provided in
this Agreement, including Section 11(a)(iii) hereof, will be sufficient to
permit the exercise in full of all outstanding Rights.

          (b)  So long as the shares of Preferred Stock (and, following the
occurrence of a Triggering Event, Common Stock and/or other securities) issuable
and deliverable upon the exercise of the Rights may be listed on any national
securities exchange or The Nasdaq National Market (or any successor), the
Company shall use its reasonable best efforts to cause, from and after such time
as the Rights become exercisable, all shares reserved for such issuance to be
listed on such exchange or The Nasdaq National Market (or any successor), upon
official notice of issuance upon such exercise.

                                       10
<PAGE>

          (c)  The Company shall use its reasonable best efforts to (i) file, as
soon as practicable following the earliest date after the first occurrence of a
Section 11(a)(ii) Event on which the consideration to be delivered by the
Company upon exercise of the Rights has been determined in accordance with
Section 11(a)(iii) hereof, a registration statement under the Act with respect
to the securities purchasable upon exercise of the Rights on an appropriate
form, (ii) cause such registration statement to become effective as soon as
practicable after such filing, and (iii) cause such registration statement to
remain effective (with a prospectus at all times meeting the requirements of the
Act) until the earlier of (A) the date as of which the Rights are no longer
exercisable for such securities, and (B) the date of the expiration of the
Rights.  The Company will also take such action as may be appropriate under, or
to ensure compliance with, the securities or "blue sky" laws of the various
states in connection with the exercisability of the Rights.  The Company may
temporarily suspend, for a period of time not to exceed ninety (90) days after
the date set forth in clause (i) of the first sentence of this Section 9(c), the
exercisability of the Rights in order to prepare and file such registration
statement and permit it to become effective.  Upon any such suspension, the
Company shall issue a public announcement, in each case with simultaneous
written notice to the Rights Agent, stating that the exercisability of the
Rights has been temporarily suspended, as well as a public announcement at such
time as the suspension is no longer in effect.  In addition, if the Company
shall determine that a registration statement is required following the
Distribution Date, and a Section 11(a)(ii) Event has not occurred, the Company
may temporarily suspend the exercisability of Rights until such time as a
registration statement has been declared effective.  Notwithstanding any
provision of this Agreement to the contrary, the Rights shall not be exercisable
in any jurisdiction if the requisite qualification or exemption in such
jurisdiction shall not have been obtained, the exercise thereof shall not be
permitted under applicable law or a registration statement shall not have been
declared effective.

          (d)  The Company covenants and agrees that it will take all such
actions as may be necessary to ensure that all one one-hundredths of a share of
Preferred Stock (and, following the occurrence of a Triggering Event, Common
Stock and/or other securities) delivered upon exercise of Rights shall, at the
time of delivery of the certificates for such shares (subject to payment of the
Purchase Price), be duly and validly authorized and issued and fully paid and
nonassessable.

          (e)  The Company further covenants and agrees that it will pay, when
due and payable, any and all transfer taxes and governmental charges which may
be payable in respect of the issuance or delivery of the Rights Certificates and
of any certificates for a number of one one-hundredths of a share of Preferred
Stock (or Common Stock and/or other securities, as the case may be) upon the
exercise of Rights.  The Company shall not, however, be required to pay any
transfer tax which may be payable in respect of any transfer or delivery of
Rights Certificates to a Person other than, or the issuance or delivery of a
number of one one-hundredths of a share of Preferred Stock (or Common Stock
and/or other securities, as the case may be) in respect of a name other than
that of, the registered holder of the Rights Certificates evidencing Rights
surrendered for exercise or to issue or deliver any certificates for a number of
one one-hundredths of a share of Preferred Stock (or Common Stock and/or other
securities, as the case may be) in a name other than that of the registered
holder upon the exercise of any Rights until such tax shall have been paid (any
such tax being payable by the holder of such Rights Certificate at the time of
surrender) or until it has been established to the Company's satisfaction that
no such tax is due.

          Section 10.    Preferred Stock Record Date.
                         ---------------------------

          Each Person in whose name any certificate for a number of one one-
hundredths of a share of Preferred Stock (or Common Stock and/or other
securities, as the case may be) is issued

                                       11
<PAGE>

upon the exercise of Rights shall for all purposes be deemed to have become the
holder of record of such fractional shares of Preferred Stock (or Common Stock
and/or other securities, as the case may be) represented thereby on, and such
certificate shall be dated, the date upon which the Rights Certificate
evidencing such Rights was duly surrendered and payment of the Purchase Price
(and all applicable transfer taxes) was made; provided, however, that if the
                                              --------  -------
date of such surrender and payment is a date upon which the Preferred Stock (or
Common Stock and/or other securities, as the case may be) transfer books of the
Company are closed, such Person shall be deemed to have become the record holder
of such shares (fractional or otherwise) on, and such certificate shall be
dated, the next succeeding Business Day on which the Preferred Stock (or Common
Stock and/or other securities, as the case may be) transfer books of the Company
are open. Prior to the exercise of the Rights evidenced thereby, the holder of a
Rights Certificate shall not be entitled to any rights of a stockholder of the
Company with respect to shares or other securities for which the Rights shall be
exercisable, including, without limitation, the right to vote, to receive
dividends or other distributions or to exercise any preemptive rights, and shall
not be entitled to receive any notice of any proceedings of the Company, except
as provided herein.

          Section 11.    Adjustment of Purchase Price, Number and Kind of Shares
                         -------------------------------------------------------
or Number of Rights.
-------------------

          The Purchase Price, the number and kind of shares covered by each
Right and the number of Rights outstanding are subject to adjustment from time
to time as provided in this Section 11.

         (a)(i) In the event the Company shall at any time after the
     date of this Agreement (A) declare a dividend on the Preferred
     Stock payable in shares of Preferred Stock, (B) subdivide the
     outstanding Preferred Stock, (C) combine the outstanding
     Preferred Stock into a smaller number of shares, or (D) issue any
     shares of its capital stock in a reclassification of the
     Preferred Stock (including any such reclassification in
     connection with a consolidation or merger in which the Company is
     the continuing or surviving corporation), except as otherwise
     provided in this Section 11(a) and Section 7(e) hereof, the
     Purchase Price in effect at the time of the record date for such
     dividend or of the effective date of such subdivision,
     combination or reclassification, and the number and kind of
     shares of Preferred Stock or capital stock, as the case may be,
     issuable on such date, shall be proportionately adjusted so that
     the holder of any Right exercised after such time shall be
     entitled to receive, upon payment of the Purchase Price then in
     effect, the aggregate number and kind of shares of Preferred
     Stock or capital stock, as the case may be, which, if such Right
     had been exercised immediately prior to such date and at a time
     when the Preferred Stock transfer books of the Company were open,
     such holder would have owned upon such exercise and been entitled
     to receive by virtue of such dividend, subdivision, combination
     or reclassification. If an event occurs which would require an
     adjustment under both this Section 11(a)(i) and Section 11(a)(ii)
     hereof, the adjustment provided for in this Section 11(a)(i)
     shall be in addition to, and shall be made prior to, any
     adjustment required pursuant to Section 11(a)(ii) hereof.

          (ii) Subject to Section 24 hereof, in the event any Person
     at any time after the Rights Dividend Declaration Date becomes an
     Acquiring Person, then each holder of a Right (except as provided
     below and in Section 7(e) hereof) shall thereafter have the right
     to receive, upon exercise thereof at a price equal to the then
     current Purchase Price in accordance with the terms of this
     Agreement, in lieu of a number of one one-

                                       12
<PAGE>

     hundredths of a share of Preferred Stock, such number of shares
     of Common Stock of the Company as shall equal the result obtained
     by (x) multiplying the then current Purchase Price by the then
     number of one one-hundredths of a share of Preferred Stock for
     which a Right was exercisable immediately prior to the first
     occurrence of a Section 11(a)(ii) Event and (y) dividing that
     product (which, following such first occurrence shall thereafter
     be referred to as the "Purchase Price" for each Right and for all
     purposes of this Agreement) by 50% of the current market price
     (determined pursuant to Section 11(d) hereof) per share of Common
     Stock on the date of such first occurrence (such number of
     shares, the "Adjustment Shares").

          (iii) In the event that the number of shares of Common Stock
     which are authorized by the Company's certificate of
     incorporation, as amended, but not outstanding or reserved for
     issuance for purposes other than upon exercise of the Rights, is
     not sufficient to permit the exercise in full of the Rights in
     accordance with the foregoing subparagraph (ii) of this Section
     11(a), the Company shall: (A) determine the value of the
     Adjustment Shares issuable upon the exercise of a Right (the
     "Current Value"), and (B) with respect to each Right, make
     adequate provision to substitute for the Adjustment Shares, upon
     payment of the applicable Purchase Price, (1) cash, (2) a
     reduction in the Purchase Price, (3) Common Stock or other equity
     securities of the Company (including, without limitation, shares,
     or units of shares, of preferred stock, such as the Preferred
     Stock, which the Board of Directors of the Company has deemed to
     have substantially the same value or economic rights as shares of
     Common Stock (such shares of preferred stock, "common stock
     equivalents")), (4) debt securities of the Company, (5) other
     assets, or (6) any combination of the foregoing, having an
     aggregate value equal to the Current Value (less the amount of
     any reduction in the Purchase Price), where such aggregate value
     has been determined by the Board of Directors of the Company
     based upon the advice of a nationally recognized investment
     banking firm selected by the Board of Directors of the Company;
     provided, however, if the Company shall not have made adequate
     provision to deliver value pursuant to clause (B) above within
     thirty (30) days following the later of (x) the first occurrence
     of a Section 11(a)(ii) Event and (y) the date on which the
     Company's right of redemption pursuant to Section 23(a) expires
     (the later of (x) and (y) being referred to herein as the
     "Section 11(a)(ii) Trigger Date"), then the Company shall be
     obligated to deliver, upon the surrender for exercise of a Right
     and without requiring payment of the Purchase Price, shares of
     Common Stock (to the extent available) and then, if necessary,
     cash, which shares and/or cash have an aggregate value equal to
     the Spread. For purposes of the preceding sentence, the term
     "Spread" shall mean the excess of (i) the Current Value over (ii)
     the Purchase Price. If the Board of Directors of the Company
     shall determine in good faith that it is likely that sufficient
     additional shares of Common Stock could be authorized for
     issuance upon exercise in full of the Rights, the thirty (30) day
     period set forth above may be extended to the extent necessary,
     but not more than ninety (90) days after the Section 11(a)(ii)
     Trigger Date, in order that the Company may seek stockholder
     approval for the authorization of such additional shares (such
     thirty (30) day period, as it may be extended, the "Substitution
     Period"). To the extent that action is to be taken pursuant to
     the first and/or third sentences of this Section 11(a)(iii), the
     Company (x) shall provide, subject to Section 7(e) hereof, that
     such action shall apply uniformly to all outstanding Rights, and
     (y) may suspend the exercisability of the Rights until the
     expiration of the Substitution Period in order

                                       13
<PAGE>

     to seek such stockholder approval for such authorization of
     additional shares and/or to decide the appropriate form of
     distribution to be made pursuant to such first sentence and to
     determine the value thereof. In the event of any such suspension,
     the Company shall issue a public announcement stating that the
     exercisability of the Rights has been temporarily suspended, as
     well as a public announcement at such time as the suspension is
     no longer in effect. For purposes of this Section 11(a)(iii), the
     value of each Adjustment Share shall be the current market price
     (as determined pursuant to Section 11(d) hereof) per share of
     Common Stock on the Section 11(a)(ii) Trigger Date and the value
     of any "common stock equivalent" shall be deemed to equal the
     current market price (as determined pursuant to Section 11(d)
     hereof) per share of the Common Stock on such date.

          (b)  In case the Company shall fix a record date for the issuance of
rights (other than the Rights), options or warrants to all holders of Preferred
Stock entitling them to subscribe for or purchase (for a period expiring within
forty-five (45) calendar days after such record date) Preferred Stock (or shares
having the same rights, privileges and preferences as the shares of Preferred
Stock ("equivalent preferred stock")) or securities convertible into Preferred
Stock or equivalent preferred stock at a price per share of Preferred Stock or
per share of equivalent preferred stock (or having a conversion price per share,
if a security convertible into Preferred Stock or equivalent preferred stock)
less than the current market price (as determined pursuant to Section 11(d)
hereof) per share of Preferred Stock on such record date, the Purchase Price to
be in effect after such record date shall be determined by multiplying the
Purchase Price in effect immediately prior to such record date by a fraction,
the numerator of which shall be the number of shares of Preferred Stock
outstanding on such record date, plus the number of shares of Preferred Stock
which the aggregate offering price of the total number of shares of Preferred
Stock and/or equivalent preferred stock so to be offered (and/or the aggregate
initial conversion price of the convertible securities so to be offered) would
purchase at such current market price, and the denominator of which shall be the
number of shares of Preferred Stock outstanding on such record date, plus the
number of additional shares of Preferred Stock and/or equivalent preferred stock
to be offered for subscription or purchase (or into which the convertible
securities so to be offered are initially convertible).  In case such
subscription price may be paid by delivery of consideration part or all of which
may be in a form other than cash, the value of such consideration shall be as
determined in good faith by the Board of Directors of the Company, whose
determination shall be described in a statement filed with the Rights Agent and
shall be binding on the Rights Agent and the holders of the Rights.  Shares of
Preferred Stock owned by or held for the account of the Company shall not be
deemed outstanding for the purpose of any such computation.  Such adjustment
shall be made successively whenever such a record date is fixed, and in the
event that such rights, options or warrants are not so issued, the Purchase
Price shall be adjusted to be the Purchase Price which would then be in effect
if such record date had not been fixed.

          (c) In case the Company shall fix a record date for the making of a
distribution to all holders of Preferred Stock (including any such distribution
made in connection with a consolidation or merger in which the Company is the
continuing corporation) of evidences of indebtedness, cash (other than a regular
periodic cash dividend out of the earnings or retained earnings of the Company),
assets (other than a dividend payable in Preferred Stock, but including any
dividend payable in stock other than Preferred Stock) or subscription rights or
warrants (excluding those referred to in Section 11(b) hereof), the Purchase
Price to be in effect after such record date shall be determined by multiplying
the Purchase Price in effect immediately prior to such record date by a
fraction, the numerator of which shall be the current market price (as
determined pursuant to

                                       14
<PAGE>

Section 11(d) hereof) per share of Preferred Stock on such record date, less the
fair market value (as determined in good faith by the Board of Directors of the
Company, whose determination shall be described in a statement filed with the
Rights Agent and shall be binding on the Rights Agent and the holders of the
Rights) of the portion of the cash, assets or evidences of indebtedness so to be
distributed or of such subscription rights or warrants applicable to a share of
Preferred Stock and the denominator of which shall be such current market price
(as determined pursuant to Section 11(d) hereof) per share of Preferred Stock.
Such adjustments shall be made successively whenever such a record date is
fixed, and in the event that such distribution is not so made, the Purchase
Price shall be adjusted to be the Purchase Price which would have been in effect
if such record date had not been fixed.

          (d) (i) For the purpose of any computation hereunder, other
     than computations made pursuant to Section 11(a)(iii) hereof, the
     "current market price" per share of Common Stock on any date
     shall be deemed to be the average of the daily closing prices per
     share of such Common Stock for the thirty (30) consecutive
     Trading Days (as such term is hereinafter defined) immediately
     prior to but not including such date, and for purposes of
     computations made pursuant to Section 11(a)(iii) hereof, the
     "current market price" per share of Common Stock on any date
     shall be deemed to be the average of the daily closing prices per
     share of such Common Stock for the ten (10) consecutive Trading
     Days immediately following but not including such date; provided,
     however, that in the event that the current market price per
     share of the Common Stock is determined during a period following
     the announcement by the issuer of such Common Stock of (A) a
     dividend or distribution on such Common Stock payable in shares
     of such Common Stock or securities convertible into shares of
     such Common Stock (other than the Rights), or (B) any
     subdivision, combination or reclassification of such Common
     Stock, and the ex-dividend date for such dividend or
     distribution, or the record date for such subdivision,
     combination or reclassification shall not have occurred prior to
     the commencement of the requisite thirty (30) Trading Day or ten
     (10) Trading Day period, as set forth above, then, and in each
     such case, the "current market price" shall be properly adjusted
     to take into account any trading during the period prior to such
     ex-dividend date or record date. The closing price for each day
     shall be the last sale price, regular way, or, in case no such
     sale takes place on such day, the average of the closing bid and
     asked prices, regular way, in either case as reported in the
     principal consolidated transaction reporting system with respect
     to securities listed or admitted to trading on the New York Stock
     Exchange or, if the shares of Common Stock are not listed or
     admitted to trading on the New York Stock Exchange, as reported
     in the principal consolidated transaction reporting system with
     respect to securities listed on the principal national securities
     exchange on which the shares of Common Stock are listed or
     admitted to trading or, if the shares of Common Stock are not
     listed or admitted to trading on any national securities
     exchange, the last quoted price or, if not so quoted, the average
     of the high bid and low asked prices in the over-the-counter
     market, as reported by The Nasdaq Stock Market ("Nasdaq") or such
     other quotation system then in use, or, if on any such date the
     shares of Common Stock are not quoted by any such organization,
     the average of the closing bid and asked prices as furnished by a
     professional market maker making a market in the Common Stock
     selected by the Board of Directors of the Company. If on any such
     date no market maker is making a market in the Common Stock, the
     fair value of such shares on such date as determined in good faith
     by the Board of Directors of

                                      15
<PAGE>

     the Company shall be used. The term "Trading Day" shall mean a day on which
     the principal national securities exchange on which the shares of Common
     Stock are listed or admitted to trading is open for the transaction of
     business or, if the shares of Common Stock are not listed or admitted to
     trading on any national securities exchange, a Business Day. If the Common
     Stock is not publicly held or not so listed or traded, "current market
     price" per share shall mean the fair value per share as determined in good
     faith by the Board of Directors of the Company, whose determination shall
     be described in a statement filed with the Rights Agent and shall be
     conclusive for all purposes.

          (ii) For the purpose of any computation hereunder, the "current market
     price" per share of Preferred Stock shall be determined in the same manner
     as set forth above for the Common Stock in clause (i) of this Section 11(d)
     (other than the last sentence thereof). If the current market price per
     share of Preferred Stock cannot be determined in the manner provided above,
     or if the Preferred Stock is not publicly held or listed or traded in a
     manner described in clause (i) of this Section 11(d), the "current market
     price" per share of Preferred Stock shall be conclusively deemed to be an
     amount equal to 100 (as such number may be appropriately adjusted for such
     events as stock splits, stock dividends and recapitalizations with respect
     to the Common Stock occurring after the date of this Agreement) multiplied
     by the current market price per share of the Common Stock. If neither the
     Common Stock nor the Preferred Stock is publicly held or so listed or
     traded, "current market price" per share of the Preferred Stock shall mean
     the fair value per share as determined in good faith by the Board of
     Directors of the Company, whose determination shall be described in a
     statement filed with the Rights Agent and shall be binding on the Rights
     Agent and the holders of the Rights. For all purposes of this Agreement,
     the "current market price" of one one-hundredth of a share of Preferred
     Stock shall be equal to the "current market price" of one share of
     Preferred Stock divided by 100.

          (e)  Anything herein to the contrary notwithstanding, no adjustment in
the Purchase Price shall be required unless such adjustment would require an
increase or decrease of at least one percent (1%) in the Purchase Price;
provided, however, that any adjustments which by reason of this Section 11(e)
--------  -------
are not required to be made shall be carried forward and taken into account in
any subsequent adjustment.  All calculations under this Section 11 shall be made
to the nearest cent or to the nearest one ten-thousandth of a share of Common
Stock or other share or one one-millionth of a share of Preferred Stock, as the
case may be.  Notwithstanding the first sentence of this Section 11(e), any
adjustment required by this Section 11 shall be made no later than the earlier
of (i) three (3) years from the date of the transaction which mandates such
adjustment, or (ii) the Expiration Date.

          (f) If as a result of an adjustment made pursuant to Section 11(a)(ii)
or Section 13(a) hereof, the holder of any Right thereafter exercised shall
become entitled to receive any shares of capital stock other than Preferred
Stock, thereafter the number of such other shares so receivable upon exercise of
any Right and the Purchase Price thereof shall be subject to adjustment from
time to time in a manner and on terms as nearly equivalent as practicable to the
provisions with respect to the Preferred Stock contained in Sections 11(a), (b),
(c), (e), (g), (h), (i), (j), (k) and (m), and the provisions of Sections 7, 9,
10, 13 and 14 hereof with respect to the Preferred Stock shall apply on like
terms to any such other shares.

                                       16
<PAGE>

          (g) All Rights originally issued by the Company subsequent to any
adjustment made to the Purchase Price hereunder shall evidence the right to
purchase, at the adjusted Purchase Price, the number of one one-hundredths of a
share of Preferred Stock purchasable from time to time hereunder upon exercise
of the Rights, all subject to further adjustment as provided herein.

          (h) Unless the Company shall have exercised its election as provided
in Section 11(i), upon each adjustment of the Purchase Price as a result of the
calculations made in Sections 11(b) and (c), each Right outstanding immediately
prior to the making of such adjustment shall thereafter evidence the right to
purchase, at the adjusted Purchase Price, that number of one-hundredths of a
share of Preferred Stock (calculated to the nearest one-millionth) obtained by
(i) multiplying (x) the number of one one-hundredths of a share covered by a
Right immediately prior to this adjustment, by (y) the Purchase Price in effect
immediately prior to such adjustment of the Purchase Price, and (ii) dividing
the product so obtained by the Purchase Price in effect immediately after such
adjustment of the Purchase Price.

          (i) The Company may elect on or after the date of any adjustment of
the Purchase Price to adjust the number of Rights, in lieu of any adjustment in
the number of one one-hundredths of a share of Preferred Stock purchasable upon
the exercise of a Right.  Each of the Rights outstanding after the adjustment in
the number of Rights shall be exercisable for the number of one one-hundredths
of a share of Preferred Stock for which a Right was exercisable immediately
prior to such adjustment.  Each Right held of record prior to such adjustment of
the number of Rights shall become that number of Rights (calculated to the
nearest one-ten-thousandth) obtained by dividing the Purchase Price in effect
immediately prior to adjustment of the Purchase Price by the Purchase Price in
effect immediately after adjustment of the Purchase Price.  The Company shall
make a public announcement of its election to adjust the number of Rights,
indicating the record date for the adjustment, and, if known at the time, the
amount of the adjustment to be made.  This record date may be the date on which
the Purchase Price is adjusted or any day thereafter, but, if the Rights
Certificates have been issued, shall be at least ten (10) days later than the
date of the public announcement.  If Rights Certificates have been issued, upon
each adjustment of the number of Rights pursuant to this Section 11(i), the
Company shall, as promptly as practicable, cause to be distributed to holders of
record of Rights Certificates on such record date Rights Certificates
evidencing, subject to Section 14 hereof, the additional Rights to which such
holders shall be entitled as a result of such adjustment, or, at the option of
the Company, shall cause to be distributed to such holders of record in
substitution and replacement for the Rights Certificates held by such holders
prior to the date of adjustment, and upon surrender thereof, if required by the
Company, new Rights Certificates evidencing all the Rights to which such holders
shall be entitled after such adjustment.  Rights Certificates so to be
distributed shall be issued, executed and countersigned in the manner provided
for herein (and may bear, at the option of the Company, the adjusted Purchase
Price) and shall be registered in the names of the holders of record of Rights
Certificates on the record date specified in the public announcement.

          (j) Irrespective of any adjustment or change in the Purchase Price or
the number of one one-hundredths of a share of Preferred Stock issuable upon the
exercise of the Rights, the Rights Certificates theretofore and thereafter
issued may continue to express the Purchase Price per one one-hundredth of a
share and the number of one one-hundredths of a share which were expressed in
the initial Rights Certificates issued hereunder.

          (k) Before taking any action that would cause an adjustment reducing
the Purchase Price below the then stated value, if any, of the number of one
one-hundredths of a share of Preferred Stock issuable upon exercise of the
Rights, the Company shall take any corporate action which may,

                                       17
<PAGE>

in the opinion of its counsel, be necessary in order that the Company may
validly and legally issue fully paid and nonassessable shares of Preferred Stock
at such adjusted Purchase Price.

          (l) In any case in which this Section 11 shall require that an
adjustment in the Purchase Price be made effective as of a record date for a
specified event, the Company may elect to defer until the occurrence of such
event the issuance to the holder of any Right exercised after such record date
the number of one one-hundredths of a share of Preferred Stock and other capital
stock or securities of the Company, if any, issuable upon such exercise over and
above the number of one one-hundredths of a share of Preferred Stock and other
capital stock or securities of the Company, if any, issuable upon such exercise
on the basis of the Purchase Price in effect prior to such adjustment; provided,
                                                                       --------
however, that the Company shall deliver to such holder a due bill or other
-------
appropriate instrument evidencing such holder's right to receive such additional
shares (fractional or otherwise) or securities upon the occurrence of the event
requiring such adjustment.

          (m) Anything in this Section 11 to the contrary notwithstanding, the
Company shall be entitled to make such reductions in the Purchase Price, in
addition to those adjustments expressly required by this Section 11, as and to
the extent that the Board of Directors of the Company, in its good faith
judgment, shall determine to be advisable in order that any (i) consolidation or
subdivision of the Preferred Stock, (ii) issuance wholly for cash of any shares
of Preferred Stock at less than the current market price, (iii) issuance wholly
for cash of shares of Preferred Stock or securities which by their terms are
convertible into or exchangeable for shares of Preferred Stock, (iv) stock
dividends or (v) issuance of rights, options or warrants referred to in this
Section 11, hereafter made by the Company to holders of its Preferred Stock
shall not be taxable to such stockholders.

          (n) The Company covenants and agrees that it shall not, at any time
after the Distribution Date, (i) consolidate with any other Person (other than a
Subsidiary of the Company in a transaction which complies with Section 11(o)
hereof), (ii) merge with or into any other Person (other than a Subsidiary of
the Company in a transaction which complies with Section 11(o) hereof), or (iii)
sell or transfer (or permit any Subsidiary to sell or transfer), in one
transaction, or a series of related transactions, assets, cash flow or earning
power aggregating more than 50% of the assets or earning power of the Company
and its Subsidiaries (taken as a whole) to any other Person or Persons (other
than the Company and/or any of its Subsidiaries in one or more transactions each
of which complies with Section 11(o) hereof), if (x) at the time of or
immediately after such consolidation, merger, sale or transfer there are any
rights, warrants or other instruments or securities outstanding or agreements in
effect which would substantially diminish or otherwise eliminate the benefits
intended to be afforded by the Rights or (y) prior to, simultaneously with or
immediately after such consolidation, merger, sale or transfer, the stockholders
of the Person who constitutes, or would constitute, the "Principal Party" for
purposes of Section 13(a) hereof shall have received a distribution of Rights
previously owned by such Person or any of its Affiliates and Associates.

          (o) The Company covenants and agrees that, after the Distribution
Date, it will not, except as permitted by Section 23, Section 24 or Section 27
hereof, take (or permit any Subsidiary to take) any action if at the time such
action is taken it is reasonably foreseeable that such action will diminish
substantially or otherwise eliminate the benefits intended to be afforded by the
Rights.

                                       18
<PAGE>

          (p) In the event that the Company shall at any time after the Rights
Dividend Declaration Date and prior to the Distribution Date (i) declare a
dividend on the outstanding shares of Common Stock payable in shares of Common
Stock, (ii) subdivide the outstanding shares of Common Stock, or (iii) combine
the outstanding shares of Common Stock into a smaller number of shares, the
number of Rights associated with each share of Common Stock then outstanding, or
issued or delivered thereafter but prior to the Distribution Date, shall be
proportionately adjusted so that the number of Rights thereafter associated with
each share of Common Stock following any such event shall equal the result
obtained by multiplying the number of Rights associated with each share of
Common Stock immediately prior to such event by a fraction the numerator of
which shall be the total number of shares of Common Stock outstanding
immediately prior to the occurrence of the event and the denominator of which
shall be the total number of shares of Common Stock outstanding immediately
following the occurrence of such event.

          Section 12.    Certificate of Adjusted Purchase Price or Number of
                         ---------------------------------------------------
Shares.
-------

          Whenever an adjustment is made as provided in Section 11 or Section 13
hereof, the Company shall (a) promptly prepare a certificate setting forth such
adjustment and a brief statement of the facts and computations accounting for
such adjustment, (b) promptly file with the Rights Agent, and with each transfer
agent for the Preferred Stock and the Common Stock, a copy of such certificate,
and (c) mail a brief summary thereof to each holder of a Rights Certificate (or,
if prior to the Distribution Date, to each holder of a certificate representing
shares of Common Stock) in accordance with Section 26 hereof.  The Rights Agent
shall be fully protected in relying on any such certificate and on any
adjustment therein contained and shall not be deemed to have knowledge of such
adjustment unless and until it shall have received such certificate.
Notwithstanding the foregoing sentence, the failure of the Company to make such
certificate or give such notice shall not affect the validity or the force or
effect of the requirement for such adjustment.  Any adjustment to be made
pursuant to Section 11 or Section 13 shall be effective as of the date of the
event giving rise to such adjustment.

          Section 13.    Consolidation, Merger or Sale or Transfer of Assets,
                         ----------------------------------------------------
Cash Flow or Earning Power.
--------------------------

          (a) In the event that, following the Stock Acquisition Date, directly
or indirectly, (x) the Company shall consolidate with, or merge with and into,
any other Person (other than a Subsidiary of the Company in a transaction which
complies with Section 11(o) hereof), and the Company shall not be the continuing
or surviving corporation of such consolidation or merger, or the Company shall
effect a statutory share exchange with the outstanding shares of Common Stock
being exchanged for stock or other securities of any Person, cash or property,
(y) any Person (other than a Subsidiary of the Company in a transaction which
complies with Section 11(o) hereof) shall consolidate with, or merge with or
into, the Company, and the Company shall be the continuing or surviving
corporation of such consolidation or merger and, in connection with such
consolidation or merger, all or part of the outstanding shares of Common Stock
shall be changed into or exchanged for stock or other securities of any other
Person or cash or any other property, or (z) the Company shall sell or otherwise
transfer (or one or more of its Subsidiaries shall sell or otherwise transfer),
in one transaction or a series of related transactions, assets, cash flow or
earning power aggregating more than 50% of the assets, cash flow or earning
power of the Company and its Subsidiaries (taken as a whole) to any Person or
Persons (other than the Company or any Subsidiary of the Company in one or more
transactions each of which complies with Section 11(o) hereof) (any event
described in clauses (x), (y) or (z) of this Section 13(a) following the Stock
Acquisition Date, a "Section 13 Event"), then, and in each such case, proper
provision shall be made so that: (i) each holder of a

                                       19
<PAGE>

Right, except as provided in Section 7(e) hereof, shall thereafter have the
right to receive upon the exercise thereof at the then current Purchase Price in
accordance with the terms of this Agreement, in lieu of a number of one one-
hundredths of a share of Preferred Stock, such number of validly authorized and
issued, fully paid, nonassessable and freely tradeable shares of Common Stock of
the Principal Party (as such term is hereinafter defined), not subject to any
liens, encumbrances, rights of first refusal or other adverse claims, as shall
be equal to the result obtained by (l) multiplying the then current Purchase
Price by the number of one one-hundredths of a share of Preferred Stock for
which a Right is exercisable immediately prior to the first occurrence of a
Section 13 Event (or, if a Section 11(a)(ii) Event has occurred prior to the
first occurrence of a Section 13 Event, multiplying the number of such one one-
hundredths of a share of Preferred Stock for which a Right was exercisable
immediately prior to the first occurrence of a Section 11(a)(ii) Event by the
Purchase Price in effect immediately prior to such first occurrence), and
dividing that product (which, following the first occurrence of a Section 13
Event, shall be referred to as the "Purchase Price" for each Right and for all
purposes of this Agreement) by (2) 50% of the current market price (determined
pursuant to Section 11(d)(i) hereof) per share of the Common Stock of such
Principal Party on the date of consummation of such Section 13 Event; (ii) such
Principal Party shall thereafter be liable for, and shall assume, by virtue of
such Section 13 Event, all the obligations and duties of the Company pursuant to
this Agreement; (iii) the term "Company" shall thereafter be deemed to refer to
such Principal Party, it being specifically intended that the provisions of
Section 11 hereof shall apply only to such Principal Party following the first
occurrence of a Section 13 Event; (iv) such Principal Party shall take such
steps (including, but not limited to, the reservation of a sufficient number of
shares of its Common Stock) in connection with the consummation of any such
transaction as may be necessary to assure that the provisions hereof shall
thereafter be applicable, as nearly as reasonably may be, in relation to its
shares of Common Stock thereafter deliverable upon the exercise of the Rights;
and (v) the provisions of Section 11(a)(ii) hereof shall be of no effect
following the first occurrence of any Section 13 Event.

          (b) "Principal Party" shall mean:

          (i) in the case of any transaction described in clause (x)
     or (y) of the first sentence of Section 13(a), the Person that is
     the issuer of any securities into which shares of Common Stock of
     the Company are converted in such merger, consolidation or share
     exchange, and if no securities are so issued, the Person that is
     the other party to such merger, consolidation or share exchange;
     and

          (ii) in the case of any transaction described in clause (z)
     of the first sentence of Section 13(a), the Person that is the
     party receiving the greatest portion of the assets, cash flow or
     earning power transferred pursuant to such transaction or
     transactions;

provided, however, that in any such case, (1) if the Common Stock of such Person
--------  -------
is not at such time and has not been continuously over the preceding twelve (12)
month period registered under Section 12 of the Exchange Act, and such Person is
a direct or indirect Subsidiary of another Person the Common Stock of which is
and has been so registered, "Principal Party" shall refer to such other Person;
and (2) in case such Person is a Subsidiary, directly or indirectly, of more
than one Person, the Common Stock of two or more of which are and have been so
registered, "Principal Party" shall refer to whichever of such Persons is the
issuer of the Common Stock having the greatest aggregate market value.

                                       20
<PAGE>

          (c) The Company shall not consummate any such consolidation, merger,
exchange, sale or transfer unless the Principal Party shall have a sufficient
number of authorized shares of its Common Stock which have not been issued or
reserved for issuance to permit the exercise in full of the Rights in accordance
with this Section 13 and unless prior thereto the Company and such Principal
Party shall have executed and delivered to the Rights Agent a supplemental
agreement providing for the terms set forth in paragraphs (a) and (b) of this
Section 13 and further providing that, as soon as practicable after the date of
any consolidation, merger, exchange, sale or transfer of assets mentioned in
paragraph (a) of this Section 13, the Principal Party will:

          (i)  prepare and file a registration statement under the Act,
     with respect to the Rights and the securities purchasable upon
     exercise of the Rights on an appropriate form, and will use its
     reasonable best efforts to cause such registration statement to
     (A) become effective as soon as practicable after such filing and
     (B) remain effective (with a prospectus at all times meeting the
     requirements of the Act) until the Expiration Date;

          (ii)  deliver to holders of the Rights historical financial
     statements for the Principal Party and each of its Affiliates
     which comply in all respects with the requirements for
     registration on Form 10 under the Exchange Act (whether or not
     the Principal Party would otherwise be required to file such
     Form);

          (iii) use its reasonable best efforts, if the Common Stock
     of the Principal Party shall be listed or admitted to trading on
     the Nasdaq or on a national securities exchange, to list or admit
     to trading the Rights and the securities purchasable upon
     exercise of the Rights on the Nasdaq or such securities exchange;
     and

          (iv) obtain waivers of any rights of first refusal or
     preemptive rights in respect of the Common Stock of the Principal
     Party subject to purchase upon exercise of outstanding rights.

          (d)  The provisions of this Section 13 shall similarly apply to
successive mergers or consolidations or sales or other transfers.  In the event
that a Section 13 Event shall occur at any time after the occurrence of a
Section 11(a)(ii) Event, the Rights which have not theretofore been exercised
shall thereafter become exercisable in the manner described in Section 13(a).

          (e)  In no event shall the Rights Agent have any liability in respect
of any such Principal Party transactions, including, without limitation, the
propriety thereof.  The Rights Agent may rely and be fully protected in relying
upon a certificate of the Company stating that the provisions of this Section 13
have been fulfilled.  The Rights Agent shall not be obligated to enter into any
supplemental agreement referenced in Section 13(c) if such supplemental
agreement would change or increase the duties, liabilities or obligations of the
Rights Agent hereunder.

          Section 14.    Fractional Rights and Fractional Shares.
                         ---------------------------------------

          (a)  The Company shall not be required to issue fractions of Rights,
except prior to the Distribution Date as provided in Section 11(p) hereof, or to
distribute Rights Certificates which evidence fractional Rights.  In lieu of
such fractional Rights, there shall be paid to the registered holders of the
Rights Certificates with regard to which such fractional Rights would otherwise
be issuable, an amount in cash equal to the same fraction of the current market
value of a whole Right.  For purposes of this Section 14(a), the current market
value of a whole Right shall be the closing

                                       21
<PAGE>

price of the Rights for the Trading Day immediately prior to the date on which
such fractional Rights would have been otherwise issuable. The closing price of
the Rights for any day shall be the last sale price, regular way, or, in case no
such sale takes place on such day, the average of the closing bid and asked
prices, regular way, in either case as reported in the principal consolidated
transaction reporting system with respect to securities listed or admitted to
trading on the New York Stock Exchange or, if the Rights are not listed or
admitted to trading on the New York Stock Exchange, as reported to the principal
consolidated transaction reporting system with respect to securities listed on
the principal national securities exchange on which the Rights are listed or
admitted to trading, or if the Rights are not listed or admitted to trading on
any national securities exchange, the last quoted price or, if not so quoted,
the average of the high bid and low asked prices in the over-the-counter market,
as reported by Nasdaq or such other system then in use or, if on any such date
the Rights are not quoted by any such organization, the average of the closing
bid and asked prices as furnished by a professional market maker making a market
in the Rights selected by the Board of Directors of the Company. If on any such
date no such market maker is making a market in the Rights the fair value of the
Rights on such date as determined in good faith by the Board of Directors of the
Company shall be used.

          (b)  The Company shall not be required to issue fractions of shares of
Preferred Stock (other than fractions which are integral multiples of one one-
hundredth of a share of Preferred Stock) upon exercise of the Rights or to
distribute certificates which evidence fractional shares of Preferred Stock
(other than fractions which are integral multiples of one one-hundredth of a
share of Preferred Stock).  Fractions of shares of Preferred Stock in integral
multiples of one one-hundredth of a share may, at the election of the Company,
be evidenced by depositary receipts pursuant to an appropriate agreement between
the Company and a depositary selected by it; provided, however, that such
                                             --------  -------
agreement shall provide that the holders of such depositary receipts shall have
all the rights, privileges and preferences to which they are entitled as
beneficial owners of the shares represented by such depositary receipts.  In
lieu of fractional shares of Preferred Stock that are not integral multiples of
one one-hundredth of a share of Preferred Stock, the Company shall pay to the
registered holders of Rights Certificates at the time such Rights are exercised
as herein provided an amount in cash equal to the same fraction of the current
market value of one one-hundredth of a share of Preferred Stock.  For purposes
of this Section 14(b), the current market value of one one-hundredth of a share
of Preferred Stock shall be one one-hundredth of the closing price of a share of
Preferred Stock (as determined pursuant to Section 11(d)(ii) hereof) for the
Trading Day immediately prior to the date of such exercise.

          (c)  Following the occurrence of a Triggering Event, the Company shall
not be required to issue fractions of shares of Common Stock upon exercise of
the Rights or to distribute certificates which evidence fractional shares of
Common Stock.  In lieu of fractional shares of Common Stock, the Company shall
pay to the registered holders of Rights Certificates at the time such Rights are
exercised as herein provided an amount in cash equal to the same fraction of the
current market value of one share of Common Stock.  For purposes of this Section
14(c), the current market value of one share of Common Stock shall be the
closing price of one share of Common Stock (as determined pursuant to Section
11(d)(i) hereof) for the Trading Day immediately prior to the date of such
exercise.

          (d)  The holder of a Right by the acceptance of the Rights expressly
waives such holder's right to receive any fractional Rights or any fractional
shares upon exercise of a Right, except as permitted by this Section 14.

                                       22
<PAGE>

          Section 15.    Rights of Action.
                         ----------------

          All rights of action in respect of this Agreement, other than rights
of action vested in the Rights Agent pursuant to the terms of this Agreement,
are vested in the respective registered holders of the Rights Certificates (and,
prior to the Distribution Date, the registered holders of the Common Stock); and
any registered holder of any Rights Certificate (or, prior to the Distribution
Date, of the Common Stock), without the consent of the Rights Agent or of the
holder of any other Rights Certificate (or, prior to the Distribution Date, of
the Common Stock), may, in such holder's own behalf and for such holder's own
benefit, enforce, and may institute and maintain any suit, action or proceeding
against the Company to enforce, or otherwise act in respect of, such holder's
right to exercise the Rights evidenced by such Rights Certificate in the manner
provided in such Rights Certificate and in this Agreement.  Without limiting the
foregoing or any remedies available to the holders of Rights, it is specifically
acknowledged that the holders of Rights would not have an adequate remedy at law
for any breach of this Agreement and shall be entitled to specific performance
of the obligations hereunder and injunctive relief against actual or threatened
violations of the obligations hereunder of any Person subject to this Agreement.

          Section 16.    Agreement of Rights Holders.
                         ---------------------------
          Every holder of a Right by accepting the same consents and agrees with
the Company and the Rights Agent and with every holder of a Right that:

          (a)  prior to the Distribution Date, the Rights will be
     transferable only in connection with the transfer of Common
     Stock;

          (b)  after the Distribution Date, the Rights Certificates
     are transferable only on the registry books of the Rights Agent
     if surrendered at the principal office or offices of the Rights
     Agent designated for such purposes, duly endorsed or accompanied
     by a proper instrument of transfer and with the appropriate forms
     and certificates fully executed;

          (c)  subject to Section 6(a), Section 7(e) and Section 7(f)
     hereof, the Company and the Rights Agent may deem and treat the
     person in whose name a Rights Certificate (or, prior to the
     Distribution Date, the associated Common Stock certificate) is
     registered as the absolute owner thereof and of the Rights
     evidenced thereby (notwithstanding any notations of ownership or
     writing on the Rights Certificates or the associated Common Stock
     certificates made by anyone other than the Company or the Rights
     Agent) for all purposes whatsoever, and neither the Company nor
     the Rights Agent shall be required to be affected by any notice
     to the contrary; and

          (d)  notwithstanding anything in this Agreement to the
     contrary, neither the Company nor the Rights Agent shall have any
     liability to any holder of a Right or other Person as a result of
     its inability to perform any of its obligations under this
     Agreement by reason of any preliminary or permanent injunction or
     other order, decree, judgment or ruling issued by a court of
     competent jurisdiction or by a governmental, regulatory or
     administrative agency or commission, or any statute, rule,
     regulation or executive order promulgated or enacted by any
     governmental authority, prohibiting or otherwise restraining
     performance of such obligation;

                                       23
<PAGE>

     provided, however, the Company must use efforts to have any such
     --------  -------
     order, decree, judgment or ruling lifted or otherwise overturned
     as soon as possible.

          Section 17.    Rights Certificate Holder Not Deemed a Stockholder.
                         --------------------------------------------------

          No holder, as such, of any Rights Certificate shall be entitled to
vote, receive dividends or be deemed for any purpose to be the holder of the
number of one one-hundredths of a share of Preferred Stock or any other
securities of the Company which may at any time be issuable upon the exercise of
the Rights represented thereby, nor shall anything contained herein or in any
Rights Certificate be construed to confer upon the holder of any Rights
Certificate, as such, any of the rights of a stockholder of the Company or any
right to vote for the election of directors or upon any matter submitted to
stockholders at any meeting thereof, or to give or withhold consent to any
corporate action, or to receive notice of meetings or other actions affecting
stockholders (except as provided in Section 25 hereof), or to receive dividends
or subscription rights, or otherwise, until the Right or Rights evidenced by
such Rights Certificate shall have been exercised in accordance with the
provisions hereof.

          Section 18.    Concerning the Rights Agent.
                         ---------------------------

          (a)  The Company agrees to pay to the Rights Agent reasonable
compensation for all services rendered by it hereunder and, from time to time,
on demand of the Rights Agent, its reasonable expenses and counsel fees and
disbursements and other disbursements incurred in the administration and
execution of this Agreement and the exercise and performance of its duties
hereunder.

          (b)  The Rights Agent shall be authorized and protected and shall
incur no liability for or in respect of any action taken, suffered or omitted by
it in connection with its acceptance and administration of this Agreement in
reliance upon any Rights Certificate or certificate for Common Stock or for
other securities of the Company, instrument of assignment or transfer, power of
attorney, endorsement, affidavit, letter, notice, instruction, direction,
consent, certificate, statement, or other paper or document believed by it to be
genuine and to be signed, and executed by the proper Person or Persons, or
otherwise upon the advice of counsel as set forth in Section 20.

          Section 19.    Merger or Consolidation or Change of Name of Rights
                         ---------------------------------------------------
Agent.
-----

          (a)  Any Person into which the Rights Agent or any successor Rights
Agent may be merged or with which it may be consolidated, or any Person
resulting from any merger or consolidation to which the Rights Agent or any
successor Rights Agent shall be a party, or any Person succeeding to all or
substantially all the stock transfer business of the Rights Agent or any
successor Rights Agent, shall be the successor to the Rights Agent under this
Agreement without the execution or filing of any paper or any further act on the
part of any of the parties hereto; provided, however, that such Person would be
                                   --------  -------
eligible for appointment as a successor Rights Agent under the provisions of
Section 21 hereof.  In case at the time such successor Rights Agent shall
succeed to the agency created by this Agreement, any of the Rights Certificates
shall have been countersigned but not delivered, any such successor Rights Agent
may adopt the countersignature of a predecessor Rights Agent and deliver such
Rights Certificates so countersigned; and in case at the time any of the Rights
Certificates shall not have been countersigned, any successor Rights Agent may
countersign such Rights Certificates either in the name of the predecessor or in
the name of the successor Rights Agent; and in all such cases such Rights
Certificates shall have the full force provided in the Rights Certificates and
in this Agreement.

                                       24
<PAGE>

          (b)  In case at any time the name of the Rights Agent shall be
changed, and at such time any of the Rights Certificates shall have been
countersigned but not delivered, the Rights Agent may adopt the countersignature
under its prior name and deliver Rights Certificates so countersigned; and in
case, at that time, any of the Rights Certificates shall not have been
countersigned, the Rights Agent may countersign such Rights Certificates either
in its prior name or in its changed name; and in all such cases such Rights
Certificates shall have the full force provided in the Rights Certificates and
in this Agreement.

          Section 20.    Duties of Rights Agent.
                         ----------------------

          The Rights Agent undertakes only the duties and obligations imposed by
this Agreement upon the following terms and conditions, by all of which the
Company and the holders of Rights Certificates, by their acceptance thereof,
shall be bound:

          (a)  The Rights Agent may consult with legal counsel (who
     may be legal counsel for the Company), and the opinion of such
     counsel shall be full and complete authorization and protection
     to the Rights Agent as to any action taken or omitted by it in
     good faith and in accordance with such opinion.

          (b)  Whenever in the performance of its duties under this
     Agreement the Rights Agent shall deem it necessary or desirable
     that any fact or matter (including, without limitation, the
     identity of any Acquiring Person and the determination of
     "current market price") be proved or established by the Company
     prior to taking or suffering any action hereunder, such fact or
     matter (unless other evidence in respect thereof be herein
     specifically prescribed) may be deemed to be conclusively proved
     and established by a certificate signed by the Chairman of the
     Board, the Chief Executive Officer, the President, any Vice
     President, the Treasurer, any Assistant Treasurer, the Secretary
     or any Assistant Secretary of the Company and delivered to the
     Rights Agent; and such certificate shall be full authorization to
     the Rights Agent for any action taken or suffered in good faith
     by it under the provisions of this Agreement in reliance upon
     such certificate.

          (c)  The Rights Agent shall be liable hereunder only for its
     own gross negligence, bad faith or willful misconduct.

          (d)  The Rights Agent shall not be liable for or by reason
     of any of the statements of fact or recitals contained in this
     Agreement or in the Rights Certificates or be required to verify
     the same (except as to its countersignature on such Rights
     Certificates), but all such statements and recitals are and shall
     be deemed to have been made by the Company only.

          (e)  The Rights Agent shall not be under any responsibility
     in respect of the validity of this Agreement or the execution and
     delivery hereof (except the due execution hereof by the Rights
     Agent) or in respect of the validity or execution of any Rights
     Certificate (except its countersignature thereof); nor shall it
     be responsible for any breach by the Company of any covenant or
     condition contained in this Agreement or in any Rights
     Certificate; nor shall it be responsible for any adjustment
     required under the provisions of Section 11, Section 13 or
     Section 24 hereof or responsible for the manner, method or amount
     of any such adjustment or the ascertaining of the existence of
     facts that would require any such adjustment (except

                                       25
<PAGE>

     with respect to the exercise of Rights evidenced by Rights
     Certificates after the Rights Agent's receipt of actual notice of
     any such adjustment); nor shall it by any act hereunder be deemed
     to make any representation or warranty as to the authorization or
     reservation of any shares of Common Stock or Preferred Stock to
     be issued pursuant to this Agreement or any Rights Certificate or
     as to whether any shares of Common Stock or Preferred Stock will,
     when so issued, be validly authorized and issued, fully paid and
     nonassessable.

          (f)  The Company agrees that it will perform, execute,
     acknowledge and deliver or cause to be performed, executed,
     acknowledged and delivered all such further and other acts,
     instruments and assurances as may reasonably be required by the
     Rights Agent for the carrying out or performing by the Rights
     Agent of the provisions of this Agreement.

          (g)  The Rights Agent is hereby authorized and directed to
     accept instructions with respect to the performance of its duties
     hereunder from the Chairman of the Board, the Chief Executive
     Officer, the President, any Vice President, the Secretary, any
     Assistant Secretary, the Treasurer or any Assistant Treasurer of
     the Company, and to apply to such officers for advice or
     instructions in connection with its duties, and it shall incur no
     liability for or in respect of any action taken, suffered or
     omitted by it in good faith in accordance with instructions of
     any such officer.

          (h)  The Rights Agent and any stockholder, director,
     Affiliate, officer or employee of the Rights Agent may buy, sell
     or deal in any of the Rights or other securities of the Company
     or become pecuniarily interested in any transaction in which the
     Company may be interested, or contract with or lend money to the
     Company or otherwise act as fully and freely as though it were
     not Rights Agent under this Agreement. Nothing herein shall
     preclude the Rights Agent from acting in any other capacity for
     the Company or for any other Person.

          (i)  The Rights Agent may execute and exercise any of the
     rights or powers hereby vested in it or perform any duty
     hereunder either itself or by or through its attorneys or agents,
     and the Rights Agent shall not be answerable or accountable for
     any act, default, neglect or misconduct of any such attorneys or
     agents or for any loss to the Company resulting from any such
     act, default, neglect or misconduct; provided, however, that
                                          --------  -------
     reasonable care was exercised in the selection and the continued
     employment thereof.

          (j)  No provision of this Agreement shall require the Rights
     Agent to expend or risk its own funds or otherwise incur any
     financial liability in the performance of any of its duties
     hereunder or in the exercise of its rights if there shall be
     reasonable grounds for believing that repayment of such funds or
     adequate indemnification against such risk or liability is not
     reasonably assured to it.

          (k)  If, with respect to any Rights Certificate surrendered
     to the Rights Agent for exercise or transfer, the certificate
     attached to the form of assignment or form of election to
     purchase, as the case may be, has either not been completed or
     indicates an affirmative response to clause 1 and/or 2 thereof,
     the Rights Agent shall not take any further action with respect
     to such requested exercise or transfer without first consulting
     with the Company.

                                       26
<PAGE>

          Section 21.    Change of Rights Agent.
                         ----------------------

          The Rights Agent or any successor Rights Agent may resign and be
discharged from its duties under this Agreement upon thirty (30) days' notice in
writing mailed to the Company by registered or certified mail.  The Company may
remove the Rights Agent or any successor Rights Agent upon thirty (30) days'
notice in writing, mailed to the Rights Agent or successor Rights Agent, as the
case may be, by registered or certified mail.  If the Rights Agent shall resign
or be removed or shall otherwise become incapable of acting, the Company shall
appoint a successor to the Rights Agent.  If the Company shall fail to make such
appointment within a period of thirty (30) days after giving notice of such
removal or after it has been notified in writing of such resignation or
incapacity by the resigning or incapacitated Rights Agent or by the holder of a
Rights Certificate (who shall, with such notice, submit such holder's Rights
Certificate for inspection by the Company), then the Rights Agent (at the
Company's expense) or any registered holder of any Rights Certificate may apply
to any court of competent jurisdiction for the appointment of a new Rights
Agent.  Any successor Rights Agent, whether appointed by the Company or by such
a court, shall be (i) a Person organized and doing business under the laws of
the United States or of the State of Delaware or the State of New York (or of
any other state of the United States so long as such Person is authorized to do
business in the State of Delaware or the State of New York), in good standing,
having an office or agency in the State of New York or the State of Delaware,
which is authorized under such laws to exercise stock transfer powers and is
subject to supervision or examination by federal or state authority and which
has at the time of its appointment as Rights Agent a combined capital and
surplus of at least $50,000,000 or (ii) an Affiliate of such Person.  After
appointment, the successor Rights Agent shall be vested with the same powers,
rights, duties and responsibilities as if it had been originally named as Rights
Agent without further act or deed; but the predecessor Rights Agent shall
deliver and transfer to the successor Rights Agent any property at the time held
by it hereunder, and execute and deliver any further reasonable assurance,
conveyance, act or deed necessary for the purpose.  Not later than the effective
date of any such appointment, the Company shall file notice thereof in writing
with the predecessor Rights Agent and each transfer agent of the Common Stock
and the Preferred Stock, and mail a notice thereof in writing to the registered
holders of the Rights Certificates.  Failure to give any notice provided for in
this Section 21 or any defect therein shall not affect the legality or validity
of the resignation or removal of the Rights Agent or the appointment of the
successor Rights Agent, as the case may be.

          Section 22.    Issuance of New Rights Certificates.
                         -----------------------------------

          Notwithstanding any of the provisions of this Agreement or of the
Rights to the contrary, the Company may, at its option, issue new Rights
Certificates evidencing Rights in such form as may be approved by its Board of
Directors to reflect any adjustment or change in the Purchase Price and the
number or kind or class of shares or other securities or property purchasable
under the Rights Certificates made in accordance with the provisions of this
Agreement.  In addition, in connection with the issuance or sale of shares of
Common Stock following the Distribution Date and prior to the redemption or
expiration of the Rights, the Company (a) shall, with respect to shares of
Common Stock so issued or sold pursuant to the exercise of stock options or
under any employee plan or arrangement, granted or awarded prior to the
Distribution Date, or upon the exercise, conversion or exchange of securities
hereinafter issued by the Company, and (b) may, in any other case, if deemed
necessary or appropriate by the Board of Directors of the Company, issue Rights
Certificates representing an appropriate number of Rights in connection with
such issuance or sale; provided, however, that (i) no such Rights Certificate
                       --------  -------
shall be issued if, and to the extent that, the Company shall be advised by
counsel that such issuance would create a significant risk of material adverse
tax consequences to the Company or the Person to whom such Rights Certificate
would be

                                       27
<PAGE>

issued, and (ii) no such Rights Certificate shall be issued if, and to the
extent that, appropriate adjustment shall otherwise have been made in lieu of
the issuance thereof.

          Section 23.    Redemption and Termination.
                         --------------------------

          (a)  The Board of Directors of the Company may, at its option, at any
time prior to the earlier of (i) the Close of Business on the tenth day
following the Stock Acquisition Date (or, if the Stock Acquisition Date shall
have occurred prior to the Record Date, the Close of Business on the tenth day
following the Record Date), or (ii) the Final Expiration Date, redeem all but
not less than all of the then outstanding Rights at a redemption price of $.01
per Right, as such amount may be appropriately adjusted to reflect any stock
split, stock dividend or similar transaction occurring after the date hereof
(such redemption price being hereinafter referred to as the "Redemption Price").
Notwithstanding anything contained in this Agreement to the contrary, the Rights
shall not be exercisable after the first occurrence of a Section 11(a)(ii) Event
until such time as the Company's right of redemption hereunder has expired.  The
Company may, at its option, pay the Redemption Price in cash, shares of Common
Stock (based on the "current market price", as defined in Section 11(d)(i)
hereof, of the Common Stock at the time of redemption) or any other form of
consideration deemed appropriate by the Board of Directors.  The redemption of
the Rights by the Board of Directors may be made effective at such time, on such
basis and with such conditions as the Board of Directors in its sole discretion
may establish.

          (b)  Immediately upon the action of the Board of Directors of the
Company ordering the redemption of the Rights, evidence of which shall have been
filed with the Rights Agent and without any further action and without any
notice, the right to exercise the Rights will terminate and the only right
thereafter of the holders of Rights shall be to receive the Redemption Price for
each Right so held.  Promptly after the action of the Board of Directors
ordering the redemption of the Rights, the Company shall give notice of such
redemption to the Rights Agent and the holders of the then outstanding Rights by
mailing such notice to all such holders at each holder's last address as it
appears upon the registry books of the Rights Agent or, prior to the
Distribution Date, on the registry books of the transfer agent for the Common
Stock.  Any notice which is mailed in the manner herein provided shall be deemed
given, whether or not the holder receives the notice.  The failure to give, or
any defect in, such notice shall not affect the validity of such redemption.
Each such notice of redemption will state the method by which the payment of the
Redemption Price will be made.

          Section 24.    Exchange.
                         --------

          (a)  The Board of Directors of the Company may, at its option, at any
time after any Person becomes an Acquiring Person, exchange all or part of the
then outstanding and exercisable Rights (which shall not include Rights that
have become null and void pursuant to the provisions of Section 7(e) hereof) for
shares of Common Stock at an exchange ratio of one share of Common Stock per
Right, appropriately adjusted to reflect any stock split, stock dividend or
similar transaction occurring after the date hereof (such exchange ratio being
hereinafter referred to as the "Exchange Ratio").  Notwithstanding the
foregoing, the Board of Directors of the Company shall not be empowered to
effect such exchange at any time after any Person (other than the Company, any
Subsidiary of the Company, any employee benefit plan of the Company or of any
Subsidiary of the Company, or any Person organized, appointed or established by
the Company for or pursuant to the terms of any such plan), together with all
Affiliates and Associates of such Person, becomes the Beneficial Owner of fifty
percent (50%) or more of the Common Stock then outstanding.

                                       28
<PAGE>

          (b)  Immediately upon the action of the Board of Directors of the
Company ordering the exchange of any Rights pursuant to subsection (a) of this
Section 24 and without any further action and without any notice, the right to
exercise such Rights shall terminate and the only right thereafter of a holder
of any such Rights shall be to receive that number of shares of Common Stock
equal to the number of such Rights held by such holder multiplied by the
Exchange Ratio.  The Company shall promptly give public notice of any exchange;
provided, however, that the failure to give, or any defect in, such notice shall
--------  -------
not affect the validity of such exchange.  The Company promptly shall mail a
notice of any such exchange to all of the holders of such Rights at their last
addresses as they appear upon the registry books of the Rights Agent.  Any
notice which is mailed in the manner herein provided shall be deemed given,
whether or not the holder receives the notice.  Each such notice of exchange
will state the method by which the exchange of the Common Stock for Rights will
be effected and, in the event of any partial exchange, the number of Rights
which will be exchanged.  Any partial exchange will be effected pro rata based
on the number of Rights (other than Rights which have become null and void
pursuant to the provisions of Section 7(e) hereof) held by each holder of
Rights.

          (c)  In any exchange pursuant to this Section 24, the Company, at its
option, may substitute shares of Preferred Stock (or equivalent preferred stock,
as such term is defined in paragraph (b) of Section 11 hereof) for shares of
Common Stock exchangeable for Rights, at the initial rate of one one-hundredth
of a share of Preferred Stock (or equivalent preferred stock) for each share of
Common Stock, as appropriately adjusted to reflect adjustments in the voting
rights of the Preferred Stock pursuant to the terms thereof, so that the
fraction of a share of Preferred Stock delivered in lieu of each share of Common
Stock shall have the same voting rights as one share of Common Stock.

          (d)  In the event that there shall not be sufficient shares of Common
Stock issued but not outstanding or authorized but unissued to permit any
exchange of Rights as contemplated in accordance with this Section 24, the
Company shall take all such actions as may be necessary to authorize additional
shares of Common Stock for issuance upon exchange of the Rights.

          (e)  The Company shall not be required to issue fractions of shares of
Common Stock or to distribute certificates which evidence fractional shares of
Common Stock.  In lieu of such fractional shares of Common Stock, there shall be
paid to the registered holders of the Rights Certificates with regard to which
such fractional shares of Common Stock would otherwise be issuable, an amount in
cash equal to the same fraction of the current market value of a whole share of
Common Stock.  For the purposes of this subsection (e), the current market value
of a whole share of Common Stock shall be the closing price of a share of Common
Stock (as determined pursuant to the second sentence of Section 11(d)(i) hereof)
for the Trading Day immediately prior to the date of exchange pursuant to this
Section 24.

          Section 25.    Notice of Certain Events.
                         ------------------------

          (a)  In case the Company shall propose, at any time after the
Distribution Date, (i) to pay any dividend payable in stock of any class to the
holders of Preferred Stock or to make any other distribution to the holders of
Preferred Stock (other than a regular periodic cash dividend out of the earnings
or retained earnings of the Company), or (ii) to offer to the holders of
Preferred Stock rights or warrants to subscribe for or to purchase any
additional shares of Preferred Stock or shares of stock of any class or any
other securities, rights or options, or (iii) to effect any reclassification of
its Preferred Stock (other than a reclassification involving only the
subdivision of outstanding shares of Preferred Stock), or (iv) to effect any
consolidation or merger into or with any other Person (other

                                       29
<PAGE>

than a Subsidiary of the Company in a transaction which complies with Section
11(o) hereof), or to effect any sale or other transfer (or to permit one or more
of its Subsidiaries to effect any sale or other transfer), in one transaction or
a series of related transactions, of more than 50% of the assets, cash flow or
earning power of the Company and its Subsidiaries (taken as a whole) to any
other Person or Persons (other than the Company and/or any of its Subsidiaries
in one or more transactions each of which complies with Section 11(o) hereof),
or (v) to effect the liquidation, dissolution or winding up of the Company,
then, in each such case, the Company shall give to each holder of a Rights
Certificate and to the Rights Agent, to the extent feasible and in accordance
with Section 26 hereof, a notice of such proposed action, which shall specify
the record date for the purposes of such stock dividend, distribution of rights
or warrants, or the date on which such reclassification, consolidation, merger,
sale, transfer, liquidation, dissolution, or winding up is to take place and the
date of participation therein by the holders of the shares of Preferred Stock,
if any such date is to be fixed, and such notice shall be so given in the case
of any action covered by clause (i) or (ii) above at least twenty (20) days
prior to the record date for determining holders of the shares of Preferred
Stock for purposes of such action, and in the case of any such other action, at
least twenty (20) days prior to the date of the taking of such proposed action
or the date of participation therein by the holders of the shares of Preferred
Stock, whichever shall be the earlier.

          (b) In case a Section 11(a)(ii) Event shall occur, then, in any such
case, (i) the Company shall as soon as practicable thereafter give to each
holder of a Rights Certificate and to the Rights Agent, to the extent feasible
and in accordance with Section 26 hereof, a notice of the occurrence of such
event, which shall specify the event and the consequences of the event to
holders of Rights under Section 11(a)(ii) hereof, and (ii) all references in the
preceding paragraph to Preferred Stock shall be deemed thereafter to refer to
Common Stock and/or, if appropriate, other securities.

          Section 26.    Notices.
                         -------

          Notices or demands authorized by this Agreement to be given or made by
the Rights Agent or by the holder of any Rights Certificate to or on the Company
shall be sufficiently given or made if sent by first-class mail, postage
prepaid, addressed (until another address is filed in writing with the Rights
Agent) as follows:

          Edwards Lifesciences Corporation
          17221 Red Hill Avenue
          Irvine, California   92614
          Attention: General Counsel

Subject to the provisions of Section 21, any notice or demand authorized by this
Agreement to be given or made by the Company or by the holder of any Rights
Certificate to or on the Rights Agent shall be sufficiently given or made if
sent by first-class mail, postage prepaid, addressed (until another address is
filed in writing with the Company) as follows:

                                       30
<PAGE>

          First Chicago Trust Company of New York

          ______________________________
          ______________________________
          ______________________________
          Attention: ___________________

Notices or demands authorized by this Agreement to be given or made by the
Company or the Rights Agent to the holder of any Rights Certificate (or, if
prior to the Distribution Date, to the holder of certificates representing
shares of Common Stock) shall be sufficiently given or made if sent by first-
class mail, postage prepaid, addressed to such holder at the address of such
holder as shown on the registry books of the Company.

          Section 27.    Supplements and Amendments.
                         --------------------------

          Prior to the Distribution Date, the Company and the Rights Agent
shall, if the Company so directs, supplement or amend any provision of this
Agreement without the approval of any holders of certificates representing
shares of Common Stock.  From and after the Distribution Date, the Company and
the Rights Agent shall, if the Company so directs, supplement or amend this
Agreement without the approval of any holders of Rights Certificates in order
(i) to cure any ambiguity, (ii) to correct or supplement any provision contained
herein which may be defective or inconsistent with any other provisions herein,
(iii) to shorten or lengthen any time period hereunder, or (iv) to change or
supplement the provisions hereunder in any manner which in the opinion of the
Company may deem necessary or desirable and which shall not adversely affect the
interests of the holders of Rights Certificates (other than an Acquiring Person
or an Affiliate or Associate of an Acquiring Person); provided, this Agreement
                                                      --------
may not be supplemented or amended to lengthen, pursuant to clause (iii) of this
sentence, (A) a time period relating to when the Rights may be redeemed at such
time as the Rights are not then redeemable, or (B) any other time period unless
such lengthening is for the purpose of protecting, enhancing or clarifying the
rights of, and/or the benefits to, the holders of Rights.  Upon the delivery of
a certificate from an appropriate officer of the Company which states that the
proposed supplement or amendment is in compliance with the terms of this Section
27, the Rights Agent shall execute such supplement or amendment.  Prior to the
Distribution Date, the interests of the holders of Rights shall be deemed
coincident with the interests of the holders of Common Stock.

          Section 28.    Successors.
                         ----------

          All the covenants and provisions of this Agreement by or for the
benefit of the Company or the Rights Agent shall bind and inure to the benefit
of their respective successors and assigns hereunder.

          Section 29.    Determination and Actions by the Board of Directors,
                         ----------------------------------------------------
etc.
---

          For all purposes of this Agreement, any calculation of the number of
shares of Common Stock outstanding at any particular time, including for
purposes of determining the particular percentage of such outstanding shares of
Common Stock of which any Person is the Beneficial Owner, shall be made in
accordance with the last sentence of Rule 13d-3(d)(l)(i) of the General Rules
and Regulations under the Exchange Act.  The Board of Directors of the Company
shall have the exclusive power and authority to administer this Agreement and to
exercise all rights and powers specifically granted to the Board of Directors of
the Company or to the Company, or as may be necessary or advisable in the
administration of this Agreement, including, without limitation,

                                       31
<PAGE>

the right and power to (i) interpret the provisions of this Agreement, and (ii)
make all determinations deemed necessary or advisable for the administration of
this Agreement (including, but not limited to, a determination to redeem or not
redeem the Rights or to amend this Agreement). All such actions, calculations,
interpretations and determinations (including, for purposes of clause (y) below,
all omissions with respect to the foregoing) which are done or made by the Board
of Directors of the Company in good faith shall (x) be final, conclusive and
binding on the Company, the Rights Agent, the holders of the Rights and all
other Persons, and (y) not subject the Board of Directors of the Company to any
liability to the holders of the Rights.

          Section 30.    Benefits of this Agreement.
                         --------------------------

          Nothing in this Agreement shall be construed to give to any Person
other than the Company, the Rights Agent and the registered holders of the
Rights Certificates (and, prior to the Distribution Date, registered holders of
the Common Stock) any legal or equitable right, remedy or claim under this
Agreement; but this Agreement shall be for the sole and exclusive benefit of the
Company, the Rights Agent and the registered holders of the Rights Certificates
(and, prior to the Distribution Date, registered holders of the Common Stock).

          Section 31.    Severability.
                         ------------

          If any term, provision, covenant or restriction of this Agreement is
held by a court of competent jurisdiction or other authority to be invalid, void
or unenforceable, the remainder of the terms, provisions, covenants and
restrictions of this Agreement shall remain in full force and effect and shall
in no way be affected, impaired or invalidated; provided, however, that
                                                --------  -------
notwithstanding anything in this Agreement to the contrary, if any such term,
provision, covenant or restriction is held by such court or authority to be
invalid, void or unenforceable and the Board of Directors of the Company
determines in its good faith judgment that severing the invalid language from
this Agreement would adversely affect the purpose or effect of this Agreement,
the right of redemption set forth in Section 23 hereof shall be reinstated and
shall not expire until the Close of Business on the tenth day following the date
of such determination by the Board of Directors of the Company.

          Section 32.    Governing Law.
                         -------------

          This Agreement, each Right and each Rights Certificate issued
hereunder shall be deemed to be a contract made under the laws of the State of
Delaware and for all purposes shall be governed by and construed in accordance
with the laws of such State applicable to contracts made and to be performed
entirely within such State.

                                       32
<PAGE>

          Section 33.    Counterparts.
                         -------------
          This Agreement may be executed in any number of counterparts and each
of such counterparts shall for all purposes be deemed to be an original, and all
such counterparts shall together constitute but one and the same instrument.

          Section 34.    Descriptive Headings.
                         --------------------

          Descriptive headings of the several Sections of this Agreement are
inserted for convenience only and shall not control or affect the meaning or
construction of any of the provisions hereof.

                                       33
<PAGE>

          IN WITNESS WHEREOF, the parties hereto have caused this Agreement to
be duly executed as of the day and year first above written.

                              EDWARDS LIFESCIENCES CORPORATION

                              By: ______________________________________
                                    Name:
                                    Title:

                               FIRST CHICAGO TRUST COMPANY OF NEW YORK,
                               A DIVISION OF EQUISERVE
                               ---------------------------------------
                              AS RIGHTS AGENT

                              By: ______________________________________
                                    Name:
                                    Title:

                                      34
<PAGE>

                                                                       Exhibit A
                                                                       ---------

                                    FORM OF

                          CERTIFICATE OF DESIGNATIONS

                                      OF

                 SERIES A JUNIOR PARTICIPATING PREFERRED STOCK

                                      OF

                       EDWARDS LIFESCIENCES CORPORATION

                        Pursuant to Section 151 of the

                       Delaware General Corporation Act

          RESOLVED, that pursuant to the authority vested in the board of
directors (the "Board of Directors") of Edwards Lifesciences Corporation, a
Delaware corporation (the "Corporation"), by the Amended and Restated
Certificate of Incorporation (the "Charter"), the Board of Directors does hereby
create, authorize and provide for the issue of a series of Preferred Stock, par
value $.01 per share, of the Corporation, to be designated "Series A Junior
Participating Preferred Stock" (hereinafter referred to as the "Series A
Preferred Stock"), initially consisting of 4,000,000] shares, and to the extent
that the designations, powers, preferences and relative and other special rights
and the qualifications, limitations or restrictions of the Series A Preferred
Stock are not stated and expressed in the Charter, does hereby fix and herein
state and express such designations, powers, preferences and relative and other
special rights and the qualifications, limitations and restrictions thereof, as
follows (all terms used herein which are defined in the Charter shall be deemed
to have the meanings provided therein):

          Section 1.  Designation and Amount.  The shares of such series shall
                      ----------------------
be designated as "Series A Junior Participating Preferred Stock" and the number
of shares constituting such series shall be 4,000,000].  Such number of shares
may be increased or decreased by resolution of the Board of Directors; provided,
                                                                       --------
that no decrease shall reduce the number of shares of Series A Preferred Stock
to a number less than the number of shares then outstanding plus the number of
shares reserved for issuance upon the exercise of outstanding options, rights or
warrants or upon the conversion of any outstanding securities issued by the
Corporation convertible into shares of Series A Preferred Stock.

                                       1
<PAGE>

          Section 2.  Dividends and Distributions.
                      ---------------------------

          (A)  Subject to the prior and superior rights of the holders of any
shares of any series of Preferred Stock ranking prior and superior to the shares
of Series A Preferred Stock with respect to dividends, the holders of shares of
Series A Preferred Stock shall be entitled to receive, when, as and if declared
by the Board of Directors out of funds legally available for the purpose,
quarterly dividends payable in cash on the first business day of March, June,
September and December in each year (each such date being referred to herein as
a "Quarterly Dividend Payment Date"), commencing on the first Quarterly Dividend
Payment Date after the first issuance of a share or fraction of a share of
Series A Preferred Stock, in an amount per share (rounded to the nearest cent)
equal to the greater of (a) $.01 or (b) subject to the provision for adjustment
hereinafter set forth, 100 times the aggregate per share amount of all cash
dividends, and 100 times the aggregate per share amount (payable in kind) of all
non-cash dividends or other distributions other than a dividend payable in
shares of Common Stock or a subdivision of the outstanding shares of Common
Stock (by reclassification or otherwise), declared on the Common Stock, par
value $1.00 per share, of the Corporation (the "Common Stock") since the
immediately preceding Quarterly Dividend Payment Date, or, with respect to the
first Quarterly Dividend Payment Date, since the first issuance of any share or
fraction of a share of Series A Preferred Stock.  In the event the Corporation
shall at any time after March __, 2000 (the "Rights Declaration Date") (i)
declare any dividend on Common Stock payable in shares of Common Stock, (ii)
subdivide the outstanding Common Stock, or (iii) combine the outstanding Common
Stock into a smaller number of shares, then in each case the amount to which
holders of shares of Series A Preferred Stock were entitled immediately prior to
such event under clause (b) of the preceding sentence shall be adjusted by
multiplying such amount by a fraction the numerator of which is the number of
shares of Common Stock outstanding immediately after such event and the
denominator of which is the number of shares of Common Stock that were
outstanding immediately prior to such event.

          (B)  The Corporation shall declare a dividend or distribution on the
Series A Preferred Stock as provided in paragraph (A) above immediately after it
declares a dividend or distribution on the Common Stock (other than a dividend
payable in shares of Common Stock); provided, however, that, in the event no
                                    --------  -------
dividend or distribution shall have been declared on the Common Stock during the
period between any Quarterly Dividend Payment Date and the next subsequent
Quarterly Dividend Payment Date, subject to the prior and superior rights of the
holders of any shares of any series of Preferred Stock ranking prior to and
superior to the shares of Series A Preferred Stock with respect to dividends, a
dividend of $.01 per share on the Series A Preferred Stock shall nevertheless by
payable on such subsequent Quarterly Dividend Payment Date.

          (C)  Dividends shall begin to accrue and be cumulative on outstanding
shares of Series A Preferred Stock from the Quarterly Dividend Payment Date next
preceding the date of issue of such shares of Series A Preferred Stock, unless
the date of issue of such shares is prior to the record date for the first
Quarterly Dividend Payment Date, in which case dividends on such shares shall
begin to accrue from the date of issue of such shares, or unless the date of
issue is a Quarterly Dividend Payment Date or is a date after the record date
for the determination of holders of shares of Series A Preferred Stock entitled
to receive a quarterly dividend and before such Quarterly Dividend Payment Date,
in either of which events such dividends shall begin to accrue and be cumulative
from such Quarterly Dividend Payment Date.  Accrued but unpaid dividends shall
not bear interest.  Dividends paid on the shares of Series A Preferred Stock in
an amount less than the total amount of such dividends at the time accrued and
payable on such shares shall be allocated pro rata on a share-by-share basis
among all such shares at the time outstanding.  The Board of Directors may fix a

                                       2
<PAGE>

record date for the determination of holders of shares of Series A Preferred
Stock entitled to receive payment of a dividend or distribution declared
thereon, which record date shall be no more than 60 days prior to the date fixed
for the payment thereof.

          Section 3.  Voting Rights.
                      -------------

          The holders of shares of Series A Preferred Stock shall have the
following voting rights:

          (A)  Subject to the provision for adjustment hereinafter set forth,
each share of Series A Preferred Stock shall entitle the holder thereof to 100
votes on all matters submitted to a vote of the stockholders of the Corporation.
In the event the Corporation shall at any time after the Rights Declaration Date
(i) declare any dividend on Common Stock payable in shares of Common Stock, (ii)
subdivide the outstanding Common Stock, or (iii) combine the outstanding Common
Stock into a smaller number of shares, then in each such case the number of
votes per share to which holders of shares of Series A Preferred Stock were
entitled immediately prior to such event shall be adjusted by multiplying such
number by a fraction the numerator of which is the number of shares of Common
Stock outstanding immediately after such event and the denominator of which is
the number of shares of Common Stock that were outstanding immediately prior to
such event.

          (B)  Except as otherwise provided herein or by law, the holders of
shares of Series A Preferred Stock and the holders of shares of Common Stock
shall vote collectively as one class on all matters submitted to a vote of
stockholders of the Corporation.

          (C)  (i)  If at any time dividends on any Series A Preferred Stock
shall be in arrears in an amount equal to six (6) quarterly dividends thereon,
the occurrence of such contingency shall mark the beginning of a period (herein
called a "default period") which shall extend until such time when all accrued
and unpaid dividends for all previous quarterly dividend periods and for the
current quarterly dividend period on all shares of Series A Preferred Stock then
outstanding shall have been declared and paid or set apart for payment.  During
each default period, all holders of Preferred Stock (including holders of the
Series A Preferred Stock) with dividends in arrears in an amount equal to six
(6) quarterly dividends thereon, voting as a class, irrespective of series,
shall have the right to elect two (2) Directors.

          (ii)  During any default period, such voting right of the holders of
     Series A Preferred Stock may be exercised initially at a special meeting
     called pursuant to subparagraph (iii) of this Section 3(C) or at any annual
     meeting of stockholders, and thereafter at annual meetings of stockholders,
     provided that such voting right shall not be exercised unless the holders
     of ten percent (10%) in number of shares of Preferred Stock outstanding
     shall be present in person or by proxy.  The absence of a quorum of the
     holders of Common Stock shall not affect the exercise by the holders of
     Preferred Stock of such voting rights.  At any meeting at which the holders
     of Preferred Stock shall exercise such voting right initially during an
     existing default period, they shall have the right, voting as a class, to
     elect Directors to fill such vacancies, if any, in the Board of Directors
     as may then exist up to two (2) Directors or, if such right is exercised at
     an annual meeting, to elect two (2) Directors.  If the number which may be
     so elected at any special meeting does not amount to the required number,
     the holders of the Preferred Stock shall have the right to make such
     increase in the number of Directors as shall be necessary to permit the
     election by them of the required number.  After the holders of the
     Preferred Stock shall have exercised their right to elect Directors in any

                                       3
<PAGE>

     default period and during the continuance of such period, the number of
     Directors shall not be increased or decreased except by vote of the holders
     of Preferred Stock as herein provided or pursuant to the rights of any
     equity securities ranking senior to or pari passu with the Series A
                                            ---- -----
     Preferred Stock.

          (iii)  Unless the holders of Preferred Stock shall, during an existing
     default period, have previously exercised their right to elect Directors,
     the Board of Directors may order, or any stockholder or stockholders owning
     in the aggregate not less than ten percent (10%) of the total number of
     shares of Preferred Stock outstanding, irrespective of series, may request,
     the calling of special meeting of the holders of Preferred Stock, which
     meeting shall thereupon be called by the Chairman of the Board, the Chief
     Executive Officer, the President, a Vice President or the Secretary of the
     Corporation.  Notice of such meeting and of any annual meeting at which
     holders of Preferred Stock are entitled to vote pursuant to this paragraph
     (C)(iii) shall be given to each holder of record of Preferred Stock by
     mailing a copy of such notice to him or her at his or her last address as
     the same appears on the books of the Corporation.  Such meeting shall be
     called for a time not earlier than 10 days and not later than 60 days after
     such order or request, or in default of the calling of such meeting within
     60 days after such order or request, such meeting may be called on similar
     notice by any stockholder or stockholders owning in the aggregate not less
     than ten percent (10%) of the total number of shares of Preferred Stock
     outstanding.  Notwithstanding the provisions of this paragraph (C)(iii), no
     such special meeting shall be called during the period within 60 days
     immediately preceding the date fixed for the next annual meeting of the
     stockholders.

          (iv)   In any default period, the holders of Common Stock, and, if
     applicable, other classes of capital stock of the Corporation, shall
     continue to be entitled to elect the whole number of Directors until the
     holders of Preferred Stock shall have exercised their right to elect two
     (2) Directors voting as a class, after the exercise of which right (x) the
     Directors so elected by the holders of Preferred Stock shall continue in
     office until their successors shall have been elected by such holders or
     until the expiration of the default period, and (y) any vacancy in the
     Board of Directors may (except as provided in paragraph (C)(ii) of this
     Section 3) be filled by vote of a majority of the remaining Directors
     theretofore elected by the holders of the class of capital stock which
     elected the Director whose office shall have become vacant.  References in
     this paragraph (C) to Directors elected by the holders of a particular
     class of stock shall include Directors appointed by such Directors to fill
     vacancies as provided in clause (y) of the foregoing sentence.

          (v)    Immediately upon the expiration of a default period, (x) the
     right of the holders of Preferred Stock as a class to elect Directors shall
     cease, (y) the term of any Directors elected by the holders of Preferred
     Stock as a class shall terminate, and (z) the number of Directors shall be
     such number as may be provided for in the articles of incorporation or by-
     laws irrespective of any increase made pursuant to the provisions of
     paragraph (C)(ii) of this Section 3 (such number being subject, however, to
     change thereafter in any manner provided by law or in the articles of
     incorporation or by-laws).  Any vacancies in the Board of Directors
     effected by the provisions of clauses (y) and (z) in the preceding sentence
     may be filled by a majority of the remaining Directors.

          (D)    Except as set forth herein, holders of Series A Preferred Stock
shall have no special voting rights and their consent shall not be required
(except to the extent they are entitled to vote with holders of Common Stock as
set forth herein) for taking any corporate action.

                                       4
<PAGE>

          Section 4.  Certain Restrictions.
                      --------------------

          (A)  Whenever quarterly dividends or other dividends or distributions
payable on the Series A Preferred Stock as provided in Section 2 are in arrears,
thereafter and until all accrued and unpaid dividends and distributions, whether
or not declared, on shares of Series A Preferred Stock outstanding shall have
been paid in full, the Corporation shall not:

          (i)    declare or pay dividends on, make any other distributions on,
     or redeem or purchase or otherwise acquire for consideration any shares of
     capital stock ranking junior (either as to dividends or upon liquidation,
     dissolution or winding up) to the Series A Preferred Stock;

          (ii)   declare or pay dividends on or make any other distributions on
     any shares of stock ranking on a parity (either as to dividends or upon
     liquidation, dissolution or winding up) with the Series A Preferred Stock,
     except dividends paid ratably on the Series A Preferred Stock and all such
     parity stock on which dividends are payable or in arrears in proportion to
     the total amounts to which the holders of all such shares are then
     entitled;

          (iii)  redeem or purchase or otherwise acquire for consideration
     shares of any capital stock ranking on a parity (either as to dividends or
     upon liquidation, dissolution or winding up) with the Series A Preferred
     Stock, provided that the Corporation may at any time redeem, purchase or
     otherwise acquire shares of any such parity stock in exchange for shares of
     any capital stock of the Corporation ranking junior (either as to dividends
     or upon dissolution, liquidation or winding up) to the Series A Preferred
     Stock; or

          (iv)  purchase or otherwise acquire for consideration any shares of
     Series A Preferred Stock, or any shares of capital stock ranking on a
     parity with the Series A Preferred Stock, except in accordance with a
     purchase offer made in writing or by publication (as determined by the
     Board of Directors) to all holders of such shares upon such terms as the
     Board of Directors, after consideration of the respective annual dividend
     rates and other relative rights and preferences of the respective series
     and classes, shall determine in good faith will result in fair and
     equitable treatment among the respective series or classes.

          (B)  The Corporation shall not permit any subsidiary of the
Corporation to purchase or otherwise acquire for consideration any shares of
stock of the Corporation unless the Corporation could, under paragraph (A) of
this Section 4, purchase or otherwise acquire such shares at such time and in
such manner.

          Section 5.  Reacquired Shares.
                      -----------------

          Any shares of Series A Preferred Stock purchased or otherwise acquired
by the Corporation in any manner whatsoever shall be retired and cancelled
promptly after the acquisition thereof.  All such shares shall upon their
cancellation become authorized but unissued shares of Preferred Stock and may be
reissued as part of a new series of Preferred Stock to be created by resolution
or resolutions of the Board of Directors, subject to the conditions and
restrictions on issuance set forth herein.

                                       5
<PAGE>

          Section 6.  Liquidation, Dissolution or Winding Up.
                      --------------------------------------

          (A)  Upon any liquidation (voluntary or otherwise), dissolution or
winding up of the Corporation, no distribution shall be made to the holders of
shares of capital stock ranking junior (either as to dividends or upon
liquidation, dissolution or winding up) to the Series A Preferred Stock unless,
prior thereto, the holders of shares of Series A Preferred Stock shall have
received $100 per share, plus an amount equal to accrued and unpaid dividends
and distributions thereon, whether or not declared, to the date of such payment
(the "Series A Liquidation Preference").  Following the payment of the full
amount of the Series A Liquidation Preference, no additional distributions shall
be made to the holders of shares of Series A Preferred Stock unless, prior
thereto, the holders of shares of Common Stock shall have received an amount per
share (the "Common Adjustment") equal to the quotient obtained by dividing (i)
the Series A Liquidation Preference by (ii) 100 (as appropriately adjusted as
set forth in subparagraph (C) below to reflect such events as stock splits,
stock dividends and recapitalizations with respect to the Common Stock) (such
number in clause (ii), the "Adjustment Number").  Following the payment of the
full amount of the Series A Liquidation Preference and the Common Adjustment in
respect of all outstanding shares of Series A Preferred Stock and Common Stock,
respectively, and the payment of liquidation preferences of all other shares of
capital stock which rank prior to or on a parity with Series A Preferred Stock,
holders of Series A Preferred Stock and holders of shares of Common Stock shall
receive their ratable and proportionate share of the remaining assets to be
distributed in the ratio of the Adjustment Number to 1 with respect to such
Preferred Stock and Common Stock, on a per share basis, respectively.

          (B)  In the event, however, that there are not sufficient assets
available to permit payment in full of the Series A Liquidation Preference and
the liquidation preferences of all other series of Preferred Stock, if any,
which rank on a parity with the Series A Preferred Stock, then such remaining
assets shall be distributed ratably to the holders of such parity shares in
proportion to their respective liquidation preferences.  In the event, however,
that there are not sufficient assets available to permit payment in full of the
Common Adjustment, then such remaining assets shall be distributed ratably to
the holders of Common Stock.

          (C)  In the event the Corporation shall at any time after the Rights
Declaration Date (i) declare any dividend on Common Stock payable in shares of
Common Stock, (ii) subdivide the outstanding Common Stock, or (iii) combine the
outstanding Common Stock into a smaller number of shares, then in each such case
the Adjustment Number in effect immediately prior to such event shall be
adjusted by multiplying such Adjustment Number by a fraction the numerator of
which is the number of shares of Common Stock outstanding immediately after such
event and the denominator of which is the number of shares of Common Stock that
were outstanding immediately prior to such event.

          Section 7.  Consolidation, Merger, etc.
                      --------------------------

          In case the Corporation shall enter into any consolidation, merger,
combination or other transaction in which the shares of Common Stock are
exchanged for or changed into other stock or securities, cash and/or any other
property, then in any such case the shares of Series A Preferred Stock shall at
the same time be similarly exchanged or changed into an amount per share
(subject to the provision for adjustment hereinafter set forth) equal to 100
times the aggregate amount of capital stock, securities, cash and/or any other
property (payable in kind), as the case may be, for which or into which each
share of Common Stock is exchanged or changed.  In the event the Corporation
shall at any time after the Rights Declaration Date (i) declare any dividend on
Common

                                       6
<PAGE>

Stock payable in shares of Common Stock, (ii) subdivide the outstanding Common
Stock, or (iii) combine the outstanding Common Stock into a smaller number of
shares, then in each such case the amount set forth in the preceding sentence
with respect to the exchange or change of shares of Series A Preferred Stock
shall be adjusted by multiplying such amount by a fraction the numerator of
which is the number of shares of Common Stock outstanding immediately after such
event and the denominator of which is the number of shares of Common Stock that
were outstanding immediately prior to such event.

          Section 8.  No Redemption.
                      -------------

          The shares of Series A Preferred Stock shall not be redeemable.

          Section 9.  Ranking.
                      -------

          The Series A Preferred Stock shall rank junior to all other series of
the Corporation's Preferred Stock as to the payment of dividends and the
distribution of assets, whether or not upon the dissolution, liquidation or
winding up of the Corporation, unless the terms of any such series shall provide
otherwise.

          Section 10.  Amendment.
                       ---------

          The Charter shall not be amended in any manner which would materially
alter or change the powers, preferences or special rights of the Series A
Preferred Stock so as to affect them adversely without the affirmative vote of
the holders of at least two-thirds of the outstanding shares of Series A
Preferred Stock, voting separately as a class.

          Section 11.  Fractional Shares.
                       -----------------

          Series A Preferred Stock may be issued in fractions of a share which
shall entitle the holder, in proportion to such holder's fractional shares, to
exercise voting rights, receive dividends, participate in distributions and to
have the benefit of all other rights of holders of Series A Preferred Stock.

                                       7
<PAGE>

                                                                       Exhibit B
                                                                       ---------

                         [Form of Rights Certificate]

Certificate No. R-                                               ________ Rights

NOT EXERCISABLE AFTER MARCH __, 2010 OR EARLIER IF REDEEMED OR EXCHANGED BY
THE COMPANY. THE RIGHTS ARE SUBJECT TO REDEMPTION, AT THE OPTION OF THE COMPANY,
AT $.01 PER RIGHT, AND TO EXCHANGE ON THE TERMS SET FORTH IN THE RIGHTS
AGREEMENT. UNDER CERTAIN CIRCUMSTANCES, RIGHTS BENEFICIALLY OWNED BY AN
ACQUIRING PERSON (AS SUCH TERM IS DEFINED IN THE RIGHTS AGREEMENT) AND ANY
SUBSEQUENT HOLDER OF SUCH RIGHTS MAY BECOME NULL AND VOID. [THE RIGHTS
REPRESENTED BY THIS RIGHTS CERTIFICATE ARE OR WERE BENEFICIALLY OWNED BY A
PERSON WHO WAS OR BECAME AN ACQUIRING PERSON OR AN AFFILIATE OR ASSOCIATE OF AN
ACQUIRING PERSON (AS SUCH TERMS ARE DEFINED IN THE RIGHTS AGREEMENT).
ACCORDINGLY, THIS RIGHTS CERTIFICATE AND THE RIGHTS REPRESENTED HEREBY MAY
BECOME NULL AND VOID IN THE CIRCUMSTANCES SPECIFIED IN SECTION 7(e) OF SUCH
AGREEMENT.]/1/

___________________
/1/ The portion of the legend in brackets shall be inserted only if applicable
and shall replace the preceding sentence.

                                       1
<PAGE>

                              RIGHTS CERTIFICATE

                       Edwards Lifesciences Corporation

          This certifies that _______________, or registered assigns, is the
registered owner of the number of Rights set forth above, each of which entitles
the owner thereof, subject to the terms, provisions and conditions of the Rights
Agreement, dated as of ____________, 2000 (the "Rights Agreement"), between
Edwards Lifesciences Corporation, a Delaware corporation (the "Company"), and
First Chicago Trust Company of New York, a division of Equiserve (the "Rights
Agent"), to purchase from the Company at any time prior to 5:00 P.M. (New York
time) on March __, 2010 at the office or offices of the Rights Agent designated
for such purpose, or its successors as Rights Agent, one one-hundredth of a
fully paid, nonassessable share of Series A Junior Participating Preferred
Stock, par value $.01 per share (the "Preferred Stock"), of the Company, at a
purchase price of $__ per one one-hundredth of a share (the "Purchase Price"),
upon presentation and surrender of this Rights Certificate with the Form of
Election to Purchase and related Certificate duly executed. The number of Rights
evidenced by this Rights Certificate (and the number of shares which may be
purchased upon exercise thereof) set forth above, and the Purchase Price per
share set forth above, are the number and Purchase Price as of March __,
2000, based on the Preferred Stock as constituted at such date. The Company
reserves the right to require prior to the occurrence of a Triggering Event (as
such term is defined in the Rights Agreement) that, upon any exercise of Rights,
a number of Rights be exercised so that only whole shares of Preferred Stock
will be issued.

          Upon the occurrence of a Section 11(a)(ii) Event (as such term is
defined in the Rights Agreement), if the Rights evidenced by this Rights
Certificate are beneficially owned by (i) an Acquiring Person or an Affiliate or
Associate of any such Acquiring Person (as such terms are defined in the Rights
Agreement), (ii) a transferee of any such Acquiring Person, Associate or
Affiliate, or (iii) under certain circumstances specified in the Rights
Agreement, a transferee of a person who, after such transfer, became an
Acquiring Person or an Affiliate or Associate of such Person, such Rights shall
become null and void and no holder hereof shall have any right with respect to
such Rights from and after the occurrence of such Section 11(a)(ii) Event.

          As provided in the Rights Agreement, the Purchase Price and the number
and kind of shares of Preferred Stock or other securities which may be purchased
upon the exercise of the Rights evidenced by this Rights Certificate are subject
to modification and adjustment upon the happening of certain events, including
Triggering Events.

          This Rights Certificate is subject to all of the terms, provisions and
conditions of the Rights Agreement, which terms, provisions and conditions are
hereby incorporated herein by reference and made a part hereof and to which
Rights Agreement reference is hereby made for a full description of the rights,
limitations of rights, obligations, duties and immunities hereunder of the
Rights Agent, the Company and the holders of the Rights Certificates, which
limitations of rights include the temporary suspension of the exercisability of
such Rights under the specific circumstances set forth in the Rights Agreement.
Copies of the Rights Agreement are on file at the above-mentioned office of the
Rights Agent and are also available upon written request to the Company.

                                       2
<PAGE>

          This Rights Certificate, with or without other Rights Certificates,
upon surrender at the principal office or offices of the Rights Agent designated
for such purpose, may be exchanged for another Rights Certificate or Rights
Certificates of like tenor and date evidencing Rights entitling the holder to
purchase a like aggregate number of one one-hundredths of a share of Preferred
Stock as the Rights evidenced by the Rights Certificates surrendered shall have
entitled such holder to purchase.  If this Rights Certificate shall be exercised
in part, the holder shall be entitled to receive upon surrender hereof another
Rights Certificate or Rights Certificates for the number of whole Rights not
exercised.

          Subject to the provisions of the Rights Agreement, the Rights
evidenced by this Certificate may, in each case at the option of the Company, be
(i) redeemed by the Company at its option at a redemption price of $.01 per
Right or (ii) exchanged in whole or in part for shares of Common Stock or other
securities of the Company.  Immediately upon the action of the Board of
Directors of the Company authorizing redemption, the Rights will terminate and
the only right of the holders of Rights will be to receive the redemption price.

          No fractional shares of Preferred Stock will be issued upon the
exercise of any Right or Rights evidenced hereby (other than fractions which are
integral multiples of one one-hundredth of a share of Preferred Stock, which
may, at the election of the Company, be evidenced by depositary receipts), but
in lieu thereof a cash payment will be made, as provided in the Rights
Agreement.

          No holder of this Rights Certificate shall be entitled to vote or
receive dividends or be deemed for any purpose the holder of shares of Preferred
Stock or of any other securities of the Company which may at any time be
issuable on the exercise hereof, nor shall anything contained in the Rights
Agreement or herein be construed to confer upon the holder hereof, as such, any
of the rights of a stockholder of the Company or any right to vote for the
election of directors or upon any matter submitted to stockholders at any
meeting thereof, or to give or withhold consent to any corporate action, or, to
receive notice of meetings or other actions affecting stockholders (except as
provided in the Rights Agreement), or to receive dividends or subscription
rights, or otherwise, until the Right or Rights evidenced by this Rights
Certificate shall have been exercised as provided in the Rights Agreement.

          This Rights Certificate shall not be valid or obligatory for any
purpose until it shall have been countersigned manually by an authorized
signatory of the Rights Agent.

                                       3
<PAGE>

          WITNESS the facsimile signature of the proper officers of the Company
and its corporate seal.

Dated as of  ________________, ____

ATTEST:                                    EDWARDS LIFESCIENCES CORPORATION

____________________________               By:  ___________________________
Secretary                                          Name:
                                                   Title:
Countersigned:

Date:_______________________

FIRST CHICAGO TRUST COMPANY
OF NEW YORK, A DIVISION OF
EQUISERVE,
----------------------------
as Rights Agent

By:  _______________________
       Authorized Signatory

                                       4
<PAGE>

                 [Form of Reverse Side of Rights Certificate]

                              FORM OF ASSIGNMENT

               (To be executed by the registered holder if such

              holder desires to transfer the Rights Certificate.)

FOR VALUE RECEIVED ___________________________________________________________
hereby sells, assigns and transfers unto ______________________________________
                 (Please print name and address of transferee)
this Rights Certificate, together with all right, title and interest therein,
and does hereby irrevocably constitute and appoint __________ Attorney, to
transfer the within Rights Certificate on the books of the within-named Company,
with full power of substitution.

Dated: ___________________, ____

                                        _______________________________________
                                        Signature

Signature Guaranteed:

                                       5
<PAGE>

                                  Certificate

          The undersigned hereby certifies by checking the appropriate boxes
that:

          (1)  this Rights Certificate [_] is [_] is not being sold, assigned
     and transferred by or on behalf of a Person who is or was an Acquiring
     Person or an Affiliate or Associate of an Acquiring Person (as such terms
     are defined pursuant to the Rights Agreement);

          (2)  after due inquiry and to the best knowledge of the undersigned,
     it [_] did [_] did not acquire the Rights evidenced by this Rights
     Certificate from any Person who is, was or subsequently became an Acquiring
     Person or an Affiliate or Associate of an Acquiring Person.

Dated: _______________, ____

                                       _______________________________________
                                           Signature

Signature Guaranteed:

                                       6
<PAGE>

                                    NOTICE

          The signature to the foregoing Assignment and Certificate must
correspond to the name as written upon the face of this Rights Certificate in
every particular, without alteration or enlargement or any change whatsoever.

                         FORM OF ELECTION TO PURCHASE

 (To be executed if holder desires to exercise Rights represented by the Rights
                                 Certificate.)

TO:  EDWARDS LIFESCIENCES CORPORATION

          The undersigned hereby irrevocably elects to exercise ______ Rights
represented by this Rights Certificate to purchase the shares of Preferred Stock
issuable upon the exercise of the Rights (or such other securities of the
Company or of any other person which may be issuable upon the exercise of the
Rights) and requests that certificates for such shares (or other securities) be
issued in the name of and delivered to:

Please insert social security
or other identifying number: ______________________

______________________________________________________________________________
                        (Please print name and address)
______________________________________________________________________________

          If such number of Rights shall not be all the Rights evidenced by this
Rights Certificate, a new Rights Certificate for the balance of such Rights
shall be registered in the name of and delivered to:

Please insert social security
or other identifying number: ______________________

______________________________________________________________________________
               (Please print name and address)
______________________________________________________________________________

Dated:  _____________,

                                      ________________________________________
                                         Signature

Signature Guaranteed:

                                       7
<PAGE>

                                  Certificate

          The undersigned hereby certifies by checking the appropriate boxes
that:

          (1)  the Rights evidenced by this Rights Certificate [_] are [_] are
     not being exercised by or on behalf of a Person who is or was an Acquiring
     Person or an Affiliate or Associate of an Acquiring Person (as such terms
     are defined pursuant to the Rights Agreement);

          (2)  after due inquiry and to the best knowledge of the undersigned,
     it [_] did [_] did not acquire the Rights evidenced by this Rights
     Certificate from any Person who is, was or became an Acquiring Person or an
     Affiliate or Associate of an Acquiring Person.

Dated: ____________, ____

                                    _______________________________________
                                    Signature

Signature Guaranteed:

                                    NOTICE

          The signature to the foregoing Election to Purchase and Certificate
must correspond to the name as written upon the face of this Rights Certificate
in every particular, without alteration or enlargement or any change whatsoever.

                                       8
<PAGE>

                                                                       Exhibit C
                                                                       ---------

                 SUMMARY OF RIGHTS TO PURCHASE PREFERRED STOCK

          On March __, 2000, the Board of Directors of Edwards Lifesciences
Corporation (the "Company") declared a dividend distribution of one Right for
each outstanding share of the Company's common stock, par value $1.00 per share
("Common Stock"), to stockholders of record at the Close of Business on
March __, 2000.  Each Right entitles the registered holder to purchase from
the Company a unit consisting of one one-hundredth of a share (a "Unit") of
Series A Junior Participating Preferred Stock, par value $.01 per share (the
"Preferred Stock"), at a Purchase Price of $__ per Unit, subject to adjustment.
The following is a summary description of the Rights and is qualified in its
entirety by the Rights Agreement (the "Rights Agreement") dated as of
March __, 2000 between the Company and First Chicago Trust Company of New York,
a division of Equiserve, as Rights Agent.

          Initially, the Rights will be attached to all Common Stock
certificates representing shares then outstanding, and no separate Rights
certificates will be distributed.  The Rights will separate from the Common
Stock and the Distribution Date will occur upon the earlier of (i) 10 days
following a public announcement that a person or group of affiliated or
associated persons (an "Acquiring Person") has acquired, or obtained the right
to acquire, beneficial ownership of 15% or more of the outstanding shares of
Common Stock (the "Stock Acquisition Date") or (ii) 10 business days (or such
later date as may be determined by action of the Board of Directors prior to
such time as any person or group becomes an Acquiring Person) following the
commencement of a tender offer or exchange offer which, if consummated, would
result in a person or group beneficially owning 15% or more of the outstanding
shares of Common Stock.

          Until the Distribution Date, (i) the Rights will be evidenced by the
Common Stock certificates and will be transferred with and only with such Common
Stock certificates, (ii) new Common Stock certificates issued after March __.,
2000, will contain a notation incorporating the Rights Agreement by reference
and (iii) the surrender for transfer of any certificates for Common Stock
outstanding will also constitute the transfer of the Rights associated with the
Common Stock represented by such certificate.

          Pursuant to the Rights Agreement, the Company reserves the right to
require prior to the occurrence of a Triggering Event (as defined below) that,
upon any exercise of Rights, a number of Rights be exercised so that only whole
shares of Preferred Stock will be issued.

          The Rights are not exercisable until the Distribution Date and will
expire at the Close of Business on March __, 2010, unless earlier redeemed by
the Company as described below.

          As soon as practicable after the Distribution Date, Rights
certificates will be mailed to holders of record of the Common Stock as of the
Close of Business on the Distribution Date and, thereafter, the separate Rights
certificates alone will represent the Rights.  Except as otherwise provided in
the Rights Agreement, only shares of Common Stock issued prior to the
Distribution Date will be issued with Rights.

          In the event that, at any time following the Distribution Date, a
person or group becomes an Acquiring Person, each holder of a Right will
thereafter have the right to receive, upon

                                       1
<PAGE>

exercise, Common Stock having a value equal to two times the exercise price of
the Right. If an insufficient number of shares of Common Stock is authorized for
issuance, then the Board would be required to substitute cash, property or other
securities of the Company for the Common Stock. Notwithstanding any of the
foregoing, following the occurrence of the event set forth in this paragraph,
all Rights that are, or (under certain circumstances specified in the Rights
Agreement) were, beneficially owned by any Acquiring Person will be null and
void. However, Rights are not exercisable following the occurrence of the event
set forth in this paragraph until such time as the Rights are no longer
redeemable by the Company as set forth below.

          For example, at an exercise price of $__ per Right, each Right not
owned by an Acquiring Person (or by certain related parties) following an event
set forth in the preceding paragraph would entitle its holder to purchase $___
worth of Common Stock (or other consideration, as noted above) for $___.
Assuming that the Common Stock had a per share value of $____ at such time, the
holder of each valid Right would be entitled to purchase ____ shares of Common
Stock for $___.

          In the event that, at any time following the Stock Acquisition Date,
(i) the Company is acquired in a merger or other business combination
transaction in which the Company is not the surviving corporation, (ii) the
Company is acquired in a merger or other business combination transaction in
which the Company is the surviving corporation and all or part of the Common
Stock is converted into securities of another entity, cash or other property, or
(iii) 50% or more of the Company's assets, cash flow or earning power is sold or
transferred, each holder of a Right (except Rights which previously have been
voided as set forth above) shall thereafter have the right to receive, upon
exercise, common stock of the acquiring company having a value equal to two
times the exercise price of the Right.  The events set forth in this paragraph
and in the second preceding paragraph are referred to as the "Triggering
Events."

          The purchase price payable, and the number of Units of Preferred Stock
or other securities or property issuable, upon exercise of the Rights are
subject to adjustment from time to time to prevent dilution (i) in the event of
a stock dividend on, or a subdivision, combination or reclassification of, the
Preferred Stock, (ii) if holders of the Preferred Stock are granted certain
rights, options or warrants to subscribe for Preferred Stock or convertible
securities at less than the current market price of the Preferred Stock, or
(iii) upon the distribution to holders of the Preferred Stock of evidences of
indebtedness or assets (excluding regular periodic cash dividends) or of
subscription rights or warrants (other than those referred to above).

          With certain exceptions, no adjustment in the Purchase Price will be
required until cumulative adjustments amount to at least 1% of the Purchase
Price.  No fractional Units will be issued and, in lieu thereof, an adjustment
in cash will be made based on the market price of the Preferred Stock on the
last trading day prior to the date of exercise.

          At any time after any person or group becomes an Acquiring Person and
prior to the acquisition by such person or group of 50% or more of the
outstanding shares of Common Stock, the Board of Directors of the Company may
exchange the Rights (other than Rights owned by such person or group which will
have become void), in whole or in part, at an exchange ratio of one share of
Common Stock, or one one-hundredth of a share of Preferred Stock (or of a share
of a class or series of the Company's preferred stock having equivalent rights,
preferences and privileges), per Right (subject to adjustment).

                                       2
<PAGE>

          In general, the Company may redeem the Rights in whole, but not in
part, at a price of $.01 per Right (subject to adjustment and payable in cash,
Common Stock or other consideration deemed appropriate by the Board of
Directors) at any time until ten days following the Stock Acquisition Date.
Immediately upon the action of the Board of Directors authorizing any
redemption, the Rights will terminate and the only right of the holders of
Rights will be to receive the redemption price.

          Until a Right is exercised, the holder thereof, as such, will have no
rights as a stockholder of the Company, including, without limitation, the right
to vote or to receive dividends.  While the distribution of the Rights will not
result in the recognition of taxable income by stockholders or the Company,
stockholders may, depending upon the circumstances, recognize taxable income
after a Triggering Event.

          The terms of the Rights may be amended by the Board of Directors of
the Company without the consent of the holders of the Rights, except that from
and after such time as any person or group of affiliated or associated persons
becomes an Acquiring Person no such amendment may adversely affect the interests
of the holders of the Rights.

          A copy of the Rights Agreement is available free of charge from the
Company.  This description of the Rights does not purport to be complete and is
qualified in its entirety by reference to the Rights Agreement, which is
incorporated herein by reference.

                                       3<PAGE>

                                                                   Exhibit 10.10

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                      SERVICES AND DISTRIBUTION AGREEMENT

                                 by and between

                         BAXTER HEALTHCARE CORPORATION

                                   as Baxter

                                      and

                       ALLEGIANCE HEALTHCARE CORPORATION

                                 as Allegiance
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                               TABLE OF CONTENTS

                                                                            Page
                                                                            ----
1.   Definitions; Rules of Construction.                                       1

2.   Grant of Distribution Rights.                                             6

3.   Distributor Model and Kit Model.                                          6

4.   Exclusivity.                                                              7

5.   Term.                                                                    10

6.   Prices and Fees.                                                         11

7.   Invoicing and Payments.                                                  14

8.   Allegiance's Duties.                                                     16

9.   Baxter's Duties.                                                         16

10.  Standard of Care.                                                        16

11.  Transfer of Title and Risk of Loss.                                      16

12.  Warranties.                                                              17

13.  Trademarks.                                                              17

14.  Termination.                                                             18

15.  Indemnity.                                                               22

16.  Insurance.                                                               26

17.  Compliance with Laws.                                                    26

18.  Force Majeure.                                                           28

19.  Confidentiality.                                                         28

20.  Limitation of Liability and Remedy.                                      30

21.  Miscellaneous Provisions.                                                32

22.  Dispute Resolution and Arbitration.                                      34

                                       i
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

23.  Assignment.                                                              35

                                       ii
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                                LIST OF EXHIBITS

Exhibit A Products and Perfusion Services
Exhibit B Allegiance's Duties
Exhibit C Baxter's Duties
Exhibit D Price List for BCS Kit Components

                                      iii
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                      SERVICES AND DISTRIBUTION AGREEMENT

          This SERVICES AND DISTRIBUTION AGREEMENT (this "Agreement"), dated as
of October 1, 1996 (the "Effective Date"), by and between BAXTER HEALTHCARE
CORPORATION, a Delaware corporation with its principal offices at One Baxter
Parkway, Deerfield, Illinois 60015 (hereinafter called "Baxter") and ALLEGIANCE
HEALTHCARE CORPORATION, a Delaware corporation with its principal offices at
1430 Waukegan Road, McGaw Park, Illinois 60085 (hereinafter called
"Allegiance").

                                   RECITALS

          Baxter and its parent corporation, Baxter International Inc. ("Baxter
International"), have spun-off various businesses by transferring those
businesses toAllegiance Corporation ("Allegiance Corporation") (or its
subsidiaries) and distributing all of the stock of Allegiance Corporation to the
stockholders of Baxter International as a dividend.  As a result of the
distribution of that dividend, Baxter International and Allegiance Corporation,
and their respective subsidiaries, are separate and independent corporations.

          As a consequence of the foregoing actions, Allegiance will acquire,
inter alia, certain business units, including the U.S. Distribution business,
----------
that have previously provided various sales and distribution services to
business units owned by Baxter.

          Baxter and Allegiance recognize that it is advisable for Allegiance to
continue providing physical distribution and sales support and related services
to Baxter.

                                   AGREEMENT

          In consideration of the mutual undertakings contained herein, and for
other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, Baxter and Allegiance agree as follows:

1.   Definitions; Rules of Construction.

     1.1  Definitions.  As used in this Agreement:

          1.1.1  "Affiliate" shall mean any Person controlling,

                                       1
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

     controlled by, or under direct or indirect common control with a party
     hereto. For the purpose of this definition, the term "control" means the
     power to direct the management of an entity, directly or indirectly,
     whether solely through the ownership of voting securities (as in the case
     of subsidiary), by contract, or otherwise; and the terms "controlling" and
     "controlled" have meanings correlative to the foregoing. Allegiance
     Corporation and Baxter International shall not be deemed to be Affiliates
     of each other.

          1.1.2     "Agreement" shall mean this Services and Distribution
Agreement dated as of October 1, 1996, including all Exhibits and Schedules
attached hereto.

          1.1.3     "BCS Kit Components" shall mean the Products listed on
Exhibit D hereto.

          1.1.4     "Competitor" shall mean (a) with respect to Baxter, any
Person (including an affiliate of such Person) that during the most recently
completed fiscal year has annual net revenues from sales of products competitive
with Products greater than 20% of the total annual net revenues of Baxter from
Products during the most recently completed fiscal year; and (b) with respect to
Allegiance, any Person (including an affiliate of such Person) that during the
most recently completed fiscal year has annual net revenues from the
distribution of medical, surgical and laboratory products greater than 20% of
the total annual net revenues of Allegiance during the most recently completed
fiscal year.

          1.1.5     "Component Price" shall mean the price for each BCS Kit
Component (including components for BCS Kits that are included as part of PBDS
Kits) as set forth on Exhibit D, which shall be subject to annual adjustment by
mutual agreement of the parties.  If, for any given calendar year, the parties
cannot agree to an adjustment by October 1st of the immediately preceding year,
the price for each BCS Kit Component shall be adjusted by the percentage change
in the Producer's Price Index for the prior year over the preceding calendar
year.

          1.1.6     "Cost Management" shall mean the dedication of resources by
Allegiance or its Affiliates to deliver cost improvement services to customers.
Cost Management services shall be comprised of activities which reduce product
consumption, improve utilization of assets, improve logistics, and reduce or
eliminate operating costs.  Cost Management transactions shall be those
transactions performed by Allegiance pursuant to any comprehensive Cost
Management contract which

                                       2
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

permits Allegiance to share with a customer the risk and reward of cost savings
generated by Cost Management. As part of such Cost Management transactions,
Allegiance may also provide some or all of the following services: (a) ValueLink
(as defined herein); (b) PBDS (as defined herein); (c) consulting services; (d)
on-site clinical resources; (e) contract materials management; and (f)
consolidated service centers. Cost Management transactions shall include sales
of PBDS Kits that include Products.

          1.1.7     "Distributor List Price" shall mean the unit prices shown on
Exhibit A for each Product.

          1.1.8     "Gross Profit" shall mean Baxter's standard gross profit as
shown on Baxter's internal management profit and loss statements, consistent
with Baxter's historical accounting policies and procedures and generally
accepted accounting principles.  Should these policies and procedures materially
change, Baxter shall inform Allegiance and adjust the calculations accordingly.

          1.1.9     "Gross Profit Growth" shall mean the percentage increase of
Gross Profit calculated by dividing year-to-date total Gross Profit by the total
Gross Profit of the immediately preceding entire calendar year for all Products
sold as part of Cost Management transactions except as provided in Section 6.3.

          1.1.10    "Kit" shall mean an aggregation by Allegiance of Baxter,
Allegiance, and/or third-party products packaged together or repackaged for
specific uses and procedures including, without limitation, such aggregations
for programs known prior to the Effective Date as Baxter Custom Sterile ("BCS")
and Procedure-Based Delivery Systems ("PBDS").

          1.1.11    "Line of Products" shall mean any specifically identified
group of related Products set forth in Exhibit A of this Agreement.

          1.1.12    "List Price" shall mean the price for each Product as
specified in Baxter's published price list.

          1.1.13    "Notice" shall mean notice given in accordance with Section
21.1.

          1.1.14    "Perfusion Services" shall mean those perfusion services
described in Exhibit A hereto.

                                       3
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

          1.1.15    "Person" shall mean an individual, corporation, partnership,
limited liability company, unincorporated syndicate, unincorporated
organization, trust, trustee, executor, administrator or other legal
representative, governmental authority or agency, or any group of Persons acting
in concert.

          1.1.16    "Products" shall mean the products and accessories
manufactured by or on behalf of Baxter or its Affiliates and listed in Exhibit A
hereto and the parts and components necessary for the repair and replacement
thereof.

          1.1.17    "Term" shall mean the period of time provided in Section 5
hereof, including any and all extensions thereof.

          1.1.18    "Territory" shall mean the District of Columbia and the
fifty states comprising the United States of America.

          1.1.19    "Transfer" shall mean any assignment, transfer, sale or
other disposition to a Person that is not an Affiliate of the Transferor,
including any Transfer by way of merger or consolidation or otherwise by
operation of law.

          1.1.20    "ValueLink" shall mean the just-in-time inventory management
service known as ValueLink(R).

     1.2  Other Terms.  Terms defined in other Sections of this Agreement will
have the meanings therein provided.

     1.3  Rules of Construction.

          1.3.1     In this Agreement, unless a clear contrary intention
appears:

               1.3.1.1   the singular number includes the plural number and vice
     versa;

               1.3.1.2   reference to any Person includes such Person's
     successors and assigns but, if applicable, only if such successors and
     assigns are permitted by this Agreement;

               1.3.1.3   reference to any gender includes the other gender;

               1.3.1.4   reference to any Section or Exhibit or Schedule means
     such Section of this Agreement or such Exhibit or Schedule to this
     Agreement, as the case may be, and references in any Section or definition
     to any clause

                                       4
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

     means such clause of such Section or definition;

               1.3.1.5   "herein", "hereunder", "hereof", "hereto", and words of
     similar import shall be deemed references to this Agreement as a whole and
     not to any particular Section or other provision hereof or thereof;

               1.3.1.6   "including" (and with correlative meaning "include")
     means including without limiting the generality of any description
     preceding such term;

               1.3.1.7   "distribute" or "distribution" shall be used
     interchangeably to refer to Allegiance's duties under either the
     Distributor Model or the Kit Model and shall not alone imply a legal
     distributor relationship;

               1.3.1.8   relative to the determination of any period of time,
     "from" means "from and including", "to" means "to but excluding" and
     "through" means "through and including";

               1.3.1.9   reference to any law (including statutes and
     ordinances) means such law as amended, modified, codified or reenacted, in
     whole or in part, and in effect from time to time, including rules and
     regulations promulgated thereunder; and

               1.3.1.10  accounting terms used herein shall have the meanings
     historically attributed to them by Baxter and its subsidiaries based upon
     Baxter's internal financial policies and procedures in effect prior to the
     spin-off described in the recitals above.

               1.3.1.11  in the event of any conflict between the provisions of
     the body of this Agreement and the Exhibits or Schedules hereto, the
     provisions of the body of this Agreement shall control; and

               1.3.1.12  the headings contained in this Agreement have been
     inserted for convenience of reference only, and are not to be used in
     construing this Agreement.

          1.3.2     This Agreement was negotiated by the parties with the
benefit of legal representation, and any rule of construction or interpretation
otherwise requiring this Agreement to be construed or interpreted against either
party shall not apply to any construction or interpretation hereof.  Subject to
Section 21.5 hereof, this Agreement shall be interpreted and construed to the
maximum extent possible so as to uphold the

                                       5
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

enforceability of each of the terms and provisions hereof, it being understood
and acknowledged that this Agreement was entered into by the parties after
substantial and extended negotiations and with full awareness by the parties of
the terms and provisions hereof and the consequences thereof.

2.   Grant of Distribution Rights.

     2.1  Grant. With respect to sales of all Products and Perfusion Services,
Baxter hereby grants to Allegiance and Allegiance hereby accepts the right,
which shall be exclusive as set forth in Section 4, to provide sales, sales
support, customer service, and physical distribution services, as specified in
Section 8, to customers in the Territory under the Distributor Model and Kit
Model.

     2.2  Exceptions and Limitations. Baxter reserves all rights not expressly
granted to Allegiance hereunder.  Except as otherwise provided herein,
Allegiance shall not grant to any subagents or subdistributors any of its rights
or obligations hereunder.

     2.3  Additional Product Referral. Any customer request related to heart
valves, vascular grafts or annuloplasty rings to be included in Cost Management
services will be forwarded by Allegiance to Baxter with a recommendation from
Allegiance to the customer that Baxter is Allegiance's preferred vendor.  Where
appropriate, Baxter and Allegiance will work together to attempt to convert the
customer to Products and Allegiance services.

3.   Distributor Model and Kit Model.

     3.1. Distributor Model.  Allegiance shall maintain the principal
contractual relationship with the customer for sales, sales support, accounts
receivable, and customer service in connection with the supply of the Products
and Perfusion Services in connection with the provision by Allegiance of Cost
Management, ValueLink and other services consolidated on an Allegiance invoice
for Products, Perfusion Services and Allegiance products (as required by the
customer).  Baxter shall use reasonable efforts to cooperate with Allegiance and
to facilitate Allegiance's fulfillment of its obligations hereunder. Baxter
shall provide to Allegiance the Distributor List Price to be paid by Allegiance
to Baxter and a suggested direct sale price (the "Suggested Sales Price") in
connection with each Distributor Model transaction, provided, however, that
Allegiance shall have the sole right and responsibility for negotiating and
contracting with each customer the delivered price of the Products and

                                       6
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

Perfusion Services. If customer has a contract with Baxter for such Products
and/or Perfusion Services, or if customer had such a contract with Baxter that
expired in the 90 day period immediately preceding the applicable customer
order, the Suggested Sales Price shall be the contract price. If a customer does
not have a contract with Baxter or if the customer's contract expired more than
90 days prior to such customer's order, the List Price will be the Suggested
Sales Price. If Baxter has a contract with any customer for Baxter's provision
of Products and Perfusion Services to such customer, and such customer
subsequently requests Cost Management, ValueLink, and/or other services
consolidated on an Allegiance invoice for such Products and/or Perfusion
Services and, if applicable, Allegiance products, all such sales of Products
and/or Perfusion Services to such customer shall apply to any minimum purchase
commitments or quantity discounts contained in Baxter's contract with such
customer.

     3.2. Kit Model.  Allegiance shall maintain the principal contractual
relationship with the customer for sales, sales support, accounts receivable,
and customer service in connection with the provision by Allegiance of Kits.
Baxter shall provide to Allegiance the Component Price for each Product that
Allegiance orders from Baxter for use as a component for a Kit. Allegiance shall
have the sole right and responsibility for negotiating and contracting with each
customer the delivered price of the Kits.  If Baxter has an agreement with any
customer for Baxter's provision of Products to such customer and such customer
subsequently requests Kits, all such Kit Model sales of Products to such
customer shall apply to any minimum purchase commitments or quantity discounts
contained in Baxter's agreement with such customer.

     3.3. Transition to Consignment Model.  At such time as a consignment model
becomes available and each party agrees that use of such consignment model would
be economically beneficial to both parties, the parties agree to use reasonable
business efforts to convert both Distributor Model and Kit Model transactions to
the consignment model.  If Baxter and Allegiance are unable to reach agreement
regarding the consignment model, the existing terms of this Agreement shall
remain in effect.

4.   Exclusivity.

     4.1  Restrictions on Allegiance.

          4.1.1     With respect to Cost Management transactions, Allegiance,
its Affiliates, and any other Person acting on its or

                                       7
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

their behalf, shall not, directly or indirectly, market or promote any product
or accept orders through agents or otherwise, to or from any customer or any
Affiliate of any customer for any product that competes in the Territory with
any Products or Perfusion Services. However, the taking and fulfillment by
Allegiance of orders for products that compete with Products in Cost Management
transactions under contracts in existence as of the Effective Date and for the
term of such contracts shall not be deemed to be a breach of this Section.
Without limiting the generality of the foregoing and at all times subject to
availability of the Products and Perfusion Services, Allegiance, its Affiliates,
and any other Person acting on its or their behalf, shall not, directly or
indirectly, market or promote any product that competes with any Product,
Products and/or Perfusion Services as Allegiance's (a) first-line substitute or
for competitive comparison, or (b) as a substitute for any other product
competitive with any Product, Products and/or Perfusion Services. This Section
shall not apply if the applicable Products or Perfusion Services are unavailable
and such unavailability is due substantially to Baxter's acts or omissions.

          4.1.2     With respect to non-Cost Management transactions, Allegiance
may market, promote, distribute and sell products which compete with Products.

          4.1.3     Allegiance, its Affiliates, and any other Person acting on
its or their behalf, shall not, directly or indirectly, develop or manufacture
any product that competes in the Territory with any Products and Perfusion
Services.

          4.1.4     Allegiance, its Affiliates, and any other Person acting on
its or their behalf, shall not, directly or indirectly, market to or solicit
orders from, or distribute any Product through distributors, agents, or
otherwise, to or from any customer or any Affiliate of any customer located
outside of the Territory.

     4.2  Restrictions on Baxter.  With respect to Cost Management transactions,
Baxter, its Affiliates, and any other Person acting on its or their behalf,
shall not, directly or indirectly, provide or engage any Person other than
Allegiance to provide physical distribution services or to act as Baxter's agent
for distribution services in the Territory with respect to the Products and
Perfusion Services, provided that Baxter shall have the right to:

                                       8
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

          4.2.1     distribute the Products and Perfusion Services in the
Territory directly to customers other than distributors, from Baxter
manufacturing facilities and/or Baxter's replenishment centers;

          4.2.2     distribute the Products and Perfusion Services to Baxter's
Affiliates;

          4.2.3     distribute Products and Perfusion Services to customers
within the Territory other than through Allegiance (and Baxter shall be relieved
of its obligation to pay fees pursuant to Section 6.2) if and to the extent
Allegiance is unable to so distribute the Products or Perfusion Services due to
(a) regulatory requirements; (b) Allegiance's material failure to meet agreed-
upon performance standards; or (c) Allegiance being otherwise prohibited or
prevented from selling and/or distributing the Products or Perfusion Services or
refusing or being unable to sell and/or distribute the Products and Perfusion
Services to any customer or class of customers other than by customer decision;

          4.2.4     sell and distribute products which are not Products as
defined herein through relationships that do not include Allegiance; and

          4.2.5     develop and implement a cardiovascular cost management
program through which the Products and Perfusion Services may be sold in the
Territory.  The physical distribution of Products for such a cost management
program, which may include Perfusion Services, shall either be direct from
Baxter or through Allegiance.

This Agreement shall in no way limit the right of Baxter and its Affiliates to
market, sell, or otherwise distribute the Products and Perfusion Services
outside the Territory.

     4.3  Exceptions.

          4.3.1     Each party shall have the right to request exceptions to the
exclusivity restrictions for individual customers.  Such exceptions shall
require written approval of Allegiance's Regional President or Baxter's (CVG)
Vice President of Sales, as applicable, but shall not be unreasonably withheld.
Exceptions shall not be permitted with respect to sales of Perfusion Services.

          4.3.2     After the Effective Date, requests from customers for PBDS
Kits which include third-party products which compete with Products shall be
handled as follows: (a) Allegiance

                                       9
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

will suggest Products as the recommended substitutes for the competing products,
and Baxter will recommend Allegiance as the preferred PBDS service provider; and
(b) Allegiance and Baxter will use reasonable sales and marketing efforts
including working jointly with each party's sales representatives wherever
possible to convert the customer to Products and Allegiance services. If after
such efforts a customer continues to refuse to convert to Products or Allegiance
services, Allegiance and Baxter shall be released from the exclusivity
requirements imposed by Section 4.1 solely with respect to sales of PBDS Kits to
such customer.

     4.4  Product Exclusivity.  Baxter shall have the right, but not the
obligation to:  (a) add Products to Exhibit A and this Agreement which are new
products developed by Baxter that are of the same type and have similar
distribution characteristics as the Products set forth in this Agreement; and
(b) delete from Exhibit A and this Agreement any Product, the manufacture and
sale of which has been generally discontinued by Baxter.  Baxter and Allegiance
may agree to add to Exhibit A newly developed or acquired products that are not
of the same type or that do not have the same distribution characteristics as
the Products set forth in Exhibit A as of the Effective Date, but neither Baxter
nor Allegiance is under any obligation to do so.  Upon such agreement, Exhibit A
shall be deemed to be amended to reflect any such Product additions and
deletions without any further act by any party hereto.  Baxter shall use
commercially reasonable efforts to provide at least 30 days prior written notice
to Allegiance of each such addition or deletion.  Exhibit A, as amended and
supplemented from time to time, is incorporated by reference herein and forms
part of this Agreement.  Baxter may update Exhibit A effective January 1 of each
calendar year provided that Baxter gives Allegiance 90 days prior written notice
of such update.

5.   Term.  The initial Term of this Agreement shall begin on the Effective Date
and, except as otherwise provided in this Agreement, end at the end of the day
on December 31, 2001.  The Term may be extended for successive additional
periods, subject to the parties agreeing upon the terms and conditions of such
an extension.  Each party may in its absolute discretion determine whether or
not the terms of any such proposed extension are acceptable and may refuse to
agree to any such extension for any reason whatsoever.  Commencing no later than
July 1, 1998, the parties shall negotiate in good faith regarding modifications
to the terms and conditions of this Agreement for the period commencing October
1, 1998, to provide additional benefits to both parties.

                                       10
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

6.   Prices and Fees.  Allegiance and Baxter will keep confidential all amounts
by either party to the other.

     6.1  For all Products purchased by Allegiance except those Products ordered
as BCS Kit components, Allegiance shall pay to Baxter as the purchase price an
amount equal to the aggregate Distributor List Price in effect at the time of
the order placement of all such Products.

     6.2  After Allegiance has sold Products to the customer (except those
Products sold as BCS Kit components), Baxter shall reimburse Allegiance for any
amount by which the Distributor List Price exceeds the Suggested Sales Price
("Vendor Rebate"), and Baxter shall also pay Allegiance the following fees:

          6.2.1   For (a) all sales of Products other than through Cost
Management transactions and (b) the initial fee for sales of Products included
in PBDS Kits sold to customers not having a comprehensive Cost Management
agreement with Allegiance, the fee shall be * * * of the Suggested Sales Price.
Therefore, for all such sales, Baxter shall pay Allegiance the Vendor Rebate
plus * * * of the Suggested Sales Price.

          6.2.2   The fee for sales of Products included as part of Cost
Management transactions (including Products included in PBDS Kits) shall be * *
* of the Suggested Sales Price, determined as follows:

          (a) * * * if Gross Profit Growth is less than or equal to * * *;

          (b) * * * if Gross Profit Growth is greater than * * * but less than
or equal to * * *; or

          (c) * * * if Gross Profit Growth is greater than * * *.

If at any time during a calendar year, Gross Profit Growth exceeds * * * , and
the * * * or * * * fee * * * applies, such * * * will apply for all subsequent
sales made during such year and retroactively for all sales of PBDS Kits and to
all Cost Management transactions made to date for the year.

          6.2.3   As additional fees for Products sold as part of PBDS Kits to
customers not under a comprehensive Cost Management agreement with Allegiance,
Baxter shall pay the difference between the fee calculated as if Section 6.2.2
applied, and the * * * fee paid pursuant to Section 6.2.1.  Such additional fees
will be calculated at the end of each applicable quarter.

                                       11
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

          6.2.4   If any calculation under this Section 6.2 results in a
negative amount, Allegiance shall pay Baxter such amount.

     6.3  If a customer enters into a cardiovascular cost management program
with Baxter as permitted under Section 4.2.5, and at that time such customer is
a Cost Management customer of Allegiance, then, for any calculation of Gross
Profit Growth made thereafter, the year-to-date Gross Profit on sales by
Allegiance shall be subtracted from total year-to-date Gross Profit, and the
total Gross Profit on sales by Allegiance to such customer for the prior year
shall be subtracted from total Gross Profit for the preceding entire calendar
year.

     6.4  If a customer who has been purchasing Product from Baxter or from
Allegiance other than through PBDS or a comprehensive Cost Management agreement
enters into a comprehensive Cost Management agreement with Allegiance or begins
purchasing PBDS Kits containing the Products, then:

          6.4.1   for subsequent calculations of Gross Profit Growth, the year-
to-date Gross Profit will include Gross Profit on year-to-date sales made to
that customer (by Baxter or Allegiance) and the prior year Gross Profit will
include Gross Profit on sales made during the prior year to such customer (by
Baxter or Allegiance);

          6.4.2   For each calendar quarter thereafter, Allegiance will refund
to Baxter the difference between (a) the fees calculated pursuant to Section
6.2.2 and 6.2.3, and (b) * * *, multiplied by the volume of Product sales made
to such customer by Baxter or Allegiance during the quarter preceding the
quarter in which the transition occurred.

     6.5     If the parties' business information systems and/or data processing
systems are unable to accommodate the applicable percentages set forth in this
Section 6, the parties shall agree upon a procedure for monthly payment with a
quarterly adjustment to achieve the effects of the deal set forth herein.

     6.6  BCS Kit Components.  Allegiance shall pay to Baxter as the purchase
price of the Products purchased by Allegiance as components for BCS Kits an
amount equal to the aggregate Component Price.

     6.7  Perfusion Services.  For all sales of Perfusion Services (whether
invoiced by Allegiance or Baxter), Baxter shall

                                       12
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

pay Allegiance * * * of the sales growth of Perfusion Services (excluding the
effect of acquisitions and divestitures). For purposes of this Section, sales
growth shall be calculated as Perfusion Services net sales in any quarter less
                                                                          ----
Perfusion Services net sales in the corresponding quarter of 1996, provided,
that for calculating such growth for the fourth quarter of 1996, the Perfusion
Services net sales for the fourth quarter of 1995 shall be used. The method used
to exclude the effect of acquisitions and divestitures will be as follows; (a)
for acquisitions, the current quarter sales of the acquisition will be added to
the base sales of the corresponding quarter of 1996, and (b) for divestitures,
the current quarter sales of the divestiture will be subtracted from the base
sales of the corresponding quarter of 1996. This process will continue until a
full twelve months have elapsed since the acquisition or divestiture.

     6.8  Field Corrective Action ("FCA") Fees and Expenses.

          6.8.1     In addition to the other fees and charges set forth in this
Section 6, in 1997 and subsequent years Baxter will pay Allegiance an annual fee
equal to (a) * * * times (b) the total number of Product lines affected by FCAs
in such year in excess of * * *.  For purposes of this Section, any FCAs caused
by Allegiance's negligence shall be excluded.  In addition, for each catalog
number affected by an FCA, the total "lines" shall be an amount equal to the sum
of (a) the number of notification processing responses completed by Allegiance
facilities for that FCA, plus (b) the number of dispositions completed by
Allegiance facilities for that FCA.  Baxter shall not owe Allegiance any FCA fee
under this Section,  nor shall Baxter be entitled to any fee or credit from
Allegiance, if in 1997 or any subsequent year, the total number of lines
affected by FCAs does not exceed 1546.  For 1996, the FCA fee will be computed
based on the excess of total Product lines affected by FCAs in the last three
months of 1996 over the average quarterly total of Product lines affected by
FCAs in calendar year 1995.

          6.8.2     Additional FCA Services.  Baxter shall pay Allegiance the
                    -----------------------
fees agreed upon for any additional FCA services requested and approved by
Baxter and provided by Allegiance pursuant to Section 1.6.2 of Exhibit B.

          6.8.3     Third-Party Invoices.  Pursuant to Section 1.6.2 of Exhibit
                    --------------------
B, Baxter shall reimburse Allegiance for all third-party invoices relating to
additional FCA services requested and approved by Baxter and actually paid by
Allegiance.

                                       13
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

     6.9  Packaging Failure.  Baxter shall reimburse Allegiance for Allegiance's
actual out-of-pocket expenses (including, without limitation, expenses for
repackaging and return of Product) incurred in respect of failure of shipping
cartons for Products, provided that such failure is not due to Allegiance's acts
or omissions.  Such reimbursement shall be paid quarterly and shall be due
within 30 days after receipt of Allegiance's invoice therefor together with full
supporting documentation.

7.   Invoicing and Payments.

     7.1  General.

          7.1.1     Baxter will invoice Allegiance on a daily basis according to
the terms of this Agreement.  On or before the tenth day of each calendar month
during the Term, Baxter shall submit a report to Allegiance including its Gross
Profit and Gross Profit Growth, and sales growth of Perfusion Services.

          7.1.2     For sales of Products to Allegiance, Baxter shall submit
invoices to Allegiance upon the shipment of Products to Allegiance.  Allegiance
shall pay all such invoices net 60 days from the date of the invoice.

          7.1.3     For all fees due under Sections 6.2.1 and 6.2.2, such fees
shall be paid net 15 days from the end of the applicable month.

          7.1.4     For all fees and refunds due under Sections 6.2.3, 6.3 and
6.4, such fees and refunds shall be paid net 30 days from the end of the
applicable calendar quarter.

          7.1.5     For sales of Perfusion Services, Baxter shall pay Allegiance
for any fees due hereunder on a quarterly basis net 30 days from the end of the
applicable calendar quarter.  For sales of Perfusion Services invoiced by
Allegiance, Allegiance shall pay the full invoice amount to Baxter within 30
days of the invoice date.

          7.1.6     For sales to Allegiance of BCS Kit Components, Baxter will
submit invoices daily to Allegiance upon shipment to Allegiance's BCS facility.
Allegiance shall pay all such invoices net 60 days from the date of the invoice.

          7.1.7     Baxter will pay or cause its Affiliates to pay all amounts
due to Allegiance pursuant to this Agreement within 30 days after receipt of any
such invoice.

          7.1.8     If any amounts due have not been received by

                                       14
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

the due date, such overdue amounts shall bear interest from the due date at the
rate of * * * per month, or portion thereof, until received. If payment is
delayed because a report required by Section 7.1.1 has not been received,
interest will not accrue until 30 days after receipt of such report.

          7.1.9     Either party shall have the right to withhold any amounts
due hereunder if such party in good faith disputes the amount claimed by the
other party to be due hereunder and such party notifies the other party of such
dispute within 30 days after the due date of any such payment.  The foregoing
right to withhold payment of disputed amounts shall be limited to amounts
disputed in good faith.

     7.2  Reimbursable Expenses.  Within 15 days of Baxter's receipt of any
invoice, Baxter shall reimburse Allegiance for Allegiance's actual out-of-pocket
expenses incurred for freight for Products (a) received by Allegiance at its
distribution centers from Baxter's replenishment centers; and (b) shipped by
Allegiance using special transportation requiring a premium charge paid by
Allegiance, billed by Baxter, and collected by Baxter from the customer.

     7.3  Audit.  Allegiance may audit Baxter's books and records and Baxter may
audit Allegiance's books and records for the purpose of determining compliance
with the terms of this Agreement.  The party requesting the audit may use
independent auditors, who may participate fully in such audit.  In the event
that an audit is proposed with respect to information which the party to be
audited wishes not to disclose to the other party ("Restricted Information"),
then on the written demand of the party to be audited the individuals conducting
the audit with respect to Restricted Information will be limited to the
independent auditors of the party requesting the audit.  In such event, the
party to be audited shall pay the costs of the independent auditors conducting
such audit, but only with respect to that portion of the audit relating to the
Restricted Information.  Such independent auditors shall enter into an agreement
with the parties hereto, on terms that are agreeable to both parties hereto,
under which such independent auditors shall agree to maintain the
confidentiality of the information obtained during the course of such audit and
establishing what information such auditors will be permitted to disclose to
report the results of any audit of Restricted Information to the party
requesting the audit.  Any such audit shall be conducted during regular business
hours, in a manner that does not interfere unreasonably with the operations of
the party being audited.  Such audits shall be conducted not more than once in
any one year period

                                       15
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

unless the next preceding audit disclosed a material failure to conform to the
terms of this Agreement. Subject to the foregoing limitations, any such audit
shall be conducted when requested by Notice given not less than 30 days prior to
the commencement of the audit.

8.   Allegiance's Duties.  During the Term, Allegiance shall maintain the
facilities and personnel necessary to provide the physical distribution services
and related services in connection with its appointment hereunder including,
without limitation, the facilities and personnel necessary to fulfill
Allegiance's duties as set forth in Exhibit B attached hereto and made a part
hereof.

9.   Baxter's Duties.  During the Term, Baxter shall maintain the facilities and
personnel necessary to manufacture and distribute the Products and Perfusion
Services as provided for hereunder including, without limitation, the facilities
and personnel necessary to fulfill Baxter's duties as set forth in Exhibit C
attached hereto and made a part hereof.

10.  Standard of Care.  Each party will use (and will cause its Affiliates to
use) commercially reasonable efforts in the performance of its obligations
hereunder and will do so with the same degree of care, skill and prudence
customarily exercised when engaged in similar activities for itself and its
Affiliates. Subject to the provisions of Section 20 hereof, if a party's
performance is inaccurate, incomplete, or untimely, such party shall, if
practical, promptly perform or reperform such obligations.  In performing its
responsibilities hereunder, each party shall accord the other party and its
Affiliates the same priority as it provides itself and its Affiliates under
comparable circumstances.  Without limiting the generality of the foregoing, in
the provision of services under comparable circumstances, a party will not
discriminate against the other party or any of its Affiliates solely because the
other party or one of its Affiliates is the recipient of such services.  The
parties agree to consult with each other with respect to performance of their
obligations hereunder.  Each party shall give due consideration to any
suggestion by the other to improve performance.

     10.1 Uniform Commercial Code.  The parties agree that the provisions of
Section 2-306(2) of the Uniform Commercial Code shall not apply to services or
any other activities or obligations of either of the parties hereunder.

11.  Transfer of Title and Risk of Loss.  Title and risk of loss for the
Products shall pass from Baxter to Allegiance upon

                                       16
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

receipt of Products by Allegiance.

12.  Warranties.

     12.1 Product Warranty.  Baxter warrants to Allegiance that, at the time of
delivery to Allegiance:  (a) the Products shall not be adulterated or misbranded
within the meaning of the Federal, Food, Drug and Cosmetic Act, as amended and
the regulations issued thereunder, or products that may not, under the provision
of Section 404, 505, 514 or 515 of said Act, be introduced into interstate
commerce, or banned devices under Section 516 of said Act; and (b) Baxter shall
have good and marketable title to all such Products free and clear of all liens
or encumbrances (other than any created by Allegiance).

     12.2 Disclaimer.  THE FOREGOING WARRANTY IS EXCLUSIVE AND IN LIEU OF ALL
OTHER WARRANTIES OF ANY KIND, WHETHER STATUTORY, WRITTEN, ORAL, EXPRESS OR
IMPLIED, INCLUDING ANY WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE AND
MERCHANTABILITY.  IN NO EVENT, WHETHER AS A RESULT OF BREACH OF CONTRACT, TORT
LIABILITY (INCLUDING NEGLIGENCE) OR OTHERWISE, SHALL BAXTER BE LIABLE TO
ALLEGIANCE FOR ANY SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES.

     12.3 Limitation of Liability.  ANY LIABILITY OF BAXTER TO ALLEGIANCE UNDER
THE WARRANTY CONTAINED IN THIS SECTION 12.3 SHALL BE LIMITED TO THE TOTAL PRICE
PAID BY ALLEGIANCE FOR THE PRODUCTS WHICH ARE THE SUBJECT OF SUCH LIABILITY PLUS
ALL COSTS FOR TRANSPORTATION AND OTHER DIRECT EXPENSES INCURRED BY ALLEGIANCE
WITH RESPECT TO SUCH PRODUCTS.

13.  Trademarks.

     13.1 Ownership.  Allegiance acknowledges that Baxter or its Affiliates are
the owners or licensees of the trademarks and trade names which Baxter and its
Affiliates use in the promotion and sale of the Products and Perfusion Services
hereunder, and that Allegiance has no right or interest in such trademarks or
trade names.  Before commencing any use of the trademarks or trade names
connoting Baxter in connection with any catalog, promotional, packaging, or
other materials, which use has not been previously approved in writing by
Baxter, Allegiance agrees to provide Baxter with proposed specimens of use of
such trademarks or trade names and to obtain Baxter's written approval of such
proposed use.

     13.2 Infringement.  Allegiance shall notify Baxter promptly

                                       17
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

of any and all infringements or improper use by any third party of the
trademarks and trade names connoting Baxter should Allegiance discover
reasonable cause for believing that such infringement or improper use is taking
place and shall provide to Baxter all information which Allegiance has available
thereon. Baxter shall have sole discretion and control with regard to any
proceedings relating to infringement or improper use of its trademarks and trade
names. Allegiance may choose to be represented by its own counsel in any such
proceedings but such representation shall be solely at Allegiance's expense.

     13.3 Equitable Remedies.  Allegiance acknowledges that Baxter would not
have any adequate remedy at law for the breach by Allegiance of any one or more
of the covenants contained in this Section 13 and agrees that, in the event of
such breach, Baxter may, in addition to the other remedies which may be
available to it, file a suit in equity to enjoin Allegiance from any further
breach of any of the terms of this Section 13.

14.  Termination.

     14.1 Change in Control.

          14.1.1   General. In the event of a Change in Control of either party
                   -------
hereto or any Affiliate thereof to which any of the rights or obligations
hereunder have been assigned as permitted by Section 23, the party (the
"Affected Party") with respect to which the Change in Control has occurred,
either directly or with respect to one of its Affiliates, shall give Notice to
the other party (the "Non-Affected Party") within 30 days of the occurrence of
such Change in Control.  The Non-Affected Party may terminate this Agreement, in
whole but not in part, in the event of any such Change in Control with respect
to the Affected Party by giving Notice of such termination to the Affected Party
as provided below.  In the event of a Change in Control of an Affiliate of the
Affected Party to which any of the rights or obligations hereunder have been
assigned as permitted by Section 23, the Non-Affected Party may terminate this
Agreement with respect to such Affiliate by giving Notice to the Affected Party
as provided below.  The Non-Affected Party may exercise the rights of
termination described in the two preceding sentences by giving a Notice of
termination, specifying the date of termination, to the Affected Party at any
time prior to the end of the 60th day following the receipt by the Non-Affected
Party of the applicable Notice of Change in Control given by the Affected Party
pursuant to the first sentence of this Section 14.1.1.  In the event that the
applicable Change in Control involves a Competitor of the Non-Affected Party,
the date of

                                       18
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

termination specified by the Non-Affected Party in the Notice of termination
shall be the last day of the calendar month which is not earlier than the sixth
full calendar month following the date of the Notice of termination and not
later than the twelfth full calendar month following the date of the Notice of
termination. In the event that the applicable Change in Control does not involve
a Competitor of the Non-Affected Party, the date of termination specified by the
Non-Affected Party in the Notice of termination shall be the later of (i) the
last day of the twelfth full calendar month following the date of the Notice of
termination and (ii) December 31, 1998.

          14.1.2  Definitions.  For purposes hereof, "Change in Control" shall
                  -----------
mean (i) the acquisition, directly or indirectly, by any Person or Persons of
more than 30% of the voting stock of either party to this Agreement or any
Affiliate thereof, (ii) any merger or consolidation involving the Affected Party
or any Affiliate of the Affected Party that requires a vote of the stockholders
of the Ultimate Parent of the Affected Party, (iii) the acquisition by the
Ultimate Parent of the Affected Party or any Affiliate of the Ultimate Parent of
the Affected Party of any Person that (a) is a Rival of the Ultimate Parent of
the Non-Affected Party and (b) after such acquisition, constitutes a
"significant subsidiary" of the Affected Party within the meaning of Rule 1-
02(w) of Regulation S-X of the Regulations of the Securities and Exchange
Commission, substituting 50 percent for 10 percent in the tests used therein to
determine significant subsidiary, and (iv) only in the case of an Affiliate of
the Affected Party, the Transfer of all or substantially all of the business and
assets of such Affiliate.  For the purposes hereof, "Rival" shall mean (a) with
respect to Baxter, any Person (including an Affiliate of such Person) that
during its most recently completed fiscal year has annual net revenues greater
than 20 percent of the total annual consolidated net revenues of Baxter
International during its most recently completed fiscal year; and (b) with
respect to Allegiance, any Person (including an Affiliate of such Person) that
during its most recently completed fiscal year has annual net revenues greater
than 20 percent of the total annual consolidated net revenues of Allegiance
Corporation during the most recently completed fiscal year.  For the purposes
hereof, "Ultimate Parent" means Baxter International in the case of Baxter and
Allegiance Corporation in the case of Allegiance.

          14.1.3  Transfers by Baxter.  In the event that Baxter or any of its
                  -------------------
Affiliates shall Transfer all or substantially all of the business and assets
relating to any Line of Products as permitted by Section 23, Allegiance may
terminate this Agreement

                                       19
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

with respect to such Line of Products in the same manner as provided in Section
14.1.1. In the event that Baxter or any of its Affiliates shall Transfer all or
substantially all of the business and assets relating to the Products as
permitted by Section 25, Allegiance may terminate this Agreement in its entirety
in the same manner as provided in Section 14.1.1.

          14.1.4  Transfers by Allegiance.  In the event that Allegiance or any
                  -----------------------
of its Affiliates shall Transfer any portion of its business and assets relating
to Allegiance's distribution network as permitted by Section 23, which portion
accounted for net sales during the most recently completed fiscal year in excess
of $250 million, Baxter may terminate this Agreement with respect to the
Transferred portion of the distribution network in the same manner as provided
in Section 14.1.1.

          14.1.5  Obligation to Negotiate.  If demanded in writing by the Non-
                  -----------------------
Affected Party, the Affected Party shall be obligated, during the period
following a Notice of termination from the Non-Affected Party, to negotiate in
good faith to establish terms and conditions that are acceptable to the Non-
Affected Party for an extension of the Term beyond the date of termination
specified in the Notice of termination in light of the Change in Control,
provided, however, the Non-Affected Party may in its absolute discretion
determine whether any proposed terms and conditions are acceptable and may
refuse to agree to any such terms and conditions for any reason whatsoever.

          14.1.6  Confidential Information  During the period commencing with
                  ------------------------
any such Change in Control and continuing through the end of the Term (and
thereafter, if appropriate), the Affected Party shall take any and all action
reasonably requested by the Non-Affected Party to protect any confidential
information of the Non-Affected Party from disclosure to or use by any Affiliate
of the Affected Party other than a Person that, immediately prior to the
occurrence of the Change in Control, was an Affiliate of the Affected Party that
regularly accessed such confidential information for a reasonable business
purpose.

     14.2 Other Terminations.  Each Party shall have the right to terminate this
Agreement effective upon delivery of Notice to the other party if the other
party:  (a) makes an assignment for the benefit of creditors, or becomes
bankrupt or insolvent, or is petitioned into bankruptcy, or takes advantage of
any state, federal or foreign bankruptcy or insolvency act, or if a receiver or
receiver/manager is appointed for all or any substantial part of its property
and business and such receiver or receiver/manager remains undischarged for a
period of 30 days,

                                       20
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

(b)  has its corporate existence terminated by voluntary or involuntary
dissolution; or (c) materially defaults in the performance of any of its
covenants or obligations contained in this Agreement and such default is not
remedied to the nondefaulting party's reasonable satisfaction within 30 days
after Notice to the defaulting party of such default, or if such default is not
capable of rectification within 30 days, if the defaulting party has not
promptly commenced to rectify the default within such 30 day period and is not
proceeding diligently to rectify the default.

     14.3 Procedures on Termination.  In the event of any termination of this
Agreement and if and when requested by Allegiance, Baxter will promptly remove
all inventory of Products owned by Baxter from facilities of Allegiance or any
of its Affiliates.  Such removal will be effected during normal business hours
after reasonable advance Notice to Allegiance and will be done in a manner that
will not unreasonably disrupt the normal business operations of Allegiance or
Baxter.

     Except as otherwise required pursuant to Sections 19 and 21.9, each party
shall destroy or return to the other party all records made or obtained in the
course of performance hereunder containing information regarding the other party
or its customers that is protected from disclosure under Section 19.  In the
event that any party shall elect to destroy any records as permitted above, such
party shall provide the other party with written confirmation of any such
destruction.

     14.4 Continued Service.  In the event that this Agreement is terminated
pursuant to this Section 14, Baxter and Allegiance shall comply fully with this
Agreement and use reasonable efforts to service adequately existing customers of
the Products until such termination becomes effective.

     14.5 Pending Orders.  On the expiration or termination of this Agreement
for any reason, Allegiance shall continue to honor customer's orders for
Products placed up to the date of expiration or termination, and Baxter shall
pay the fees due to Allegiance on the terms and conditions set forth in this
Agreement.  Any consideration due hereunder that is calculated based upon a
specified time period shall be prorated for any partial period of time between
the end of the last such period and the date of expiration or termination.  In
the event that Allegiance has elected to terminate this Agreement because of the
failure of Baxter to pay amounts due hereunder, Allegiance shall be obligated to
perform under the first sentence of this Section 14.5 only after Baxter shall
have paid all amounts due and owing

                                       21
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

to Allegiance hereunder.

     14.6 Sell-Off.  Notwithstanding any provision of this Agreement or any
other agreement between Baxter, Allegiance, and/or their respective Affiliates,
the parties acknowledge that Allegiance and its Affiliates shall be entitled to
continue to sell or otherwise dispose of the Products within the Territory from
and after the effective date of the expiration or termination of this Agreement
if such Products were owned by Allegiance on the date of termination.

     14.7 True-Up.  No later than 12 months after expiration or termination of
this Agreement, Baxter shall report to Allegiance all discounts and bonuses
accrued but not earned and/or earned but not accrued on sales made hereunder,
and Baxter shall submit either a payment or an invoice for the net of such
amounts.

 15. Indemnity.

     15.1 Baxter's Obligation.  Baxter agrees to indemnify and hold Allegiance
and the Allegiance Indemnified Parties harmless from and against, and in respect
of, any and all claims by, and liabilities to, third parties ("Third-Party
Claims") asserted against or incurred by, and any and all expenses (including
all fees and expenses of counsel, travel costs and other out-of-pocket costs) in
connection with pending or threatened litigation or other proceedings regarding
such Third-Party Claims ("Expenses") incurred by, Allegiance or any of the
Allegiance Indemnified Parties (as hereinafter defined) which arise out of or
relate to:

          15.1.1  any actual or alleged patent, copyright or trademark
infringement, or violation of any other proprietary right, arising out of the
purchase, sale or use of Products pursuant to this Agreement;

          15.1.2  any tort claim, including claims for personal injury, wrongful
death or property damage, to the extent such claims are based upon any wrongful
or negligent act or omission by Baxter (or its employees or agents) in the
course of its performance of this Agreement;

          15.1.3  defects in Products;

          15.1.4  any actual or alleged breach of warranty or obligation, if
any, accompanying the Product or Products, subject to the limitations in Section
12 to the extent provided therein; and

                                       22
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

          15.1.5  any claim for personal injury, wrongful death or property
damage arising out of the use of a Product;

provided that this Section 15.1 shall not apply to any Third-Party Claim or
--------
Expense to the extent that the parties agree, or it is finally determined
pursuant to Section 15.4 that the Third-Party Claim or Expense is within the
scope of Allegiance's indemnity obligation set forth in Sections 15.2.1 and
15.2.2 below.

     The Allegiance Indemnified Parties shall mean and include (A) Allegiance's
Affiliates (B) the respective directors, officers, agents and employees of and
counsel to Allegiance and its Affiliates, (C) each other person, if any,
controlling Allegiance or any of its Affiliates, and (D) the successors,
assigns, heirs and personal representatives of any of the foregoing.  Expenses
shall be reimbursed or advanced when and as incurred promptly upon submission by
Allegiance or any Allegiance Indemnified Party of statements to Baxter.

     15.2 Allegiance's Obligation.  Allegiance agrees to indemnify and hold
Baxter and the Baxter Indemnified Parties harmless from and against, and in
respect of, any and all Third-Party Claims asserted against or incurred by, and
any and all Expenses incurred by, Baxter or any of the Baxter Indemnified
Parties (as hereinafter defined) which arise out of or relate to:

          15.2.1  any tort claim, including claims for personal injury, wrongful
death or property damage, to the extent such claims are based upon any wrongful
or negligent act or omission by Allegiance (or its employees or other agents) in
the course of its performance of this Agreement including, but not limited to,
any Third-Party Claims or Expenses caused by any such wrongful or negligent act
or omission constituting a representation concerning the characteristics or
method of usage of Products, or relating to the storage, handling, or delivery
of Products or selection of Products for inclusion in Kits; and

          15.2.2  any actual or alleged patent, copyright or trademark
infringement, or violation of any other proprietary right, arising out of any
act or omission of Allegiance or any of its Affiliates in connection with the
sale of Kits or relating to any intellectual property owned by Allegiance or any
of its Affiliates and used in connection with the sale of Kits.

The Baxter Indemnified Parties shall mean and include (A) Baxter's Affiliates,
(B) the respective directors, officers,

                                       23
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

agents and employees of and counsel to Baxter and its Affiliates, (C) each other
person, if any, controlling Baxter or any of its Affiliates, and (D) the
successors, assigns, heirs and personal representatives of any of the foregoing.
Expenses shall be reimbursed or advanced when and as incurred promptly upon
submission by Baxter or any Baxter Indemnified Party of statements to
Allegiance.

     15.3 Third-Party Claims.  If any third party shall make any claim or
commence any arbitration proceeding or suit against any one or more of the
Baxter Indemnified Parties or the Allegiance Indemnified Parties (hereafter,
"Indemnified Persons") with respect to which an Indemnified Person intends to
make any claim for indemnification against Allegiance under Section 15.2 or
against Baxter under Section 15.1 (as the case may be, the "Indemnifying
Party"), such Indemnified Persons shall promptly give written notice to the
Indemnifying Party of such third party claim, arbitration proceeding or suit and
the following provisions shall apply.

     15.4 Control of Proceedings.

          15.4.1  The Indemnifying Party shall have 20 business days after
receipt of the notice referred to in Section 15.3 to notify the Indemnified
Party that it elects to conduct and control the defense of such claim,
proceeding or suit.  If the Indemnifying Party does not give the foregoing
notice, the Indemnified Party shall have the right to defend, contest, settle or
compromise such claim, proceeding or suit in the exercise of its exclusive
discretion subject to the provisions of Section 15.5, and the Indemnifying Party
shall, upon request from any of the Indemnified Persons, promptly pay to such
Indemnified Persons in accordance with the other terms of this Section the
amount of any Third-Party Claim resulting from their liability to the third
party claimant and all related Expense.

          15.4.2  If the Indemnifying Party gives the foregoing notice, the
Indemnifying Party shall have the right to undertake, conduct and control,
through counsel reasonably acceptable to the Indemnified Party, and at its sole
expense, the conduct and settlement of such claim, proceeding or suit, and the
Indemnified Party shall cooperate with the Indemnifying Party in connection
therewith, provided that (i) the Indemnifying Party shall not thereby permit any
lien, encumbrance or other adverse charge to thereafter attach to any asset of
any Indemnified Person; (ii) the Indemnifying Party shall not thereby permit any
injunction against any Indemnified Person; (iii) the Indemnifying Party shall
permit the Indemnified Person and counsel chosen by the

                                       24
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

Indemnified Person and reasonably acceptable to the Indemnifying Party to
monitor such conduct or settlement and shall provide the Indemnified Person and
such counsel with such information regarding such claim, proceeding or suit as
either of them may reasonably request (which request may be general or
specific), but the fees and expenses of such counsel shall be borne by the
Indemnified Person unless (1) the Indemnifying Party and the Indemnified Person
shall have mutually agreed to the retention of such counsel or (2) the named
parties to any such claim, proceeding or suit include the Indemnified Person and
the Indemnifying Party and in the reasonable opinion of counsel to the
Indemnified Person representation of both parties by the same counsel would be
inappropriate due to actual or likely conflicts of interest between them, in
either of which cases the reasonable fees and disbursements of counsel for such
Indemnified Person shall be reimbursed by the Indemnifying Party to the
Indemnified Person; and (iv) the Indemnifying Party shall agree promptly to
reimburse to the extent required under this Section the Indemnified Person for
the full amount of any Third-Party Claim resulting from such claim, proceeding
or suit and all related Expense incurred by the Indemnified Person.

          15.4.3  In no event shall the Indemnifying Party without the prior
written consent of the Indemnified Person, settle or comprise any claim or
consent to the entry of any judgment that does not include as an unconditional
term thereof the giving by the claimant or the plaintiff to the Indemnified
Person a release from all liability in respect of such claim.

          15.4.4  If the Indemnifying Party shall not have undertaken the
conduct and control of the defense of any claim, suit or proceeding as provided
above, the Indemnifying Party shall nevertheless be entitled through counsel
chosen by the Indemnifying Party and reasonably acceptable to the Indemnified
Person to monitor the conduct or settlement of such claim by the Indemnified
Person, and the Indemnified Person shall provide the Indemnifying Party and such
counsel with such information regarding such action or suit as either of them
may reasonably request (which request may be general or specific), but all costs
and expenses incurred in connection with such monitoring shall be borne by the
Indemnifying Party.

     15.5 Settlement of Third-Party Claims by the Indemnified Person.  So long
as the Indemnifying Party is contesting any such claim, suit or proceeding in
good faith, the Indemnified Person shall not pay or settle any such claim,
proceeding or suit. Notwithstanding the foregoing, the Indemnified Person shall
have the right to pay or settle any such claim, proceeding or suit,

                                       25
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

provided that in such event the Indemnified Person shall waive any right to
indemnity therefor by the Indemnifying Party, and no amount in respect thereof
shall be claimed as Third-Party Claim or Expense under this Section 15.

     If the Indemnifying Party shall not have undertaken the conduct and control
of the defense of any claim, suit or proceeding as provided above, the
Indemnified Person, on not less than 30 days' prior written Notice to the
Indemnifying Party, may make settlement (including payment in full) of such
claim and such settlement shall be binding upon the parties hereto for the
purposes hereof, unless within said 30-day period the Indemnifying Party shall
have requested the Indemnified Person to contest such claim at the expense of
the Indemnifying Party.  In such event, the Indemnified Person shall promptly
comply with such request and the Indemnifying Party shall have the right to
direct the defense of such claim or any litigation based thereon subject to all
of the conditions of Section 15.4.  Anything in this Section 15 to the contrary
notwithstanding, if the Indemnified Person advises the Indemnifying Party that
it has determined to make settlement of a claim, the Indemnified Person shall
have the right to do so at its own cost and expense, without any requirement to
contest such claim at the request of the Indemnifying Party, but without any
right under the provisions of this Section 15 for indemnification by the
Indemnifying Party.

16.  Insurance. Each party is responsible for carrying any insurance desired by
it in its sole discretion, including comprehensive general liability insurance,
insurance to cover its facilities, products liability insurance and business
interruption insurance.

17.  Compliance with Laws.

     17.1 Allegiance Compliance.  Allegiance shall, to the extent material to
Allegiance and its Affiliates taken as a whole, comply (or cause compliance)
with all existing and future federal, state and other laws and regulations in
the Territory applicable to the conduct of Allegiance's business, the provision
of Perfusion Services or the possession of Products pursuant to this Agreement
including, without limitation, the following:

          17.1.1  giving prompt written notice to Baxter if Allegiance should
become aware of any actual defect or condition which may alter the quality of
the Products and Perfusion Services in any material respect or may render any of
the Products and Perfusion Services in violation of any applicable

                                       26
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

law or regulation of the Territory including, without limitation, any violation
which could require any alteration of the specifications of any Product, affect
the sale of any Product, cause revocation of any regulatory approval with
respect to any Product or its sale hereunder, or give rise to a claim against
Baxter by any person, and Allegiance shall promptly notify Baxter upon becoming
aware of any changes in any laws or regulations in the Territory applicable to
the manufacture, sale, packaging, labeling, possession or use of the Products;

          17.1.2    keeping appropriate records of all lot coded and serial
numbered Products shipped to customers; and

          17.1.3    making prompt return of any and all Products affected by
holds or recalls if so requested by Baxter.

     To the extent applicable to the subject matter of this Agreement, and
pursuant to the requirements of 42 CFR 420.300 et. seq., Allegiance hereby
agrees to make available to the Secretary of Health and Human Services ("HHS"),
the Comptroller of the General Accounting Office ("GAO"), or their authorized
representatives, all contracts, books, documents and records relating to the
nature and extent of costs hereunder for a period of four (4) years after the
furnishing of services hereunder.  In addition, if any part of any Product is to
be provided by subcontract, Allegiance hereby agrees to require by contract that
such subcontractor make available to the HHS and GAO, or their authorized
representatives, all contracts, books, documents and records relating to the
nature and costs thereunder for a period of four (4) years after the furnishing
of services thereunder.

     17.2 Baxter Compliance.  Baxter shall, to the extent material to Baxter and
its Affiliates take as a whole, comply (or cause compliance) with all existing
and future laws and regulations in the Territory applicable to the conduct of
Baxter's business or the manufacture, packaging, labeling and sale to Allegiance
of Products pursuant to this Agreement, including, without limitation, the
following:

          17.2.1    giving prompt written notice to Allegiance if Baxter should
become aware of any actual defect or condition which may alter the quality of
the Products or Perfusion Services in any material respect or may render any of
the Products or Perfusion Services in violation of any applicable law or
regulation of the Territory, including, without limitation, any violation which
could require any alteration of the specifications of any Product, affect the
sale of any Product, cause revocation of any federal, state or other regulatory

                                       27
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

approval with respect to any Product or its sale hereunder or give rise to a
claim against Allegiance by any person; and

          17.2.2    giving prompt written notice to Allegiance of any and all
Products affected by holds or recalls and, if Baxter requests Allegiance to
return any of such Products to Baxter, promptly reimburse Allegiance for the
price of such returned Products paid by Allegiance under this Agreement and the
direct cost of returning such Products to Baxter.

     The Products and Perfusion Services provided hereunder will not be provided
in violation of any applicable Equal Employment Opportunity requirements
including those set forth in Section 202 of Executive Order 11246, as amended.

18.  Force Majeure.  The obligations of either party to perform under this
Agreement shall be excused during each period of delay caused by matters (not
including lack of funds or other financial causes) such as strikes, supplier
delays, shortages of raw materials, government orders or acts of God, which are
reasonably beyond the control of the party obligated to perform; provided that
nothing contained in this Agreement shall affect either party's ability or
discretion with respect to any strike or other employee dispute or disturbance
and all such strikes, disputes or disturbances shall be deemed to be beyond the
control of such party.  A condition of force majeure shall be deemed to continue
only so long as the affected party shall be taking all reasonable actions
necessary to overcome such condition.  In the event that either party hereto
shall be affected by a condition of force majeure, such party shall give the
other party prompt Notice thereof, which Notice shall contain the affected
party's estimate of the duration of such condition and a description of the
steps being taken or proposed to be taken to overcome such condition of force
majeure.  Any delay occasioned by any such cause shall not constitute a default
under this Agreement, and the obligations of the parties shall be suspended
during the period of delay so occasioned.  During any period of force majeure,
the party that is not directly affected by such condition of force majeure shall
be entitled to take any reasonable action necessary to mitigate the effects of
such condition of force majeure, and the provisions of Section 4 shall be
suspended to the extent necessary to permit any such action.

19.  Confidentiality.

     19.1 Allegiance Information.  Baxter agrees to hold, and to use reasonable
efforts to cause its employees and representatives to hold, in confidence all
marketing and pricing information of a

                                       28
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

confidential nature pertaining to the Territory received by Baxter from
Allegiance after the Effective Date or obtained from Allegiance in the course of
an audit pursuant to Section

7.3, in a manner consistent with Baxter's treatment of its own confidential
information.  Baxter shall not use such information for any purpose other than
as contemplated under this Agreement or verifying compliance with this
Agreement, without Allegiance's prior written consent.

     19.2 Baxter Information.  Allegiance agrees to hold, and to use reasonable
efforts to cause its employees and representatives to hold, in confidence all
information concerning Baxter, furnished to or obtained by Allegiance after the
Effective Date all marketing and pricing information of a confidential nature
pertaining to the Territory received by Allegiance, in a manner consistent with
Allegiance's treatment of its own confidential information.  Allegiance shall
not use such information for any purpose other than as contemplated under this
Agreement, without Baxter's prior written consent.

     19.3 General. The obligations of confidentiality and non-disclosure imposed
under this Section 19 shall not apply to data and information that the recipient
can demonstrate:

          19.3.1    is published or is or otherwise becomes available to the
general public as part of the public domain without breach of this Agreement;

          19.3.2    has been furnished or made known to the recipient without
any obligation to keep it confidential by a third party under circumstances
which are not known to the recipient to involve a breach of the third party's
obligations to a party hereto;

          19.3.3    was developed independently of information furnished to the
recipient under this Agreement; or

          19.3.4    was known to the recipient at the time of receipt thereof
from the other party, is not otherwise subject to (a) the confidentiality
restrictions contained in the Reorganization Agreement dated as of September 30,
1996 between Baxter International and Allegiance Corporation, or (b) any other
obligation to keep it confidential and was obtained from a third party under
circumstances which were known to the recipient to involve a breach of the third
party's obligations to a party

                                       29
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

hereto.

     19.4 Equitable Relief.  Each party (the "first party") acknowledges that
the other party would not have an adequate remedy at law for the breach by the
first party of any one or more of the covenants contained in this Section 19 and
agrees that, in the event of such breach, the other party may, in addition to
the other remedies which may be available to it, apply to a court for an
injunction to prevent breach of this Section 19 and to enforce specifically the
terms and provisions of this Section.

     19.5 Required Disclosures.  The provisions of this Section shall not
preclude disclosures required by law; provided, however, that each party will
use reasonable efforts to notify the other, prior to making any such disclosure,
and permit the other to take such steps as it deems appropriate, including
obtaining a protective order, consistent with applicable law, to minimize any
loss of confidentiality.

     19.6 Security.  Each party shall be responsible for preventing unauthorized
remote access by such party's own agents and employees to data transferred to or
otherwise made available to the other party under this Agreement.

20.  Limitation of Liability and Remedy.

     20.1 Damages.  In no event, whether based on contract, indemnity, warranty,
tort (including negligence), strict liability or otherwise, shall either party
or any of its directors, officers, employees or agents, be liable for special,
exemplary, or punitive damages.  The foregoing limitation and disclaimer shall
apply irrespective of whether the possibility of such special, exemplary, or
punitive damages had been disclosed in advance or could have reasonably been
foreseen.

     The limitations and disclaimers of obligations and liabilities contained in
this Section 20 are intended to apply to the fullest extent permitted by law;
provided that such limitations and disclaimers shall not limit amounts payable
with respect to any express indemnity provided for in this Agreement.

     20.2 Exclusive Remedies.

          20.2.1  Baxter's Exclusive Remedies.  Except in the case of the gross
                  ---------------------------
negligence or willful misconduct of Allegiance or its Affiliates, Baxter's
exclusive remedies against Allegiance for any breach of, or other act or
omission arising out of or relating to, this Agreement shall be:

                                       30
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

               20.2.1.1  the right to receive payment of amounts owed under
     Sections 6 and 7 hereof;

               20.2.1.2  the right to require reperformance of any service to
     the extent required pursuant to Section 9;

               20.2.1.3  the right to indemnification as provided in Section 15;

               20.2.1.4  the right to injunction, specific performance or other
     equitable non-monetary relief when available under applicable law;

               20.2.1.5  the right to terminate this Agreement for material
     breach as set forth in Section 14; and

               20.2.1.6  the right to actual damages for breach of Section 19.

            20.2.2  Allegiance's Exclusive Remedies.   Except in the case of the
                    -------------------------------
gross negligence or willful misconduct of Baxter or its Affiliates, Allegiance's
exclusive remedies against Baxter for any breach of, or other act or omission
arising out of or relating to, this Agreement shall be:

               20.2.2.1  the right to receive payment of amounts owed under
     Sections 6 and 7 hereof;

               20.2.2.2  with respect to Distributor Model transactions only,
     the right to require Baxter to repair or replace (at Baxter's option and
     expense) any Product that proves not to be in conformity with applicable
     labeling or specifications, and Baxter shall pay the transportation and
     other costs incurred by Allegiance with respect to any Products returned to
     Baxter for repair or replacement under this Section 20.2.2.2, or at
     Baxter's option, reimburse Allegiance for any such costs;

               20.2.2.3  the right to indemnification as provided in Section 15;

               20.2.2.4  the right to injunction, specific performance or other
     equitable non-monetary relief when available under applicable law;

               20.2.2.5  the right to terminate this Agreement for material
     breach as set forth in Section 14; and

               20.2.2.6  the right to actual damages for

                                      31
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

breach of Section 19.

21.  Miscellaneous Provisions.

     21.1 Notices.  All notices and other communications required under this
Agreement shall be in writing and shall be deemed to have been given if
delivered by hand, or sent by courier or facsimile transmission (provided that
in the case of facsimile transmission, a confirmation copy of the notice shall
be delivered by hand or sent by courier within 2 days of transmission),
addressed:

     To Baxter:

            Baxter Healthcare Corporation
            CardioVascular Group
            17221 Red Hill Avenue
            Irvine, California 92714
            Attention:  General Counsel
     with copies to:

            Baxter Healthcare Corporation
            One Baxter Parkway
            Deerfield, Illinois 60015
            Attention:  General Counsel

     if to Allegiance to:

            Allegiance Healthcare Corporation
            McGaw Park Building
            1430 Waukegan Road
            Waukegan, Illinois  60085
            Attention:  General Counsel

     with a copy to:

            Allegiance Healthcare Corporation
            McGaw Park Building
            1430 Waukegan Road
            Waukegan, Illinois  60085
            Attention:  President--Distribution

until notice of a change in address or addressee is given as provided in this
Section 21.1.  All notices given in accordance with this Section 21.1 shall be
effective, if delivered by hand or by courier, at the time of delivery, and, if
communicated by facsimile transmission, at the time of transmission.

                                       32
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

     21.2   Entire Agreement.  This Agreement is the entire agreement between
the parties hereto with respect to the subject matter hereof, there being no
prior written or oral promises or representations not incorporated herein.

     21.3   Choice of Law.  This Agreement shall be governed by and construed
and enforced in accordance with the laws of the State of Illinois and the
federal laws of the United States of America applicable therein, as though all
acts and omissions related hereto occurred in Illinois. Any lawsuit arising from
or related to this Agreement shall only be brought in the United States District
Court for the Northern District of Illinois or the Circuit Court of Lake County,
Illinois. To the extent permissible by law, the parties hereby consent to the
jurisdiction and venue of such courts. Each party hereby waives, releases and
agrees not to assert, and agrees to cause its Affiliates to waive, release and
not assert, any rights such party or its Affiliates may have under any foreign
law or regulation that would be inconsistent with the terms of this Agreement as
governed by Illinois law.

     21.4   Amendment; Waiver.  No amendment or modification of the terms of
this Agreement shall be binding on either party unless reduced to writing and
signed by an authorized representative of the party to be bound. The waiver by
either party of any particular default by the other party shall not affect or
impair the rights of the party so waiving with respect to any subsequent default
of the same or a different kind; nor shall any delay or omission by either party
to exercise any right arising from any default by the other affect or impair any
rights which the nondefaulting party may have with respect to the same or any
future default.

     21.5   Severability. In the event that any of the provisions of this
Agreement is held to be invalid, illegal, void or otherwise unenforceable in any
jurisdiction by reason of any rule of law, administrative decision, judicial
decision, public policy or otherwise, such provision shall be ineffective in
such jurisdiction to the extent of such invalidity, illegality, voidness or
unenforceability without affecting, impairing or invalidating the remaining
provisions, if any, of this Agreement. Any such invalid, illegal, void or
otherwise unenforceable provisions shall be replaced by valid and enforceable
substitute provisions which are as similar as possible to such invalid, illegal,
void or otherwise unenforceable provisions in terms of economic and other
commercial effect upon the parties, which substitute provisions shall be
established pursuant to the dispute resolution procedure set forth in Section
22.2.

                                       33
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

     21.6   Relationship of the Parties.  By virtue of this Agreement, neither
party constitutes the other as its agent (except as otherwise expressly
provided), partner, joint venturer, or legal representative and neither party
has express or implied authority to bind the other in any manner whatsoever.

     21.7   Survival.  The rights and obligations of the parties under Sections
7.3, 12, 14.5, 14.6, 15, 19, 20, and 22, as well as all rights and obligations
with respect to any amounts that remain unpaid under Sections 6 or 7 hereof as
of the date of termination, shall survive any termination of this Agreement.

     21.8   Counterparts.  For convenience of the parties hereto, this Agreement
may be executed in one or more counterparts, each of which shall be deemed an
original for all purposes.

     21.9   Records Retention.  Each party will retain all information obtained
or created in the course of performance hereunder in accordance with the records
retention guidelines of the other party existing from time to time. Each party
has advised the other of its respective guidelines as in effect on the Effective
Date and will advise the other party of any subsequent changes therein.

     21.10  Beneficiaries.  Except for the provisions of Section 15 hereof,
which are also for the benefit of the other Persons indemnified, this Agreement
is solely for the benefit of the parties hereto and their respective Affiliates,
successors and permitted assigns and shall not confer upon any other Person any
remedy, claim, liability, reimbursement or other right in excess of those
existing without reference to this Agreement.

22.  Dispute Resolution and Arbitration.

     22.1   Escalation.  The parties agree that they will attempt to settle any
claim or controversy arising out of this Agreement through good faith
negotiations in the spirit of mutual cooperation between business executives
with authority to resolve the controversy.  Prior to taking action as provided
in Section 22.2, the parties shall first submit such claim or controversy to the
appropriate Divisional Presidents of each party for resolution, and if such
Divisional Presidents are unable to resolve such claim or controversy, either
party may request that their respective chief executive officers, or their
respective delegees, attempt to resolve the dispute.  The officers or delegees
to whom any such claim or controversy is submitted as provided above shall
attempt to resolve the dispute through good faith negotiations over a reasonable
period, not to exceed 30

                                       34
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

days in the aggregate unless otherwise agreed. Such 30 day period shall be
deemed to commence on the date of a Notice from either party describing the
particular claim or controversy.

     22.2   Arbitration.  Any dispute, claim or controversy arising out of or
relating to this Agreement, or the breach or validity hereof, whether at common
law or pursuant to any statute, regulation, rule or policy, that is not resolved
by good faith negotiations in the spirit of mutual cooperation pursuant to
Section 22.1 will, upon the written request of either party, be resolved by
binding arbitration conducted in accordance with the Rules of the CPR Institute
for Dispute Resolution by a sole arbitrator who is a member of the National
Health Lawyers Association or another mutually agreeable individual.  Such
arbitrator shall set a schedule for determination of such dispute that is
reasonable under the circumstances.  Such arbitrator shall determine the dispute
in accordance with this Agreement and the substantive rules of law (but not the
rules of procedure) that would be applied by a federal court sitting in
Illinois. The arbitration shall take place in Lake County, Illinois.  The
arbitration will be governed by the United States Arbitration Act, 9 U.S.C.
(S)(S) 1-16 and the Patent Arbitration Act, 35 U.S.C. (S) 294.  Judgment upon
the award rendered by the arbitrator may be entered by any court having
jurisdiction.  Where this Agreement provides for future agreement by the
parties, failure to reach such agreement shall not constitute a dispute subject
to the provisions of this Section 22 except as expressly provided otherwise.

     22.3.  Injunctive Relief.  Nothing contained in this Section 22 shall
prevent either party from resorting to judicial process if injunctive or other
equitable relief from a court is necessary to prevent serious and irreparable
injury to one Party or to others.  The use of arbitration procedures will not be
construed under the doctrine of laches, waiver or estoppel to affect adversely
either party's right to assert any claim or defense.

23.  Assignment.

     23.1.  General.  This Agreement shall be binding upon and inure to the
benefit of the parties hereto and their respective successors and permitted
assigns, provided, however, that, except as provided below, neither party may
Transfer its interest in the Agreement, including Transfers by operation of law
such as by way of merger or consolidation, without the prior written consent of
the other party, which consent may not be unreasonably withheld.

Notwithstanding the foregoing sentence, either party may Transfer

                                       35
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

its rights and obligations under this Agreement to any corporation or other
entity that shall acquire all or substantially all of such party's business and
assets and assume in writing all of such party's obligations hereunder and
deliver a signed copy of such assumption instrument to the other party; and,
upon the other party's receipt of such assumption instrument, the assigning
party shall be fully released and discharged from its obligations under this
Agreement. In the event of such a Transfer, the Non-Affected Party shall have
the right to terminate this Agreement as provided in Section 14.

     23.2.  Certain Other Transfers by Baxter.  Notwithstanding the foregoing
provisions of this Section 23, to the extent that (a) any Person that is not a
Competitor of Allegiance shall acquire all or substantially all of Baxter's
business and assets relating to any Line of Products, or (b) any Person shall
acquire all or substantially all of Baxter's business and assets relating to the
Products; then Baxter may Transfer the portion of its rights hereunder relating
to such Line of Products or all of its rights hereunder, respectively, to such
acquiring Person, provided that any such acquiring Person shall assume in
writing all of Baxter's obligations hereunder which correspond to the portion of
rights Transferred, and shall deliver a signed copy of such assumption
instrument to Allegiance.  Baxter shall remain liable for all of the obligations
under this Agreement notwithstanding any such Transfer.  In the event of any
Transfer described in this paragraph, Allegiance shall have the right to
terminate the portion of this Agreement relating to such Line of Products as
provided in Section 14.

     23.3.  Certain Other Transfers by Allegiance. Notwithstanding the foregoing
provisions of this Section 23, to the extent that any Person shall acquire all
or any portion of Allegiance's business and assets relating to the Allegiance's
distribution network, Allegiance may Transfer the portion of its rights
hereunder relating to such portion of its distribution network to such acquiring
Person, provided that any such acquiring Person shall assume in writing the
portion of Allegiance's obligations hereunder relating to the portion of the
distribution network so Transferred, and shall deliver a signed copy of such
assumption instrument to Baxter. Allegiance shall remain liable for all of the
obligations under this Agreement notwithstanding any such Transfer. In the event
of any Transfer described in this paragraph, Baxter shall have the right to
terminate this Agreement as provided in Section 14.

                                       36
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

* * * * * *

          IN WITNESS WHEREOF, the parties have by their duly authorized officers
executed this Agreement as of the date first above written.

BAXTER:                             ALLEGIANCE:
------                              ----------

BAXTER HEALTHCARE CORPORATION       ALLEGIANCE HEALTHCARE

                                    CORPORATION

By: /s/ Michael A. Mussallem        By: /s/ William L. Feather
    -------------------------           -------------------------
Name:   Michael A. Mussallem        Name:  William L. Feather

Title:  Group Vice President--      Title: Senior Vice President

          CardioVascular                      and General Counsel

                                       37
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                              EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                     13-Aug-96
===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION                PRICE/UOM   UOM   QPC
===============================================================================================
<S>     <C>                           <C>                                 <C>         <C>   <C>
BEN     CUSTOM/BOSPACS                SEE SCHEDULE 1                                   N/A

BEN     DURAPAC100                    DURAFLO II TREATED MEMBRANE           * * *      EA    1

BEN     DPAC200                       INCLUDES DURAPAC100, SPIRALGLD        * * *      EA    1

BEN     SPRGHSRG                      SPIRALGOLD MEMBRANE OXYGENATOR        * * *      EA    1

BEN     SPRLGD                        SPIRALGOLD MEMBRANE OXYGENATOR        * * *      CS    4

BEN     SPRLGDIC                      SPIRALGOLD MEMBRANE OXYGENATOR        * * *      EA    1

BEN     SPRLGHSR                      SPIRALGOLD MEMBRANE OXYGENATOR        * * *      EA    1

BEN     BMR1500                       RESERVOIR, HARD SHELL VENOUS          * * *      CS    4

BEN     HSR4000                       RESERVOIR, HSR4000                    * * *      CS    4

BEN     HSR4000G                      RESERVOIR, HSR4000 GOLD               * * *      CS    4

BEN     SPRLIC                        SPIRAL OXY IC RESERVOIR               * * *      EA    1

BEN     BMR1900GOLD                   DURAFLO II TREATED BMR1900 STE        * * *      CS    4

BEN     BMR800GOLD                    VENOUS RESERVOIR WITH DURAFLO         * * *      CS    4

BEN     BEN10PLS                      OXYGENATOR, ADULT BUBBLE/FILM         * * *      CS    4

BEN     BEN5                          OXYGENATOR, PEDIATRIC BUBBLE          * * *      CS    4

BEN     BI02                          OXYGENATOR INFANT BUBBLE              * * *      CS    4

BEN     BCR2500                       CARDIOTOMY RESERVOIR W/FILTER         * * *      CS    6

BEN     BCR3500                       CARDIOTOMY RESERVOIR W/FILTER         * * *      CS    6

BEN     BCR2000                       CARDIOTOMY RESERVOIR, 2 LITER         * * *      CS    6

BEN     BCR3000                       CARDIOTOMY RESERVOIR 3 LITER          * * *      CS    6

BEN     BCR3538                       CARDIOTOMY/AUTOTRANSFUSION            * * *      CS    6

BEN     CATR3500                      CARDIOTOMY AUTOTRANSFUSION            * * *      CS    6

BEN     CATRDELUX                     DELUX PACK ASSY                       * * *      CS    6

BEN     CELL3000                      AUTOTRANSFUSION SUCTION               * * *      CS    6

BEN     CELL3000F                     AUTOTRANSFUSION SUCTION               * * *      CS    6

BEN     HSRPAC                        HSR PAC                               * * *      CS    4

BEN     BCR3500GOLD                   DURAFLO II HEPARIN TREATED            * * *      CS    6

BEN     CAS6                          CARDIOPLEGIA,                         * * *      CS    12

BEN     CCASOC                        CARDIOPLEGIA, ADMINISTRATION          * * *      CS    2
</TABLE>

                                    1 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                              EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                     13-Aug-96
===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION                PRICE/UOM   UOM   QPC
===============================================================================================
<S>     <C>                           <C>                                   <C>        <C>  <C>
BEN     HE30GOLD                      BLOOD CARDIOPLEGIA HEAT               * * *      CS    4

BEN     CCASB                         CARDIOPLEGIA, COOLING AND             * * *      CS    4

BEN     CCASH                         HOLDER FOR CCASR AND MAGNETIC         * * *      EA    1

BEN     HE30H                         HE-30 CARDIOPLEGIA                    * * *      EA    1

BEN     HE30HL                        HE-30 CARDIOPLEGIA                    * * *      EA    1

BEN     CASBLG                        BLOOD CARDIOPLEGIA TABLE LINE         * * *      CS    6

BEN     SM0200                        SATURATION METER                      * * *      EA    1

BEN     SMBC0240                      SATURATION BTRY CHGR (120V)           * * *      EA    1

BEN     SMBC0242                      SATURATION BTRY CHGR (22OV)           * * *      EA    1

BEN     SMBC0243                      SATURATION BTRY CHGR (100V)           * * *      EA    1

BEN     SMBP0230                      SATURATION BATTERY PAC                * * *      EA    1

BEN     SMH0220                       SATURATION HOLDER                     * * *      EA    1

BEN     SMP0210                       SATURATION PROBE                      * * *      EA    1

BEN     OTC0250                       OPTICAL TRANSMISSION CELLS            * * *      CS    12

BEN     OTC0380                       OPTICAL TRANSMISSION CELLS            * * *      CS    12

BEN     OTC0500                       OPTICAL TRANSMISSION CELLS            * * *      CS    12

BEN     OTC0250G                      OPTICAL TRANSMISSION CELLS            * * *      CS    12

BEN     OTC0380G                      OPTICAL TRANSMISSION CELLS            * * *      CS    12

BEN     OTC0500G                      OPTICAL TRANSSUSSION CELLS            * * *      CS    12

BEN     AF1040                        FILTER, ARTERIAL ADULT 40M            * * *      CS    6

BEN     AF540                         FILTER, ARTERIAL 40MICRON             * * *      CS    6

BEN     AF1025D                       FILTER, ARTERIAL ADULT 25M            * * *      CS    6

BEN     AF1040D                       FILTER, ARTERIAL ADULT 40M            * * *      CS    6

BEN     AF540D                        FILTER, ARTERIAL 40MICRON             * * *      CS    6

BEN     4C7700                        FILTER-TRANSFUSION                    * * *      CS    24

BEN     4C7704                        FILTER TRANSFUSION-SET                * * *      CS    12

BEN     GF10                          FILTER, GAS LINE                      * * *      CS    48

BEN     RF10                          FILTER, RECIRCULATION                 * * *      CS    24

BEN     PDS200                        PLEURAL DRAINAGE SYSTEM               * * *      CS    6
</TABLE>

                                    2 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                              EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                     13-Aug-96
===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION                PRICE/UOM   UOM   QPC
===============================================================================================
<S>     <C>                           <C>                                   <C>        <C>  <C>
BEN     CBP7000                       BLOOD HAEMOCONCENTRATOR SYSTEM        * * *      CS    2

BEN     HQ7000                        QUICK-PRIME HEMOCONCENTRATOR          * * *      CS    10

BEN     HQ7005                        HQ7005 HAEMOCENTRATOR                 * * *      CS    6

BEN     HQ7005L                       HAEMOCONCENTRATOR WITH LEUR           * * *      CS    6

BEN     HQH1                          HEMOCONCENTRATOR HOLDER FOR           * * *      EA    1

BEN     C110B                         CONNECTOR, NON-STERILE                * * *      CS    20

BEN     C110S                         CONNECTOR, STERILE                    * * *      CS    12

BEN     C115B                         CONNECTOR, NON-STERILE                * * *      EA    1

BEN     C115S                         CONNECTOR, STERILE                    * * *      CS    12

BEN     C120B                         CONNECTOR, NON-STERILE                * * *      CS    20

BEN     C120S                         CONNECTOR, STERILE                    * * *      CS    12

BEN     C125B                         CONNECTOR, NON-STERILE                * * *      CS    20

BEN     C125S                         CONNECTOR, STERILE                    * * *      CS    12

BEN     C130B                         CONNECTOR, NON-STERILE                * * *      CS    20

BEN     C130S                         CONNECTOR, STERILE                    * * *      CS    12

BEN     C135B                         CONNECTOR, NON-STERILE                * * *      CS    20

BEN     C1355                         CONNECTOR, STERILE                    * * *      CS    12

BEN     C140B                         CONNECTOR, NON-STERILE                * * *      CS    20

BEN     C140S                         CONNECTOR, STERILE                    * * *      CS    12

BEN     C145B                         CONNECTOR, NON-STERILE                * * *      CS    20

BEN     C145S                         CONNECTOR, STERILE                    * * *      CS    12

BEN     C220B                         CONNECTOR, NON-STERILE                * * *      CS    20

BEN     C220S                         CONNECTOR, STERILE                    * * *      CS    12

BEN     C225B                         CONNECTOR, NON-STERILE                * * *      CS    20

BEN     C225S                         CONNECTOR, STERILE                    * * *      CS    12

BEN     C230B                         CONNECTOR, NON-STERILE                * * *      CS    20

BEN     C230S                         CONNECTOR, STERILE                    * * *      CS    12

BEN     C235B                         CONNECTOR, NON-STERILE                * * *      CS    20

BEN     C235S                         CONNECTOR, STERILE                    * * *      CS    12
</TABLE>

                                    3 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                              EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                     13-Aug-96
=================================================================================================
 DIV        MODEL           SIZE               DESCRIPTION                PRICE/UOM    UOM   QPC
=================================================================================================
<S>     <C>                           <C>                                   <C>        <C>  <C>
BEN     C240B                         CONNECTOR, NON-STERILE                * * *      CS    20

BEN     C240S                         CONNECTOR, STERILE                    * * *      CS    12

BEN     C245B                         CONNECTOR, NON-STERILE                * * *      CS    20

BEN     C245S                         CONNECTOR, STERILE                    * * *      CS    12

BEN     C250B                         CONNECTOR, NON-STERILE                * * *      EA    1

BEN     C260B                         CONNECTOR, NON-STERILE                * * *      CS    20

BEN     C260S                         CONNECTOR, STERILE                    * * *      CS    12

BEN     C310B                         CONNECTOR, NON-STERILE                * * *      CS    20

BEN     C310S                         CONNECTOR, STERILE                    * * *      CS    12

BEN     C320B                         CONNECTOR, NON-STERILE                * * *      CS    20

BEN     C320S                         CONNECTOR, STERILE                    * * *      CS    12

BEN     C325B                         CONNECTOR, NON-STERILE                * * *      CS    20

BEN     C325S                         CONNECTOR, STERILE                    * * *      CS    12

BEN     C330B                         CONNECTOR, NON-STERILE                * * *      CS    20

BEN     C330S                         CONNECTOR, STERILE                    * * *      CS    12

BEN     C335B                         CONNECTOR, NON-STERILE                * * *      CS    20

BEN     C335S                         CONNECTOR, STERILE                    * * *      CS    12

BEN     C340B                         CONNECTOR, NON-STERILE                * * *      CS    20

BEN     C340S                         CONNECTOR, STERILE                    * * *      CS    12

BEN     C345B                         CONNECTOR, NON-STERILE                * * *      CS    20

BEN     C345S                         CONNECTOR, STERILE                    * * *      CS    12

BEN     C420B                         CONNECTOR, NON-STERILE                * * *      CS    20

BEN     C420S                         CONNECTOR, STERILE                    * * *      CS    12

BEN     C425B                         CONNECTOR, NON-STERILE                * * *      CS    20

BEN     C425S                         CONNECTOR, STERILE                    * * *      CS    12

BEN     C430B                         CONNECTOR, NON-STERILE                * * *      CS    20

BEN     C430S                         CONNECTOR, STERILE                    * * *      CS    12

BEN     C435B                         CONNECTOR, NON-STERILE                * * *      CS    20

BEN     C435S                         CONNECTOR, STERILE                    * * *      CS    12
</TABLE>

                                    4 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                              EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                     13-Aug-96
===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION                PRICE/UOM   UOM   QPC
===============================================================================================
<S>     <C>                           <C>                                   <C>       <C>   <C>
BEN     C440B                         CONNECTOR, NON-STERILE                * * *     CS    20

BEN     C440S                         CONNECTOR, STERILE                    * * *     CS    12

BEN     C445S                         CONNECTOR, STERILE                    * * *     CS    12

BEN     C460B                         CONNECTOR, NON-STERILE                * * *     CS    20

BEN     C460S                         CONNECTOR, STERILE                    * * *     CS    12

BEN     C465B                         CONNECTOR, NON-STERILE                * * *     EA    1

BEN     C465S                         CONNECTOR, STERILE                    * * *     CS    12

BEN     C470B                         CONNECTOR, NON-STERILE                * * *     CS    20

BEN     C470S                         CONNECTOR, STERILE                    * * *     CS    12

BEN     C475B                         CONNECTOR, NON-STERILE                * * *     CS    20

BEN     C475S                         CONNECTOR, STERILE                    * * *     CS    12

BEN     C480B                         CONNECTOR, NON-STERILE                * * *     CS    20

BEN     C480S                         CONNECTOR, STERILE                    * * *     CS    12

BEN     C485S                         CONNECTOR, STERILE                    * * *     CS    12

BEN     C490B                         CONNECTOR, NON-STERILE                * * *     CS    20

BEN     C490S                         CONNECTOR, STERILE                    * * *     CS    12

BEN     SMTC0250                      OXYSAT TEST CELL 1/4 X 1/4            * * *     EA    1

BEN     GC12                          1/2 STRAIGHT CONNECTOR                * * *     CS    12

BEN     GC1238                        1/2 X 3/8 REDUCING CONNECTOR          * * *     CS    12

BEN     GC123838                      1/2 X 3/8 X 3/8 REDUCING Y            * * *     CS    12

BEN     GC123838L                     1/2 X 3/8 X 3/8 REDUCING Y            * * *     CS    12

BEN     GC1238L                       1/2 X 3/8 REDUCING CONNECTOR          * * *     CS    12

BEN     GC12L                         1/2 STRAIGHT CONNECTOR W/LUER         * * *     CS    12

BEN     GC14                          1/4 STRAIGHT CONNECTOR                * * *     CS    12

BEN     GC14L                         1/4 STRAIGHT CONNECTOR W/LUER         * * *     CS    12

BEN     GC14Y                         1/4 EQUAL Y CONNECTOR                 * * *     CS    12

BEN     GC14YL                        1/4 EQUAL Y CONNECTOR W/LUER          * * *     CS    12

BEN     GC316                         3/16 STRAIGHT CONN                    * * *     CS    12

BEN     GC316L                        3/16 STRAIGHT CONN W/LUER             * * *     CS    12
</TABLE>

                                    5 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                              EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                     13-Aug-96
===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION                PRICE/UOM   UOM   QPC
===============================================================================================
<S>     <C>                           <C>                                   <C>        <C>  <C>
BEN     GC38                          3/16 STRAIGHT CONNECTOR               * * *      CS    12

BEN     GC3814                        3/8 X 1/4 REDUCING CONNECTOR          * * *      CS    12

BEN     GC3814L                       3/8 X 1/4 REDUCING CONNECTOR          * * *      CS    12

BEN     GC38L                         3/8 STRAIGHT CONN W/LUER              * * *      CS    12

BEN     GC38Y                         3/8 EQUAL Y CONNECTOR                 * * *      CS    12

BEN     GC38YL                        3/8 EQUAL Y CONNECTOR W/LUER          * * *      CS    12

BEN     C521B                         DISPOSABLE LOCKNUTS                   * * *      CS    20

BEN     C521S                         DISPOSABLE LOCKNUTS                   * * *      CS    12

BEN     C531B                         DISPOSABLE LOCKNUTS                   * * *      CS    20

BEN     C531S                         DISPOSABLE LOCKNUTS                   * * *      CS    12

BEN     C532B                         DISPOSABLE LOCKNUTS                   * * *      CS    20

BEN     C532S                         DISPOSABLE LOCKNUTS                   * * *      CS    12

BEN     BCD65                         CONNECTOR DISPENSER                   * * *      EA    1

BEN     BPL12                         QUICK PRIME LINE                      * * *      CS    12

BEN     BPL48                         QUICK PRIME LINE                      * * *      CS    12

BEN     BPL48Y                        QUICK PRIME LINE                      * * *      CS    12

BEN     TF1438                        1/4 TO 3/8 VENT SUCKER                * * *      CS    5

BEN     TF3812                        3/8 TO 1/2 ARTERIAL PUMPHEAD          * * *      CS    5

BEN     PL33                          PURGE LINE                            * * *      CS    6

BEN     SCB02                         TUBING, STERILE                       * * *      CS    5

BEN     SCB06                         TUBING, STERILE                       * * *      CS    5

BEN     SDB02                         TUBING, STER 1/4 X 1/16 X 2           * * *      CS    5

BEN     SDB04                         TUBING, STER 1/4 X 1/16 X 4           * * *      CS    5

BEN     SDB06                         TUBING, STERILE                       * * *      CS    5

BEN     SDB08                         TUBING, STER 1/4 X 1/16 X 8           * * *      CS    5

BEN     SDB10                         TUBING, STER 1/4 X 1/16 X 10          * * *      CS    5

BEN     SDB12                         TUBING, STER 1/4 X 1/16 X 12          * * *      CS    5

BEN     SDC04                         TUBING, STER 1/4 X 3/32 X 4           * * *      CS    5

BEN     SDC06                         TUBING, STER 1/4 X 3/32 X 6           * * *      CS    5
</TABLE>

                                    6 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                              EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                     13-Aug-96
===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION                PRICE/UOM   UOM   QPC
===============================================================================================
<S>     <C>                           <C>                                   <C>        <C>  <C>
BEN     SDC08                         TUBING, STER 1/4 X 3/32 X 8           * * *      CS    5

BEN     SDC10                         TUBING, STER 1/4 X 3/32 X 10          * * *      CS    5

BEN     SDC12                         TUBING, STER 1/4 X 3/32 X 12          * * *      CS    5

BEN     SFB02                         TUBING, STER 3/8 X 1/16 X 2           * * *      CS    5

BEN     SFB04                         TUBING, STER 3/8 X 1/16 X 4           * * *      CS    5

BEN     SFB06                         TUBING, STER 3/8 X 1/16 X 6           * * *      CS    5

BEN     SFB08                         TUBING, STER 3/8 X 1/16 X 8           * * *      CS    5

BEN     SFB10                         TUBING, STER 3/8 X 1/16 X 10          * * *      CS    5

BEN     SFB12                         TUBING, STERILE TUBING                * * *      CS    5

BEN     SFC02                         TUBING, STERILE                       * * *      CS    5

BEN     SFC04                         TUBING, STERILE                       * * *      CS    5

BEN     SFC06                         TUBING, STERILE                       * * *      CS    5

BEN     SFC08                         TUBING, STERILE                       * * *      CS    5

BEN     SFC10                         TUBING, STERILE                       * * *      CS    5

BEN     SFC12                         TUBING, STERILE TUBING                * * *      CS    5

BEN     SHC02                         TUBING, STER 1/2 X 3/32 X 2           * * *      CS    5

BEN     SHC04                         TUBING, STER 1/2 X 3/32 X 4           * * *      CS    5

BEN     SHC06                         TUBING, STER 1/2 X 3/32 X 6           * * *      CS    5

BEN     SHC08                         TUBING, STER 1/2 X 3/32 X 8           * * *      CS    5

BEN     SHC10                         TUBING, STERILE TUBING                * * *      CS    5

BEN     GT123365L                     1/2 X 3/32 BYPASS 65 GOLD             * * *      CS    5

BEN     GT123370L                     1/2 X 3/32 BYPASS 70 GOLD             * * *      CS    5

BEN     GT141665L                     1/4 X 1/16 BYPASS 65 GOLD             * * *      CS    5

BEN     GT141670L                     114 X 1/16 BYPASS 70 GOLD             * * *      CS    5

BEN     GT383365L                     3/8 X 3/32 BYPASS 65 GOLD             * * *      CS    5

BEN     GT393370L                     3/8 X 3/32 (9.5 X 2.4) TUBING         * * *      CS    5

BEN     RBA02                         TUBING, PACK 1/3 X 1/32 X 100         * * *      EA    1

BEN     RCB02                         TUBING PACK 3/16 X 1/16 X 100         * * *      EA    1

BEN     RDB02                         TUBING, PACK 1/4 X 1/16 X 100         * * *      EA    1
</TABLE>

                                    7 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                              EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                     13-Aug-96
===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION                PRICE/UOM   UOM   QPC
===============================================================================================
<S>     <C>                           <C>                                   <C>        <C>  <C>
BEN     RDC02                         TUBING, PACK 1/4 X 3/32 X 100         * * *      EA    1

BEN     RFB02                         TUBING, PACK 3/8 X 1/16 X 100         * * *      EA    1

BEN     RFCO2                         TUBING, PACK 3/2 X 3/32 X 100         * * *      EA    1

BEN     RHB02                         TUBING, PACK 1/2 X 1/16 X 100         * * *      EA    1

BEN     RHC02                         TUBING, PACK 1/2 X 3/32 X 100         * * *      EA    1

BEN     AFH                           HOLDER, FILTER                        * * *      EA    1

BEN     AFHE                          EXTENSION ARTL FILTER HOLDER          * * *      EA    1

BEN     BCMHL                         HOLDER, BCM OXYGENATOR                * * *      EA    1

BEN     BOS2H                         HOLDER. INFANT OXYGENATOR             * * *      EA    1

BEN     BOSCMSL                       SAMPLE LINE ARTERIAL/VENOUS           * * *      CS    12

BEN     HQD90                         RIGHT ANGLE HANSEN QUICK              * * *      CS    2

BEN     UNIVOXHL                      HOLDER FOR UNIVOX MEMBRANE            * * *      EA    1

BEN     UNIVOXHLA                     HOLDER ADAPTOR FOR UNIVOX             * * *      EA    1

BEN     UNIVOXHLB                     BACK PLATE HOLDER FOR UNIVOX          * * *      EA    1

BEN     UPA3814G                      PERFUSION ADAPTER W/ DURAFLO          * * *      CS    12

BEN     VOXHLB                        HOLDER VOXHLB                         * * *      EA    1

BEN     3500HL                        GAS MIXER                             * * *      EA    1

BEN     CARDH                         HOLDER FOR CARDIOTOMY                 * * *      EA    1

BEN     CATRCP                        CONVERSION/DRAINAGE PAC FOR           * * *      CS    6

BEN     CATRPAC                       PACCONVERSION                         * * *      CS    6

BEN     CATRDS                        DRAINAGE SET, AUTOTRANSFUSION         * * *      CS    6

BEN     CATRFM                        CATR 3500 DISPOSABLE FLOW             * * *      CS    12

BEN     CATRH                         HOLDER, FOR CARDIOTOMY                * * *      EA    1

BEN     CATRICU                       CATR-3500 ICU CONVERSION SET          * * *      CS    6

BEN     BAGW                          MEDICAL WASTE BAG                     * * *      CS    50

BEN     HAMPER                        MEDI WASTE HAMPER                     * * *      EA    1

BEN     HSRA                          HOLDER, ADAPTER                       * * *      EA    1

BEN     HSRH                          HOLDER, HSR4000 POST-OP               * * *      EA    1

BEN     S099                          SUCTION WAND-RMI                      * * *      CS    10
</TABLE>

                                    8 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                              EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                     13-Aug-96
===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION                PRICE/UOM   UOM   QPC
===============================================================================================
<S>     <C>                           <C>                                   <C>        <C>  <C>
BEN     S100                          YANKAUER SUCTION HANDLE               * * *      CS    2

BEN     THERMA                        THERMISTOR PROBE                      * * *      EA    1

BEN     TIEGUN                        STA STRAP GUN                         * * *      EA    1

BEN     40TEDDYS                      BEAR, BABYVOX/BENTLEY                 * * *      EA    1

BEN     MANH                          MANIFOLD HOLDER                       * * *      EA    1

BEN     RS1200CS                      POLE SET                              * * *      EA    1

BEN     CELL3243                      COMPLETE CELL SAVER PAC               * * *      CS    4

BEN     CELL3243F                     ONE CSP243, ONE CSP208, AND           * * *      CS    4

BEN     CELL3263                      1 CSP263, 1 CSP208, 1 CELL3000        * * *      CS    4

BEN     CELL3263F                     ONE CSP263, ONE SCP208                * * *      CS    4

BEN     CELL4241                      CELL SAVER KIT WITH 241/208           * * *      CS    4

BEN     CELL4261                      ONE CSP261. ONE CSP208                * * *      CS    4

BEN     CELL4261F                     ONE CSP261, ONE CSP208                * * *      CS    4

BEN     CSP3000                       COMPLETE CELL SAVER PAC               * * *      CS    4

BEN     CSP3043                       1 CSP243, CSP208 & BCR.3000           * * *      CS    4

BEN     CSP3063                       ONE CSP263, ONE CSP208,               * * *      CS    4

BEN     CSP3500                       COMPLETE CELL SAVER PAC               * * *      CS    4

BEN     CSP3343                       1 BCR3500/1 CSP243/1 CSP208           * * *      CS    4

BEN     CSP3563                       1 CSP263, 1 CSP208. 1 BCR5S00         * * *      CS    4

BEN     CSP3573                       CSP173, CSP208, BCR3500               * * *      CS    4

BEN     CSP4543                       CSP4543                               * * *      CS    4

BEN     CSP4561                       ONE CSP261, ONE CSP208,               * * *      CS    4

BEN     CSP160                        HAEMO LITE 2 FAST PACK (100ML)        * * *      CS    2

BEN     CSP162                        HAEMO-LITE 2 FAST PACK                * * *      CS    2

BEN     CSP170                        HAEMOLITE 2 PLUS 100 ML BOWL          * * *      CS    2

BEN     CSP172                        HAEMOLITE 2 PLUS 200ML BOWL           * * *      CS    2

BEN     CSP172F                       HAEMOLITE 2 PLUS 200ML BOWL           * * *      CS    2

BEN     CSP180                        HAEMOLITE 3 FAST PACK 125ML           * * *      CS    4

BEN     CSP192FJ                      HAEMOLITE 3 FAST PACK 125 ML          * * *      CS    4
</TABLE>

                                    9 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                              EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                       13-Aug-96
==================================================================================================
 DIV        MODEL           SIZE               DESCRIPTION                PRICE/UOM     UOM    QPC
==================================================================================================
<S>     <C>                           <C>                                   <C>         <C>    <C>
BEN     CSP250                        CELL SAVER FAST PACK                  * * *       CS     2

BEN     CSP250                        CELL SAVER FAST BACK                  * * *       CS     2

BEN     CSP255                        CELL SAVER LOW VOLUME FAST            * * *       CS     2

BEN     CSP260                        CELL SAVER 5 FAST PACK 225ML          * * *       CS     4

BEN     CSPZ60F                       CELL SAVER 5 FAST PACK 225ML          * * *       CS     4

BEN     CSP265                        HIGH SPEED, LOW VOLUME CELL           * * *       CS     4

BEN     CSP265F                       HIGH SPEED, LOW VOLUME CELL           * * *       CS     4

BEN     CSP125                        PEDIATRIC CELL SAVER PAC              * * *       CS     8

BEN     CSP161                        HAEMO LITE 2 BOWL SET (100ML)         * * *       CS     20

BEN     CSP163                        CELL SAVER HAEMO-LITE 2 BOWL          * * *       CS     20

BEN     CSP173                        HAEMOLITE 2 PLUS 200ML BOWL           * * *       CS     20

BEN     CSPl8l                        HAEMOLITE 3 125ML BOWL SET            * * *       CS     8

BEN     CSP182                        HAEMOLITE 3 225ML FAST PACK           * * *       CS     4

BEN     CSP182F                       HAEMOLITE 3 FAST PAC                  * * *       CS     4

BEN     CSP183                        HAEMOLITE 3 225ML BOWL SET            * * *       CS     8

BEN     CSP225                        CELL SAVER PAC                        * * *       CS     8

BEN     CSP231                        PED OH PAC W/ BOSS BOWL               * * *       CS     8

BEN     CSP233                        OH PACK, WITH BOSS BOWL               * * *       CS     8

BEN     CSP241                        HAEMONETICS CSP 241                   * * *       CS     8

BEN     CSP243                        CELL SAVER BASIC HIGH SPEED PA        * * *       CS     8

BEN     CSP243A                       CELL SAVER HI-SPD PK/MODIFIED         * * *       CS     8

BEN     CSP243B                       HIGH SPEED CELL SAVER PACK            * * *       CS     8

BEN     CSP261                        CELL SAVER5 LOW VOLUME BOWL SE        * * *       CS     8

BEN     CSP263                        CELL SAVER5 HGH SPEED BOWL SE         * * *       CS     8

BEN     CSP217                        1 EA CSP210 1 EA CSP208               * * *       CS     10

BEN     CSP500                        PLASMA SAVER SET                      * * *       CS     16

BEN     CSP183J                       HAEMOLITE 3 225ML BOWL SET            * * *       CS     8

BEN     CSP20                         CELL SAVER SUCTION ASSEMBLY           * * *       CS     20
</TABLE>

                                   10 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                              EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                         13-Aug-96

==================================================================================================
 DIV        MODEL         SIZE               DESCRIPTION                  PRICE/UOM     UOM    QPC
==================================================================================================
<S>     <C>               <C>         <C>                                 <C>           <C>   <C>
BEN     CSP208                        ASSEMBLY, BASIC A&A                   * * *       CS    20

BEN     CSP207                        CELL SAVER COLLECTION                 * * *       CS    4

BEN     CSP220                        20 UM MICROFILTER RESERVOIR           * * *       CS    4

BEN     CSP1O                         PLASMA PAC SEQUESTERING               * * *       CS    8

BEN     CSP15600                      STEP DOWN ADAPTER                     * * *       CS    20

BEN     CSP16401                      1/8" WOUND DRAINAGE LINES             * * *       CS    20

BEN     CSP16402                      1/4" WOUND DRAINAGE LINES             * * *       CS    20

BEN     CSP165                        HAEMO-LITE 2 REINFUSION BAG           * * *       CS    40

BEN     CSP167                        Y CONNECTOR WITH CHECKVALVE           * * *       CS    20

BEN     CSP168                        Y CONNECTOR WITH 5 FT A&A LINE        * * *       CS    20

BEN     CSP210                        LINER AUTOTRANSFUSION                 * * *       CS    16

BEN     CSP221                        COLLECT FIRSTKIT W/20M RESERVO        * * *       CS    8

BEN     CSP240                        HAEMONETICS CSP-240                   * * *       CS    8

BEN     CSP244                        CELL SAVER BASIC HIGH SPEED PA        * * *       CS    8

BEN     CSP245                        RENFUSION BAG HIGH SPEED              * * *       CS    40

BEN     CSP246                        WASTE BAG HIGH SPEED                  * * *       CS    20

BEN     CSP247                        CELL SAVER BASIC HIGH SPEED PA        * * *       CS    12

BEN     CSP400                        R.I.S DISPOSABLE SET                  * * *       EA    1

BEN     CSP5606                       BAGS, WASTE                           * * *       CS    50

BEN     CSP7204                       ANTICOAGULANT CONCENTRATE             * * *       CS    50

BEN     CSP166                        HAEMO-LITE 25-LITER WASTE             * * *       CS    20

BEN     CSP200                        CELL SAVER COLLECTION                 * * *       CS    4

BEN     CSP120                        1.2 LT COLLECTION RESERVOIR           * * *       CS    6

BEN     CSP140                        1.2 LT COLLECTION RESERVOIR           * * *       CS    6

BEN     CSP205                        3.0 LT COLLECTION RESERVOIR           * * *       CS    4

BEN     BENCHR                        PERFUSION CHAIR                       * * *       EA    1

BEN     Divsion                       Total Models  314
</TABLE>

                                   11 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                              EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                       13-Aug-96

================================================================================================
 DIV       MODEL            SIZE               DESCRIPTION                PRICE/UOM    UOM   QPC
================================================================================================
<S>    <C>                  <C>      <C>                                  <C>          <C>   <C>
CC     782HF75                       SWAN GANZ VIP OXIMETRY CATHETER          * * *     EA    1

CC     93A-741H-7.5F                 OXIMETER T.D. SAT-2 CATHETER             * * *     EA    1

CC     93A-750H-7.5F                 SWAN GANZ EFV/OTD 21 CM                  * * *     EA    1

CC     93A-754H-7.5F                 SWAN GANZ EFV/OTD 24CM                   * * *     EA    1

CC     93A-780H-7.5F                 OXIMETER P.P. SAT 2 CATHETER             * * *     EA    1

CC     93A-783H-7.5F                 QE3/ABBOTT COMPATABLE                    * * *     EA    1

CC     93A-431H-7.5F         NEW     SWAN-GANZ EJECTION FRACTION              * * *     EA    1

CC     93A-434H-7.5F                 THERMODILUTION EJECTION                  * * *     EA    1

CC     93A-439H-7.5F                 EJECTION FRACTION VOLUMETRIC             * * *     EA    1

CC     93A-759-7.5F                  EFV/OX TD ELECTRODE FREE                 * * *     EA    1

CC     93A-759H-7.5F                 SWAN GANZ EFV/OX TD N                    * * *     EA    1

CC     93A-794H-8F           BB      SWAN GANZ HEPARIN COATED                 * * *     EA    1

CC     139H-7.5F                     SWAN GANZ CONTINUOUS CARDIAC             * * *     EA    1

CC     JP7140019                     PID REF JAPANESE                         * * *     EA    1

CC     70216H                        7F DOUBLE LUMEN, 16CM HEPARIN            * * *     CS    5

CC     70216HK                       7F DOUBLE LUMEN, 16CM HEPARIN            * * *     CS    5

CC     70216HK1                      7 FR DOUBLE LUMEN W/ INTERLINK           * * *     CS    5

CC     70216HS                       7F DOUBLE LUMEN, 16CM HEPARIN            * * *     CS    5

CC     70216HS1                      7 FR DOUBLE LUMEN W/ INTERLINK            * * *     CS    5

CC     70220H                        7F DOUBLE LUMEN, 20CM HEPARIN            * * *     CS    5

CC     70220HK                       7F DOUBLE LUMEN, 20CM HEPARIN            * * *     CS    5

CC     70220HK1                      7 FR DOUBLE LUMEN W/INTER LINK           * * *     CS    5

CC     70220HS                       7F DOUBLE LUMEN, 20CM HEPARIN            * * *     CS    5

CC     70316H                        7F TRIPLE LUMEN, 16CM HEPARIN            * * *     CS    5

CC     70316HK                       7F TRIPLE LUMEN, 16CM HEPARIN            * * *     CS    5

CC     70316HKI                      7 FR TRI LUMEN W/ INTERLINK              * * *     CS    5

CC     70316HS                       7F TRIPLE LUMEN, 16CM HEPARIN            * * *     CS    5

CC     70316HS1                      7 FR TRI LUMEN W/ INTERLINK              * * *     CS    5

CC     70320H                        7F TRIPLE LUMEN, 20CM HEPARIN            * * *     CS    5
</TABLE>

                                   12 0F 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                              EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                       13-Aug-96

================================================================================================
 DIV       MODEL            SIZE               DESCRIPTION                PRICE/UOM    UOM   QPC
================================================================================================
<S>    <C>                  <C>      <C>                                  <C>          <C>   <C>
CC     70320HI                       7F TRI LUMEN, W/ INTERLINK               * * *     CS    5

CC     70320HK                       7F TRIPLE LUMEN, 20CM HEPARIN            * * *     CS    5

CC     70320HK1                      7 FR. TRI LUMEN W/ INTERLINK             * * *     CS    5

CC     70320H                        7F TRIPLE LUMEN, 20CM HEPARIN            * * *     CS    5

CC     70320HS1                      7 FR TRI LUMEN W/ INTERLINK              * * *     CS    5

CC     70320K                        7FR TRIPLE LUMEN, 20 CM KIT              * * *     CS    5

CC     711-08-16G                    CENTRAL VENOUS CATHETER                  * * *     CS    40

CC     711-1K05-20G                  CVC EXPENDED KIT                         * * *     CS    10

CC     711-1K08-16G                  CENTRAL VENOUS CATHETER                  * * *     CS    10

CC     711-1K12-16G                  POLYURETHANE, 12 IN, 16GA                * * *     CS    10

CC     711-K08-16G                   CENTRAL VENOUS CATH BASIC KIT            * * *     CS    10

CC     M11420K                       7F SINGLE LUMEN 14GA/20CM KIT            * * *     CS    5

CC     M11620HK                      7F SINGLE LUMEN 16GA/20CM KIT            * * *     CS    5

CC     M11620HKI                     7F SINGLE LUMEN 16GA/20CM KIT            * * *     CS    5

CC     M11620K                       7F SINGLE LUMEN 16GA/20CM KIT            * * *     CS    5

CC     M27716HS                      7FR,DBL LUM,16CM HEPARIN SET             * * *     CS    5

CC     M3716HS                       7FR,TRPL LUM,16CM HEPARIN SET            * * *     CS    5

CC     217026                        SLIDE MODULE ON THEORY                   * * *     EA    1

CC     217029                        WAVEFORM ANALYSIS-SLIDE                  * * *     EA    1

CC     217032                        CARDIOPULMONARY PROFILE                  * * *     EA    1

CC     217051                        SLIDE MODULE ON CONTINUOUS               * * *     EA    1

CC     93-130-5F                     SWAN-GANZ PEDIATRlC                      * * *     EA    1

CC     93A-19OH-8F                   PULMONARY ANG CATHETER                   * * *     EA    1

CC     93A-191-7F                    PULMONARY ANGIOGRAPHY                    * * *     EA    1

CC     93A-191-8F                    PULMONARY ANGIOGRAPHY                    * * *     EA    1

CC     93A-191H-7F                   PULMONARY ANG CATHETER                   * * *     EA    1

CC     93A-191H-8F                   PULMONARY ANG CATHETER                   * * *     EA    1

CC     93-132-5F                     SWAN-GANZ PEDIATRIC 75CM LNGTH           * * *     EA    1

CC     93A-991H-8F                   8F S-G A/V PACEPORT TD CATH              * * *     EA    1
</TABLE>

                                   13 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                              EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                         13-Aug-96

==================================================================================================
 DIV        MODEL         SIZE               DESCRIPTION                  PRICE/UOM    UOM    QPC
==================================================================================================
<S>    <C>                <C>        <C>                                  <C>          <C>    <C>
CC     94-030-2.5F                   EDSLAB BALLOONLESS 2.5F TD               * * *     EA    1

CC     C145HF6                       SWAN GANZ TRUE SIZE C-TIP                * * *     EA    1

CC     T173H-6F                      6F SWAN GANZ HC                          * * *     EA    1

CC     97-K140H-5F                   SWAN GANZ VIP BIPOLAR PACING             * * *     EA    1

CC     98-100                        CHANDLER TRANS V-PACING PROBE            * * *     EA    1

CC     98-100H                       CHANDLER TRANSL.V-PACrNG PROBE           * * *     EA    1

CC     98-500                        RANSLUMNAL A-PACING PROBE                * * *     EA    1

CC     98-500H                       TRANSLUMINAL A-PACING PROBE              * * *     EA    1

CC     93-116-4F                     SWAN-GANZ FLOW DIRECTED                  * * *     EA    1

CC     111F7                         SG DBL LUMEN MONITOR CATH 7FR            * * *     EA    1

CC     114F7                         SG TRIPLE LUM MONITORING CATH            * * *     EA    1

CC     115F7                         SWAN-GANZ TRIPLE LUMEN                   * * *     EA    1

CC     123F6                         SWAN-GANZ FLOW DIRECTED                  * * *     EA    1

CC     123GF6                        SWAN GANZ FLOW DIRECTED                  * * *     EA    1

CC     93-110.5F                     SWAN-GANZ FLOW DIRECTED                  * * *     EA    1

CC     93-117.5F                     SWAN-GANZ FLOW DIRECTED                  * * *     EA    1

CC     S111F7                        SWAN-GANZ S-TIP FLOW DIRECTED            * * *     EA    1

CC     T111F7                        SG DBL LUM MONITOR CATH/TORQUE           * * *     EA    1

CC     T123F6                        HI TORQUE SG FLOW DIRECTED               * * *     EA    1

CC     131-7F                        SWAN GANZ TD CATHETER                    * * *     EA    1

CC     131F7                         SWAN GANZ TD CATHETER                    * * *     CS    5

CC     131H-7F                       SWAN-GANZ TD CATHETERS W/                * * *     EA    2

CC     131HF7                        SWAN-GANZ TD CATHETERS W/                * * *     CS    5

CC     131HVF7                       TD CATH W/CONTAMINATION SHIELD           * * *     EA    1

CC     132F5                         SWAN-GANZ PEDIATRIC 75CM LNGTH           * * *     EA    1

CC     141H-7F                       HI-SHORE TD WITH AMC THROMBO-            * * *     EA    1

CC     831F75                        SWAN-GANZ TD VIP CATHETER                * * *     CS    5

CC     831HF75                       SWAN-GANZ TD VIP CATHETER                * * *     CS    5

CC     831HVF75                      VIP CATH W/CONTAMINATION SHIEL           * * *     EA    1
</TABLE>

                                   14 0F 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                             EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                         13-Aug-96

==================================================================================================
 DIV        MODEL         SIZE               DESCRIPTION                  PRICE/UOM    UOM    QPC
==================================================================================================
<S>    <C>                <C>        <C>                                  <C>          <C>    <C>
CC     93-200-7F                     SWAN-GANZ PACING TD CATHETER             * * *     EA    1

CC     93-200H-7F                    PACING TD WITH 2 VENTRICULAR             * * *     EA    1

CC     93-205H-7F                    HEPARIN NORMAL HEART                     * * *     EA    1

CC     93A-141-7F                    SWAN-GANZ TD CATHETER                    * * *     EA    1

CC     93A-741-7.5F                  OXIMETER T.D. SAT-2 CATH                 * * *     EA    1

CC     93A-831-7.5F                  SWAN-GANZ TD VIP CATHETER                * * *     EA    1

CC     93A-831H-7.5F                 SWAN-GANZ TD VIP CATHETER                * * *     EA    1

CC     93A-834H-7.5F                 SWAN GANZ THERMODILUTION                 * * *     EA    1

CC     93A-931H-7.5F                 TD PACEPORT WITH AMC THROMBO-            * * *     EA    1

CC     C144-7F                       SWAN GANZ TRU SIZE C-TIP                 * * *     EA    1

CC     C144H-7F                      SWAN GANZ TRU SIZE C-TIP                 * * *     EA    1

CC     PCHBLK                        100 EA PACEPORT SWAN GANZ                * * *     CS    100

CC     S144-7F                       SWAN GANZ TRU SIZE S-TIP                 * * *     EA    1

CC     S144H-7F                      SWANGANZ S-TIP CONTROLCATH TD            * * *     EA    1

CC     096F6                         SWAN GANZ T.D. CATHETER                  * * *     EA    1

CC     151-7F                        SWAN-GANZ TD CATHETER W/S-TIP            * * *     EA    1

CC     151H-7F                       SWAN-GANZ TD CATHETER W/S-TIP            * * *     EA    1

CC     93A-143HT-7F                  PKG ASSY 93A-143H-7F                     * * *     EA    1

CC     93A-143T-7F                   SWAN GANZ CARDIOCATH                     * * *     EA    1

CC     97-120-5F                     SWAN GANZ BIPOLAR                        * * *     EA    1

CC     97-130-5F                     SWAN-GANZ BIPOLAR                        * * *     EA    1

CC     97-K12-5F                     SIPOLAR PACING CATHETER KIT,             * * *     EA    1

CC     97-K13-5F                     BIPOLAR PACING CATHETER                  * * *     EA    1

CC     744H-7.5F                     CCO/SVO2 SWAN GANZ CATHETER              * * *     EA    1

CC     7468F                         SWAN GANZ CCO/SV02/VIP                   * * *     EA    1

CC     746H-8F                       SWAN GANZ CCO/SV02/VIP                   * * *     EA    1

CC     93-505                        FLOW THROUGH HOUSING                     * * *     CS    8

CC     93-520                        CO-SET:BUCKET                            * * *     CS    6

CC     93-521                        CO-SET:BRACKET                           * * *     EA    1
</TABLE>

                                   15 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                              EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                         13-Aug-96

==================================================================================================
 DIV        MODEL         SIZE               DESCRIPTION                  PRICE/UOM    UOM    QPC
==================================================================================================
<S>    <C>                <C>        <C>                                  <C>          <C>    <C>
CC     93-650                        CO-SET SYRINGE                           * * *     CS    5

CC     702-741H-7.5F         SO      EDSLAB CVP 02 SAT CATH                   * * *     EA    1

CC     792019F5                      5F EDSLAB DOUBLE LUMEN                   * * *     EA    1

CC     793013A                       5F EDSLAB HYTREL URETHANE TD             * * *     EA    1

CC     793043                        4F SWAN GANZ THERMODILUTION              * * *     EA    1

CC     793046                        5F SWAN GANZ TD CATH                     * * *     EA    1

CC     794013                        7.5F VIP THERMODILUTION 10CM             * * *     EA    1

CC     796018                        RIGHT EJECTION FRACTION GUIDE            * * *     EA    1

CC     797005                        5F SWAN-GANZ THERMODILUTION              * * *     EA    1

CC     93-134-7F                     EDSLAB TD CATHETER                       * * *     EA    1

CC     93-167-7F                     7F SWAN GANZ PULMONARY                   * * *     EA    1

CC     93-631-5.5F           BB      SWAN GANZ OXIMETRY TD CATH               * * *     EA    1

CC     93-631H-5.5F          BB      SWAN GANZ OXIMETRY TD CATH               * * *     EA    1

CC     93A-095-7F                    SWAN GANZ T.D. CATHETER                  * * *     EA    1

CC     93A-100-5F                    SWAN GANZ T.D. CATHETER                  * * *     EA    1

CC     93A-105-5F                    SWAN GANZ TD CATHETER                    * * *     EA    1

CC     93A-124-5F                    SWAN GANZ THERMODILUTION CATH            * * *     EA    1

CC     93A-140H-7F                   7F THERMODILUTION CATHETER               * * *     EA    1

CC     93A-161H-7F                   SWAN GANZ HEPARIN HI-SHORE               * * *     EA    1

CC     93A1451H-7.5F         BB      SWAN GANZ ELECTRODE FREE                 * * *     EA    1

CC     93A-780-7.5F                  OXIMETER P.P. SAT 2 CATH                 * * *     EA    1

CC     93A-794-8F                    SWAN GANZ REF/OX PACEPORT CATH           * * *     EA    1

CC     93A-821H-7.5F         BB      SWAN GANZ GUIDEWIRE TD CATH              * * *     EA    1

CC     93A-834-7.5F                  SWAN GANZ THERMODILUTION                 * * *     EA    1

CC     93A-841-7.5F                  HI SHORE VIP TD W/8014 BALLOON           * * *     EA    1

CC     93A-931-7.5F                  TD PACEPORT                              * * *     EA    1

CC     93A-991-8F                    8F SWAN GANZ A-V PACEPORT                * * *     EA    1

CC     94-010-4F                     EDSLAB SURGICAL TD CATHETER              * * *     EA    1

CC     94-011-3F                     EDSLAB 3F TD PROBE AND 3.5F              * * *     EA    1
</TABLE>

                                   16 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                              EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                         13-Aug-96

==================================================================================================
 DIV        MODEL         SIZE               DESCRIPTION                  PRICE/UOM    UOM    QPC
==================================================================================================
<S>    <C>                <C>        <C>                                  <C>          <C>    <C>
CC     94-012-4F                     EDSLAB 4F TD PROBE                       * * *     EA    1

CC     TF002A-7F                     7F SWAN GANZ TRUE SIZE                   * * *     EA    1

CC     TOE135H-7.5F                  7.5F SWAN GANZ PACING TD 02              * * *     EA    1

CC     TS05H-7F                      SWAN GANZ HEPARIN COATED                 * * *     CS    5

CC     TS060H-6F                     SWAN GANZ HEPARIN TRUE SIZE              * * *     EA    1

CC     TS064-5F                      5F SWAN GANZ TRUE SIZE                   * * *     EA    1

CC     TS088H-6F                     6F SWAN GANZ TRUE SIZE TD                * * *     EA    1

CC     TS094H-3F                     3F SWAN GANZ                             * * *     EA    1

CC     TS105-5F                      5F SWAN GANZ TRUE SIZE TD                * * *     EA    1

CC     TS110H-7.5F                   7.5F SWAN GANZ TD CATH                   * * *     EA    1

CC     TS112H-8F                     8F SWAN GANZ TD W/LARGE DISTAL           * * *     EA    1

CC     TV024-5F                      SWAN GANZ TRUE SIZE VIP TD,              * * *     EA    1

CC     TV046H-7.5F                   SWAN GANZ HEPARIN VIP TD                 * * *     EA    1

CC     TV049H-7.5F                   SWAN GANZ VIP HEPARIN TD CATH            * * *     EA    1

CC     TV106H-7.5F                   7.5F SWAN GANZ HI-SHORE VIP TD           * * *     EA    1

CC     93A-113-7F                    SWAN-GANZ TD                             * * *     EA    1

CC     93A-301-7F                    SWAN-GANZ TD CATHETER, IL COC            * * *     EA    1

CC     790022                        7F S.G. DL CATH WTTli                    * * *     EA    1

CC     791031                        4F SWAN GANZ MONITORING CATH             * * *     EA    1

CC     702741H7.5F MOD               7.5F EDSLAB TD OXIMETRY CATH             * * *     EA    1

CC     794009                        4F EDSLAB TRIPLE LUMEN 02 SAT            * * *     EA    1

CC     795007                        4F SWAN GANZ TRIPLE LUMEN                * * *     EA    1

CC     93-164-4F                     SWAN GANZ PEDIATRIC                      * * *     EA    1

CC     93-166-6F                     SWAN GANZ PEDIATRIC                      * * *     EA    1

CC     94-015-4F         SO          EDSLAB DOUBLE LUMEN 02 SAT               * * *     EA    1

CC     94-015H-4F        SO          EDSLAB DOUBLE LUMEN 02 SAT               * * *     EA    1

CC     94-040-4F         SP          EDSLAB DOUBLE LUMEN 02 SAT               * * *     EA    1

CC     94-040H-4F        SP          EDSLAB DOUBLE LUMEN 02 SAT               * * *     EA    1

CC     MW054-5F                      SWAN GANZ TRUE SIZE MONITORING           * * *     EA    1
</TABLE>

                                   17 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                              EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                         13-Aug-96

==================================================================================================
 DIV        MODEL         SIZE               DESCRIPTION                  PRICE/UOM    UOM    QPC
==================================================================================================
<S>    <C>                <C>        <C>                                  <C>          <C>    <C>
CC     MW171-6F                      EDSLAB MONITORING CATHETER               * * *     EA    1

CC     OW050H-4F                     EDSLAB HEPARIN COATED DL 02              * * *     EA    1

CC     OW052H-7F                     EDSLAB TRUE SLZE OXIMETRY CATH           * * *     EA    1

CC     OW081H-5F                     5F EDSLAB DL 02                          * * *     EA    1

CC     OW082H-4F                     4F EDSLAB OX CATH WITH DISTAL            * * *     EA    1

CC     OW173H-4F                     4F OXIMETRY CATHETER WITH                * * *     EA    1

CC     0W174H-5F                     5F EDSLAB DOUBLE LUMEN 0 (2)             * * *     EA    1

CC     OX153H-2.5F                   2.5F OXIMETER PROBE W/AMC(TM)            * * *     EA    1

CC     PE074-5F                      5F SG BIPOLAR PACING FEMORAL             * * *     EA    1

CC     PE075-5F                      5F SG BIPOLAR PACING SVC INS             * * *     EA    1

CC     PO144H-7.5F                   7.5F EDSLAB 0(2) CATH                    * * *     EA    1

CC     TF002CH-7F                    7F SWAN GANZ TRUE SIZE TD                * * *     EA    1

CC     TF002H-7F                     SWAN GANZ TRUE SIZE HI SHORE             * * *     EA    1

CC     TF009H-6F                     SWAN GANZ TRUE SIZE HI SHORE             * * *     EA    1

CC     TF026H-7.5F                   SWAN GANZ HEPARlN COATED                 * * *     EA    1

CC     TF045H-7.5F                   SWAN GANZ HEPARIN COATED DUAL            * * *     EA    1

CC     TF093H.7.5F                   7.5F SWAN GANZ HI SHORE REF TD           * * *     EA    1

CC     TFN023H-7.5F                  HI SHORE HEPARIN REF/TD                  * * *     EA    1

CC     TN178H-7F                     7F SWAN GANZ THER.MODILUTION             * * *     EA    1

CC     TO017H-7.5F                   SWAN GANZ HEPARIN COATED                 * * *     EA    1

CC     TOF068H-7.5F                  7.5F SWAN GANZ REF/OX                    * * *     EA    1

CC     TON179H-7.5F                  7.5F CCO/SV02/VIP THERMO-                * * *     EA    1

CC     TP157H-7.5F                   7.5F SWAN-GANZ FLOW DIRECTED             * * *     EA    1

CC     TS158H-7.5F                   7.5F SWAN-GANZ TD CATHETER               * * *     EA    1

CC     TS160H-7F                     7F SWAN-GANZ HI-SHORE                    * * *     EA    1

CC     TS172H-6F                     6F EDWARDS SWAN-GANZ TRUE SIZE           * * *     EA    1

CC     TV167H-8F                     SWAN GANZ VIP THERMODILUTION             * * *     EA    1

CC     798008                        140CM LENGTH 24CM PORT RIGHT-            * * *     EA    1

CC     174H-7F                       7F SWAN GANZ TORQUE SUPPORT              * * *     EA    1
</TABLE>

                                   18 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                              EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                         13-Aug-96

==================================================================================================
 DIV        MODEL         SIZE               DESCRIPTION                  PRICE/UOM    UOM    QPC
==================================================================================================
<S>    <C>               <C>         <C>                                  <C>          <C>    <C>
CC     791023A                       7F SWAN GANZ PULMONARY                   * * *     EA    1

CC     SCC-31CV0001                  CENTRAL VENOUS KIT-SPECIAL ORD           * * *     CS    10

CC     SCC-59CV0001                  CENTRAL VENOUS SPEC ORDER                * * *     CS    8

CC     793011                        4F SWAN GANZ THERMODILUTION              * * *     EA    1

CC     SCC-26PA0003                  INTRODUCER SPECIAL ORDER KIT             * * *     CS    6

CC     SCC-32PA0002                  INTRODUCER SPECIAL ORDER KIT             * * *     CS    10

CC     SCC-59PA0017                  INTRODUCER SPECIAL ORDER KIT             * * *     CS    6

CC     A3501BF85                     BAXTER CANADA                            * * *     CS    10

CC     S5012F85                      8.5F INTRO CDP KIT FOR MCALLEN           * * *     CS    10

CC     SCC-653B-8.5F                 HOLLAND- INTRODUCER SPECIAL              * * *     CS    10

CC     SCC-A452B-8.5F                TB VALVE INTRODUCER KIT 8.5F             * * *     CS    10

CC     SCC-A652B-8.5F                TB VALVE INTRODUCER KIT 8.5F             * * *     CS    10

CC     791014                        7F DOUBLE BALLON CATHETER                * * *     EA    1

CC     793049                        7.5F SWAN GANZ WITH 8/14                 * * *     EA    1

CC     796                           SP/OR CUSTOMS                            * * *     EA    1

CC     798                           SP/OR CUSTOMS                            * * *     EA    1

CC     799                           SP/OR CUSTOMS                            * * *     EA    1

CC     93-600                        CO-SET:DELIVERY SYSTEM FOR               * * *     CS    10

CC     93-610                        CO-SET:DELIVERY SYSTEM FOR               * * *     CS    10

CC     93-611                        CO-SET SPECIAL ORDER                     * * *     CS    8

CC     9520A-L                       DEMO/LOANER REPAIR FLEET                 * * *     EA    1

CC     COM-2 SYS A       PRINTER     COM-2 SYSTEM A WITH A PRINTER            * * *     EA    1

CC     COM-2 SYSA/I      100v        COM-2 SYSTEM INTERNATIONAL               * * *     EA    1

CC     COM-2 SYSA/I      115V        COM 2 SYS AC-ONLY INT                    * * *     EA    1

CC     COM-2 SYSA/I      220V        COM 2 SYS AC-ONLY INT                    * * *     EA    1

CC     COM-2 SYSB/I      220V        COM-2 SYS AC/DC INTERNATIONAL            * * *     EA    1

CC     COM-2P                        COM-2 WITH PRINTER AC/DC UNIT            * * *     EA    1

CC     COM-2P-115                    COM-2P 115                               * * *     EA    1

CC     COM-2P-II5-R                  REFURBISHED                              * * *     EA    1
</TABLE>

                                   19 0F 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                              EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                         13-Aug-96

==================================================================================================
 DIV        MODEL         SIZE               DESCRIPTION                  PRICE/UOM    UOM    QPC
==================================================================================================
<S>    <C>               <C>         <C>                                  <C>          <C>    <C>
CC     COM-2P-R          220V        ASSY, CARDIAC OUTPUT COMPUTER,           * * *     EA    1

CC     9515A                         9515-A SIMULATER                         * * *     EA    1

CC     COM-2-AD          115v        ASSY, AC ADAPTER 115V                    * * *     EA    1

CC     COM-2-PC                      COM-2 POWER CORD                         * * *     EA    1

CC     COM-2CC                       PKG ASSY CONN CABLE, COM-2               * * *     EA    1

CC     COM-2FS                       PKG ASSY FOOT SWITCH, COM-2              * * *     EA    1

CC     COM-20P                       OPS, MANUAL COM-2                        * * *     EA    1

CC     COM-2PP                       PKG ASSY PRINTER PAPER COM-2             * * *     EA    1

CC     SAT-2R            115V        SAT-2 115V UNIT REFURBISHED              * * *     EA    1

CC     SAT-2R            220V        SAT-2 220V UNIT                          * * *     EA    1

CC     OM-2                          OPTICAL MODULE II                        * * *     EA    1

CC     OM-2R                         OPTICAL MODULE II                        * * *     EA    1

CC     40-OP1                        REF OP MANUAL                            * * *     EA    1

CC     40-PLC                        PATIENT LEAD CABLE                       * * *     EA    1

CC     60-EXT                        SENSOR EXTENSION CABLE                   * * *     EA    1

CC     DS-100A                       ADULT DIGIT OXYGEN TRANSDUCER            * * *     EA    1

CC     30-AD-115V                    AC ADAPTER, 115V                         * * *     EA    1

CC     30-AD-115V-R                  REFURB AC ADAPTER COM-1                  * * *     EA    1

CC     30-AD-220V                    AC ADAPTER, 220V                         * * *     EA    1

CC     30-BY                         COM-1 BATTERY                            * * *     EA    1

CC     30-CC                         COM-1 CONNECTING CABLE                   * * *     EA    1

CC     30-FS                         COM-1 FOOTSWITCH                         * * *     EA    1

CC     30-MM                         COM-1 MAINTENANCE MANUAL                 * * *     EA    1

CC     30-OP                         OPERATIONS MANUAL                        * * *     EA    1

CC     59-PTS                        PRESSURE TRANSDUCER SIMULATOR            * * *     EA    1

CC     59-PTSA                       ADAPTOR CABLE - SUMMIT                   * * *     EA    1

CC     59-UCAL                       UTAH UNIFLOW TESTER                      * * *     EA    1

CC     9460A                         CONNECTING CABLE FOR CATHETER            * * *     EA    1

CC     9511A                         COC FIELD TESTER                         * * *     EA    1
</TABLE>

                                   20 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                             EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                     13-Aug-96

===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM    QPC
===============================================================================================
<S>    <C>               <C>         <C>                               <C>         <C>    <C>
CC     9520A-MM                      9520A MAINTENANCE MANUAL            * * *       EA    1

CC     9526                          A C ADAPTER, 110V FOR               * * *       EA    1

CC     9527                          A C ADAPTER, 220V FOR               * * *       EA    1

CC     9528                          RECHARGEABLE BATTERY FOR            * * *       EA    1

CC     9850A                         INJECTATE PROBE, FOR                * * *       EA    1

CC     9870                          REMOTE FOOTSTART SWITCH             * * *       EA    1

CC     40-CCI                        REF INTERFACE CABLE                 * * *       EA    1

CC     REF-1 SYS/I       220V        REF-1 SYSTEM INTERNATIONAL          * * *       EA    1

CC     REF-1 SYSA/I      100V        REF-1 SYSTEM INTERNATIONAL          * * *       EA    1

CC     R.EF-1-R          220V        REFURBISHED REF-1  UNIT 220V        * * *       EA    1

CC     40-SCR SYS                    SIEKO PRINTER SYS                   * * *       EA    1

CC     9515R                         REF/CARDIAC OUTPUT SIMULATOR        * * *       EA    1

CC     44-1800           893425-001  CABLE ASSY, UNIFLOW                 * * *       EA    1

CC     44-1800           893211-001  ASSY, UNIFLOW CABLE                 * * *       EA    1

CC     44-1800           893419-001  CABLE ASSY, UNIFLOW                 * * *       EA    1

CC     44-1800           893217-001  CABLE, UNIFLOW                     * * *       EA    1

CC     44-1800           893225-001  ASSY, UNIFLOW CABLE                 * * *       EA    1

CC     44-1800           893403-001  CABLE                               * * *       EA    1

CC     44-1800           893488-002  ASSY, UNIFLOW CABLE                 * * *       EA    1

CC     44-1800           893203-001  ASSY, UNIFLOW CABLE                 * * *       EA    1

CC     44-1800           893427-001  ASSY-UNIFLOW CABLE                  * * *       EA    1

CC     44-1800           893428-001  INTERFACE CABLE FOR USE WITH        * * *       EA    1

CC     44-1800           893492-001  ASSY, UNIFLOW CABLE                 * * *       EA    1

CC     44-1800           893483-002  ASSY, UNIFLOW CABLE                 * * *       EA    1

CC     44-1800           893204-001  ASSY, UNIFLOW CABLE                 * * *       EA    1

CC     44-1800           893222-001  CABLE                               * * *       EA    1

CC     44-1800           893208-001  CABLE, UNIFLOW                      * * *       EA    1

CC     44-1800           893495-001  UNIFLOW DPT INTERFACE CABLE         * * *       EA    1

CC     44-1800           893132-001  INTERFACE CABLE FOR 43 SERIES       * * *       EA    1
</TABLE>

                                   21 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                             EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                     13-Aug-96

===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM    QPC
===============================================================================================
<S>    <C>               <C>         <C>                               <C>         <C>    <C>
CC     44-1800           893201-001  ASSY, UNIFLOW CABLE                 * * *       EA    1

CC     44-1800           893206-001  ASSY, UNIFLOW CABLE                 * * *       EA    1

CC     44-1800           893205-001  CABLE, UNIFLOW                      * * *       EA    1

CC     44-1800           193474-001  CABLE ASSY, UNIFLOW                 * * *       EA    1

CC     33-1800           895031-001  CABLE INTERFACE FOR USE WITH        * * *       EA    1

CC     33-1800           195033-001  CABLE INTERFACE FOR SUMMIT          * * *       EA    1

CC     33-1800           895508-001  SUMMIT CABLE INTERFACE FOR          * * *       EA    1

CC     33-1800           895507-001  INTERFACE FOR USE WITH SUMMIT       * * *       EA    1

CC     33-1800           895142-002  SUMMIT INTERFACE CABLE FOR          * * *       EA    1

CC     33-1800           895106-001  CABLE ASSY, SIMPLE                  * * *       EA    1

CC     33-1800           895083-001  SUMMIT INTERFACE CABLE FOR          * * *       EA    1

CC     33-1800           895056-001  SUMMIT INTERFACE CABLE FOR          * * *       EA    1

CC     33-1800           895034-001  CABLE INTERFACE FOR SUMMIT          * * *       EA    1

CC     33-1800           895003-001  SUMMIT CABLE INTERFACE FOR          * * *       EA    1

CC     33-1800           895021-001  CABLE ASSY, SIMPLE INTERFACE        * * *       EA    1

CC     33-1800           895020-001  SUMMIT INTERFACE CABLE FOR          * * *       EA    1

CC     33-1800           895019-001  SUMMIT CABLE INTERFACE FOR          * * *       EA    1

CC     33-1800           895018-001  INTERFACE CABLE FOR USE WITH        * * *       EA    1

CC     33-1800           895017-001  SUMMIT INTERFACE CABLE FOR          * * *       EA    1

CC     33-1800           895012-001  SUMMIT CABLE INTERFACE FOR          * * *       EA    1

CC     33-1800           895004-001  SUMMIT INTERFACE CABLE FOR          * * *       EA    1

CC     33-1800           895O38-001  CABLE INTERFACE FOR SUMMIT          * * *       EA    1

CC     33-1800           895025-001  SUMMIT CABLE INTERFACE FOR          * * *       EA    1

CC     93-522                        CO-SET:INJECTATE PROBE CABLE        * * *       EA    1

CC     93-523                        HP TEMPERATURE PROBE                * * *       EA    1

CC     93-524                        MARQUETTE-PROBE                     * * *       EA    1

CC     93-526                        CO-SET PROBE FOR SIEMENS            * * *       EA    1

CC     93-527                        PROBE-TEMP,INJECTATE MARQUETTE      * * *       EA    1

CC     93-528                        CO-SET PROBE FOR                    * * *       EA    1
</TABLE>

                                   22 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                             EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                     13-Aug-96

===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM    QPC
===============================================================================================
<S>    <C>               <C>         <C>                               <C>         <C>    <C>
CC     93-529                        CO-SET:INJECTATE PROBE CABLE        * * *       EA    1

CC     93-530                        CO-SET:INJECTATE PROBE CABLE       * * *       EA    1

CC     93-531                        CO-SET PROBE FUKUDA-DENSHI          * * *       EA    1

CC     93-533                        2" HEWLETT PACKARD CO-SET           * * *       EA    1

CC     64-EKBB                       EKG SLAVE FOR SPACLAB PCI AND       * * *       EA    1

CC     64-EKH                        EKG SLAVE FOR HP MERLIN AND         * * *       EA    1

CC     64-EKHH                       64-EKH WITH Y CONNECTOR             * * *       EA    1

CC     EXP-N SYS B       220V        OXIMETER (SV02)/VOLUMET/RIC         * * *       EA    1

CC     EXP-N SYS B       100V        OXIMETER (SV02)/VOLUMET/RIC         * * *       EA    1

CC     EXP-N-R           115V        REFURBISH EXPLORER 115V             * * *       EA    1

CC     70-AN                         ANALOG SLAVE CABLE/UNTERMNATED      * * *       EA    1

CC     70-ANH                        ANALOG SLAVE CABLE WO/Y CONN        * * *       EA    1

CC     70-ANHH                       ANALOG SLAVE CABLE, Y CONNECTOR     * * *       EA    1

CC     70-ANS                        ANALOG SLAVE CABLE                  * * *       EA    1

CC     70-ANSS                       ANALOG SLAVE CABLE W/Y CONN         * * *       EA    1

CC     70-CC                         CATHETER INTERFACE CABLE            * * *       EA    1

CC     70-CC1                        CATHETER INTERFACE CABLE            * * *       EA    1

CC     70-PRTCR                      CARTRIDGE FOR HP THINKJET           * * *       EA    1

CC     70-RS-CN                      CANON PRINTER CABLE                 * * *       EA    1

CC     70CC1E                        ASSY PATIENT CABLE:70-CC1E          * * *       EA    1

CC     70CC2                         CATHETER INTERFACE CABLE            * * *       EA    1

CC     70PRTCN                       CANON PRINTER FOR USE WITH VGS      * * *       EA    1

CC     OM2E                          ASSY-OPTICAL MODULE INTL VERS       * * *       EA    1

CC     OM2ER                         ASSY-OPTICAL MODULE INTL VERS       * * *       EA    1

CC     VGS                           MONITOR-VIGILANCE CCO/SVO2          * * *       EA    1

CC     VGS-OM                        OPERATIONS MANUAL: CCO/SVO2         * * *       EA    1

CC     VGS-R                         VIGILANCE - REFURBISHED             * * *       EA    1

CC     VGS1SYS                       VIGILANCE SYS CCO/SVO2              * * *       EA    1

CC     VGS2SYS                       VIGILANCE SYS CCO/SVO2 VGS2         * * *       EA    1
</TABLE>

                                   23 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                             EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                     13-Aug-96

===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM    QPC
===============================================================================================
<S>    <C>                  <C>      <C>                               <C>         <C>    <C>
CC     VGSFCR                        VIGILANCE - REFURBISHED             * * *       EA    1

CC     VGS1VMR                       REFURB VIGILANCE CCO/SVO2 SYS       * * *       EA    1

CC     VGSSYS                        VIGILANCE CCOISVO2 SYSTEM 115V      * * *       EA    1

CC     VGSSYSCR                      VIGILANCE CCO/SVO2 115V SYS         * * *       EA    1

CC     VGSSYSFCR                     REFURB VIGILANCE SYS 115V           * * *       EA    1

CC     VGSSYSR                       REFURB VIGILANCE CCO/SVO2 SYS       * * *       EA    1

CC     VGSTM                         VIGILANCE TECHNICAL MANUAL          * * *       EA    1

CC     PX-MK053                      MAYO CLINIC FDNT "A-KIT"            * * *       CS    10

CC     PX-MK061                      CHILDRENS HOSP "ADULT KIT"          * * *       CS    10

CC     PX-MK081                      CHILDRENS HOSP ST LOUIS             * * *       CS    10

CC     PX-MK085                      MAYO CLINIC FDNT SWAN DUAL          * * *       CS    10

CC     PX-MK086                      MAYO CLINIC FDNT "A-KIT"            * * *       CS    10

cc     PX-MK087                      DUKE UNIVERSITY                     * * *       CS    10

CC     PX-MK088                      DUKE UNIVERSITY                     * * *       CS    10

CC     PX-MK093                      SAN JUAQUIN HOSP                    * * *       CS    10

CC     PX-MK099                      MAYO CLINIC A KIT                   * * *       CS    10

CC     PX-MK142                      CHILDRENS HOSP IN DC                * * *       CS    10

CC     PX-MK237                      ALEXIAN BROS. 1X2                   * * *       CS    20

CC     PXAMK359                      BAXTER AUSTRALIA                    * * *       CS    20

CC     PXCMK315                      PLAINS HEALTH CTR                   * * *       CS    20

CC     PXCMK488                      1X2 KIT BAXTER CANADA               * * *       CS    10

CC     PXMK287                       HAHNEMAN HOSP CDP SINGLE KIT        * * *       CS    10

CC     PXMK307                       FROEDTERT ANESTHESIA KIT            * * *       CS    20

CC     PXMK363                       HEARTLAND HOSP                      * * *       CS    10

cc     PXMK364                       HEARTLAND HOSP                      * * *       CS    10

CC     PXMK367                       MIRIAM HOSP SINGLE LINE KIT         * * *       CS    20

CC     PXMK368                       MIRIAM HOSP 1X2 KIT                 * * *       CS    20

cc     PXMK411                       1X2 SAN JUAQUIN HOSP                * * *       CS    20

CC     PXMK416                       LITTLE CO OF MARY 24N               * * *       CS    10
</TABLE>

                                   24 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                             EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                     13-Aug-96

===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM    QPC
===============================================================================================
<S>    <C>                  <C>      <C>                               <C>         <C>    <C>
CC     PXMK422                       ST LUKES IN BOISE ID                * * *       CS    10

CC     PXMK433                       SINGLE LINE KIT FOR GRANDVIEW       * * *       CS    10

CC     PXMK478                       HBAR CDP KIT FOR METHODIST          * * *       CS    20

CC     PXMK485                       LAHEY CLINIC 1 B1F CDP KIT          * * *       CS    20

CC     PXMK509                       SINGLE CDP KIT FOR ST MARYS         * * *       CS    10

CC     PX-MK034                      2X2 CDP KIT FOR READING HOSP        * * *       CS    10

CC     PX-MK120                      CHILDRENS HOSP 2X2                  * * *       CS    10

CC     PX-MK244                      ST LUKES 2X2 CDP KIT                * * *       CS    10

CC     PXCMK314                      PLAINS HEALTH CTR                   * * *       CS    20

CC     PXMK332                       CATHOLIC MED CTR                    * * *       CS    10

CC     PXMK351                       2X2 TRI CDP KIT FOR CHILDRENS       * * *       CS    20

CC     PXMK355                       NORTHSHORE                          * * *       CS    10

CC     PXMK358                       PROVIDENCE HOSP 2X2 SWAN KIT        * * *       CS    20

CC     PXMK393                       2X2/3 CDP KIT FOR JEWISH HOSP       * * *       CS    20

CC     PXMK424                       ST VINCENTS 2X2                     * * *       CS    20

CC     PXMK464                       2X2 CDK KIT FOR READSBURG           * * *       CS    10

CC     PXMK474                       2X2 272 MT CARMEL                   * * *       CS    20

CC     PXMK9119                      VALLEY MEMORIAL HOSP                * * *       CS    20

CC     PXMK9146                      FTN VALLEY 2X2 KIT                  * * *       CS    20

CC     PXNMK479                      CDP KIT FOR BAXTER-AUKLAND          * * *       CS    20

CC     PX-MK031                      UNIV OF BOSTON CDP KIT 3X3          * * *       CS    10

CC     PX-MK035                      3X3 CDP KIT FOR READNG HOSP         * * *       CS    10

CC     PX-MK062                      CHILDRENS HOSP "TRIPLE KIT"         * * *       CS    10

CC     PX-MK063                      CHILDRENS HOSP "4X4"                * * *       CS    10

CC     PX-MK083                      SOUTHEAST ALABAMA MED CTR           * * *       CS    10

CC     PX-MK084                      MAYO CLINIC FDNT "CVS KIT"          * * *       CS    10

CC     PX-MK121                      ST ALEXIUS 3X3                      * * *       CS    10

CC     PX-MK139                      MAYO CLINIC 3X3                     * * *       CS    10

CC     PX-MK181                      CDP 3X3 KIT FOR MERCY-REDDING       * * *       CS    10

CC     PX-MK9582                     CHILDRENS HOSP 3X3 PED PT           * * *       CS    20
</TABLE>

                                   25 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                             EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                     13-Aug-96

===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM    QPC
===============================================================================================
<S>   <C>                   <C>     <C>                                <C>         <C>    <C>
CC    PXCMK449                      3X3 CDP KIT FOR ST BONIFACE           * * *    CS     20

CC    PXMK189                       WHITE MEMORIAL 3X3 CDP KIT            * * *    CS     10

CC    PXMK194                       HEARTLAND HOSP 3X4                    * * *    CS     10

CC    PXMK318                       3X3 KIT FOR MAMONIDES                 * * *    CS     10

CC    PXMK356                       NORTHSHORE                            * * *    CS     10

CC    PXMK366                       3X3 CDP KIT FOR POMONA VALLEY         * * *    CS     10

CC    PXMK401                       BROWNSVILLE MED CTR                   * * *    CS     10

CC    PXMK413                       3X3R CDP KIT FOR HAHNEMAN             * * *    CS     10

CC    PXMK487                       ST PETERS HOSP 3X3                    * * *    CS     10

CC    PXMK537                       3X3 CDP KIT ST ANTHONY/ST LUKE        * * *    CS     20

CC    PXMK188                       WHITE MEMORIAL 30CC CDP KIT           * * *    CS     10

CC    PXMK381                       ST JUDE HOSP                          * * *    CS     20

CC    PXMK415                       LAC/USC MED CTR 30CC KIT              * * *    CS     20

CC    PXMK7266                      CDP KIT FOR FTN VALLEY HOSP           * * *    CS     20

CC    PXMK7729                      NORTHSHORE                            * * *    CS     20

CC    PXCMK448                      2X2 CDP KIT FOR ST BONIFACE           * * *    CS     20

CC    PXAK438                       CDP 5 GANG KIT FOR ST JOSEPHS         * * *    CS     20

CC    PXCAK469                      3GANG KIT FOR PORT ARTHUR             * * *    CS     20

CC    PXCMX427                      TORONTO GENERAL                       * * *    CS     20

CC    PXMK357                       UNITED HOSP -GRAND FORK               * * *    CS     10

CC    PXMK360                       PROVIDENCE HOSP ICP KIT               * * *    CS     10

CC    PXMK410                       ENLOE ICP KIT                         * * *    CS     10

CC    PXMK456                       CDP KIT SINGLE LINE ICP KIT           * * *    CS     10

CC    PXMK4r                        SINGLE CDP KIT FOR ST JOSEPH'S        * * *    CS     20

CC    PXMK559                       ICP KIT FOR METHODIST HOSP            * * *    CS     20

CC    PXMK7859                      NORTHWESTERN MEMORIAL KIT             * * *    CS     10

CC    PXMK9715                      ST FRANCIS SINGLE LINE KIT            * * *    CS     20

CC    PXMK9716                      ST FRANCIS HOSP 2X2 W/MANIFOLD        * * *    CS     20

CC    PXMK9717                      ST FRANCIS 3X3 W/MANIFOLD             * * *    CS     20
</TABLE>

                                   26 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                             EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                     13-Aug-96

===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM    QPC
===============================================================================================
<S>   <C>                   <C>     <C>                                <C>         <C>    <C>
CC    PXMK9851                      12" FLSH KIT FOR NORTHSHORE           * * *    CS     20

CC    33-MK050                      SINGLE ART LINE KIT-MT SINAI          * * *    CS     10

CC    33-MK077                      IX2 FOR DEL PLAY COMM HOSP            * * *    CS     20

CC    33-MK084                      IX2 FOR ST JOSEPS-HAZELTON-PA         * * *    CS     10

CC    33-MK120                      SIERRA MED CTR "PA KIT"               * * *    CS     10

CC    33-MK130                      CVP SINGLE PRESS MON KIT              * * *    CS     10

CC    33-MK133                      UNIV OF PITTSBURGH SPCL ORDER         * * *    CS     10

CC    33-MK152                      1X2 KIT FOR VENICE HOSP               * * *    CS     20

CC    33-MK158                      SUMMIT REVERSED ART LINE 272          * * *    CS     20

CC    33-MK175                      SUMMIT DPT 1X2 SPECIAL ORDER          * * *    CS     10

CC    33-MK223                      IUP SUMMIT DPT KIT                    * * *    CS     20

CC    33-MK235                      SINGLE DPT W/3CC SPCL ORDER           * * *    CS     20

CC    33-MK236                      SINGLE LINE KIT FOR CLEVELAND         * * *    CS     20

CC    33-MK334                      GRADUATE CDP KIT                      * * *    CS     10

CC    33-MK335                      GRADUATE CDP KIT                      * * *    CS     10

CC    33-MK345                      33-284 FOR SCRIPPS                    * * *    CS     10

CC    33-MK350                      N.OAKLAND MED CTR 1X2                 * * *    CS     20

CC    33-MK7266                     SPECIAL ORDER 30CC KIT FOR            * * *    CS     20

CC    33-MK7884                     SUMMIT DPT KIT-SINGLE ARTERIAL        * * *    CS     10

CC    33-MK9045                     GOOD SAMARITAN HOSP                   * * *    CS     20

CC    33-MK9313                     VA-OMAHA                              * * *    CS     20

CC    33-MK9659                     SINGLE LINE SPECIAL ORDER KIT         * * *    CS     20

CC    33-MK9661                     GARDEN CITY HOSP                      * * *    CS     20

CC    33-MK9710                     SINGLE LINE SPECIAL ORDER KIT         * * *    CS     20

CC    33-MK9851                     NORTHSHORE CDP KIT                    * * *    CS     20

CC    33-MK9911                     SINGLE LINE SPECIAL ORDER KIT         * * *    CS     20

CC    33-MK049                      SUMMIT DPT 2X2 SPECIAL ORDER          * * *    CS     10

CC    33-MK131                      UNIV OF PITTSBURGH-2X2 KIT            * * *    CS     10

CC    33-MK7859                     SUMMIT 5-GANG MANIFOLD KIT            * * *    CS     10
</TABLE>

                                   27 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                             EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                     13-Aug-96

===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM    QPC
===============================================================================================
<S>   <C>                   <C>     <C>                                <C>         <C>    <C>
CC    33-MK7876                     SUMMIT 2X2 SPECIAL ORDER              * * *    CS     20

CC    33-MK7883                     SUMMIT DPT KIT-2X3                    * * *    CS     20

CC    33-MK7913                     NORTHSHORE UNIV, HOSP                 * * *    CS     10

CC    33-MK9119                     SUMMIT-DISPOSABLE TR-ANSDUCER         * * *    CS     20

CC    33-MK9146                     SPECIAL ORDER 2X2 KIT FOR             * * *    CS     20

CC    33-MK9709                     SPECIAL ORDER 2X2 KIT                 * * *    CS     20

CC    33-MK048                      X3 COLOR CODED SUMMIT KIT             * * *    CS     10

CC    33-MK086                      JO ELLEN SMITH -4X4 MACRO IV          * * *    CS     10

CC    33-MK123                      DOCTORS HOSP SPECIAL ORDER            * * *    CS     20

CC    33-MK125                      SUMMIT DPT 4X4 SPECIAL ORDER          * * *    CS     10

CC    33-MK342                      GUTHRIE HEALTHCARE SYS 3X3            * * *    CS     10

CC    33-MK347                      33-3X3 FOR SCRIPPS                    * * *    CS     10

CC    33-MK7386                     ST FRANCIS MED CTR 3X3                * * *    CS     20

CC    33-MK7455                     WASHINGTON ADVENTIST SPECIAL          * * *    CS     10

CC    33-MK7504                     NORTHSHORE HOSP                       * * *    CS     10

CC    33-MK7710                     SPECIAL ORDER 3X3                     * * *    CS     10

CC    33-MK9144                     SAMUEL MERRITS-3X3                    * * *    CS     20

CC    33-MK9373                     BAY STATE MEDICAL CENTER              * * *    CS     20

CC    33-MK9480                     STRAUB CLINIC                         * * *    CS     20

CC    33-MK9571                     SUMMIT DPT KIT 3X3                    * * *    CS     20

CC    33-MK9990                     CARDINAL GLENNON                      * * *    CS     10

CC    33-MK9993                     3X3 KIT FOR CENTENIAL HOSP            * * *    CS     10

CC    33-MK352                      UNIV OF PITTS 4 DPTS W/O FLUSH        * * *    CS     20

CC    33-MK306                      30CC 12N W/LIPID RES.                 * * *    CS     10

CC    33-MK9103                     LANCASTER GENERAL                     * * *    CS     20

CC    33-MK9410                     30CC SPECIAL ORDER KIT FOR            * * *    CS     20

CC    33-MK9688                     SPECIAL ORDER NEO-NATE                * * *    CS     20

CC    33-MK9986                     VANDERBILT UNIV                       * * *    CS     20

CC    33-MK340                      CDP KIT FOR LANCASTER GENERAL         * * *    CS     10
</TABLE>

                                   28 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                             EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                     13-Aug-96

===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM    QPC
===============================================================================================
<S>   <C>                   <C>     <C>                                <C>         <C>    <C>
CC    33MK354                       ICP KIT FOR ST ANNS HOSP              * * *    CS     20

CC    33-MK132                      UNIV OF PITTSBURGH                    * * *    CS     10

CC    51-69MK135                    GLENDALE ADVENTIST                    * * *    CS     20

CC    51-CMK024                     TORONTO GENERAL HOSPITAL              * * *    CS     20

CC    51-CMK046                     VICTORIA HOSPITAL                     * * *    CS     20

CC    51-CMK077                     CALGARY GENERAL HOSPITAL              * * *    CS     20

CC    51-CMK095                     MONTREAL GENERAL HOSPITAL             * * *    CS     20

CC    51-MK2022                     UNIVERSAL M/F NON-VENTED CAP          * * *    CS     50

CC    51-MK2025                     BIFURCATED IV SET                     * * *    CS     10

CC    51-MK2039                     PENROSE ST FRANCES                    * * *    CS     20

CC    51-MK2041                     DUKE UNIV TRI IV SET 60"              * * *    CS     20

CC    51-MK2042                     MERCY HOSP CDP KIT                    * * *    CS     20

CC    51-MK7493                     CDP BRIDGE KIT                        * * *    CS     20

CC    51-MK7597                     ST FRANCIS                            * * *    CS     20

CC    51-MK7832                     MT CARMEL                             * * *    CS     20

CC    51-MK7906                     W O BOSWELL MEM                       * * *    CS     20

CC    51-MK9017                     CDP BRIDGE KIT                        * * *    CS     20

CC    51-MK9142                     ST FRANCIS                            * * *    CS     20

CC    51-MK9212                     CDP 3 GANG MNFLD KIT                  * * *    CS     20

CC    51-MK9473                     DANIEL FREEMAN HSP                    * * *    CS     20

CC    51-MK9944                     F/F ADAPTOR                           * * *    CS     50

CC    51-MK9994                     ST ELIZABETHS                         * * *    CS     10

CC    MK106P                        PEDIATRIC M/F 6" PRESS TUBING         * * *    CS     20

CC    MK112P                        PEDIATRIC M/F 12" PRESS TUBING        * * *    CS     20

CC    MK148P                        PEDIATRIC M/F 48" PRESS TUBING        * * *    CS     20

CC    MK2047                        BROOKESVILLE REGIONAL                 * * *    CS     20

CC    MK2065                        MAYO FOUND CDP COSET KIT              * * *    CS     20

CC    MK2079                        BRIDGE FOR WESTERN MED CTR            * * *    CS     20

CC    MK212P                        PEDIATRIC M/M 12' PRESS TUBING        * * *    CS     20
</TABLE>

                                   29 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                             EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                     13-Aug-96

===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM   QPC
===============================================================================================
<S>   <C>                   <C>     <C>                                <C>         <C>   <C>
CC    PX-VK272                      RAPID CITY CDP AVMP 2X2               * * *    CS     10

CC    PX-VK276                      SW WASHINGTON HOSP 3X3 COSET          * * *    CS     10

CC    PXCVK323                      PLAINS HEALTH CTR                     * * *    CS     20

CC    PXVJ084                       CHILDRENS HOSP 3X3 VAMP JR            * * *    CS     10

CC    PXVJ287                       JR COMBO 3CC FOR LUBBOCK              * * *    CS     20

CC    PXVK023                       ALTA BATES 2X 3 COMBO                 * * *    CS     10

CC    PXVK055                       3X3 COMBO CDP KIT FOR ST MARYS        * * *    CS     10

CC    PXVK088                       ST AGNES - AVMP COMBO SINGLE          * * *    CS     10

CC    PXVK093                       ST LUKES CDP VAMP/COMBO KIT           * * *    CS     20

CC    PXVK220                       ST. AGNES - AVMP COMBO 2X2            * * *    CS     20

CC    PXVK225                       2X2 VMP FOR N COLORADO M.C.           * * *    CS     10

CC    PXVK268                       ST JOSEPHS 3X3 VAMP COMBO             * * *    CS     20

CC    PXVK274                       ST LUKES 3X3 VAMP COMBO               * * *    CS     10

CC    PXVK292                       SW WASHINGTON HOSP 2X2 V/COSET        * * *    CS     10

CC    PXVK304                       PROVIDENCE HOSP - SINGLE LINE         * * *    CS     20

CC    PXVK306                       PROVIDENCE HOSP 3X3 COMBO             * * *    CS     20

CC    PXVK327                       ST LUKES IN BOISE ID                  * * *    CS     10

CC    33-VK023                      ALTA BATES 2X3 VAMP COMBO KIT         * * *    CS     10

CC    33-VK050                      SIERRA MED CTR VAMP KIT               * * *    CS     10

CC    33-VK053                      SUMMIT/160 VAMP COMBO SPCL KIT        * * *    CS     20

CC    33-VK064                      BLOOD SAMPLING ART. KIT FOR           * * *    CS     10

CC    33-VK096                      ART LINE FOR ANESTHESIA               * * *    CS     10

CC    33-VK099                      FULL HEART KIT FOR GRADUATE           * * *    CS     10

CC    33-VK284                      48-VMP172S FOR SCRIPPS                * * *    CS     10

CC    33-VK7733                     3X3 VMP/SUMMIT SPCL ORDR FOR          * * *    CS     10

CC    33-VK7968                     SUMMIT VAMP COMBO KIT FOR             * * *    CS     20

CC    33-VK9061                     SUMMIT VAMP COMBO 2X3 KIT             * * *    CS     10

CC    33-VK9144                     SUMMIT MEDICAL CENTER 3X3             * * *    CS     20

CC    33-VK9482                     ST FRANCIS HOSP -HI                   * * *    CS     20
</TABLE>

                                   30 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                              EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                      13-Aug-96

===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM    QPC
===============================================================================================
<S>   <C>                   <C>     <C>                                <C>         <C>    <C>
CC    43-VK279                      3X3 172 VAMP COMBO                    * * *    CS     10

CC    43-VK003                      VAMP COMBO OPEN HEART KIT FOR         * * *    CS     10

CC    43-VK011                      MERCY HOSP - UNIFLO/VAMP COMBO        * * *    CS     20

CC    43-VK012                      MERCY HSP - UNIFLO/VAMP COMBO         * * *    CS     20

CC    43-VK013                      MERCY HSP - UNIFLO/VMP COMBO          * * *    CS     20

CC    43-VK017                      VAMP COMBO SPECIAL ORDER KIT          * * *    CS     20

CC    43-VK018                      VAMP COMBO SPECIAL ORDER              * * *    CS     20

CC    43-VK055                      ST MARYS - VAMP COMBO SPECIAL         * * *    CS     10

CC    43-VK088                      UNIFLOW/VAMP ANESTHESIA COMBO         * * *    CS     10

CC    43-VK093T                     ST LUKES VAMP COMBO                   * * *    CS     20

CC    43-VK214                      CUSTOM VAMP-UNIFLOW COMBO             * * *    CS     10

CC    43-VK215                      2X2 VAMP COMBO FOR VA NASHVILE        * * *    CS     20

CC    43-VK216                      SINGLE LINE DUAL Z VA NASHVILE        * * *    CS     10

CC    43-VK7619                     3X3 UNIFLOW W/VAMP ANESTHESIA         * * *    CS     10

CC    43-CMK124                     VICTORIA HOSPITAL                     * * *    CS     20

CC    43-CMK201                     SINGLE ART LINE PM KIT FOR            * * *    CS     10

CC    43-CMK203                     NO IV SET - SINGLE ART LINE FOR       * * *    CS     10

CC    43-MK036                      DONALD SHARP                          * * *    CS     20

CC    43-MK091                      DONALD SHARP / CABRILLO               * * *    CS     20

CC    43-MK092                      DONALD SHARP / CABRILLO               * * *    CS     20

CC    43-MK093                      DONALD SHARP / CABRILLO               * * *    CS     20

CC    43-MK132                      ROCHESTER GEN. HOSP.                  * * *    CS     20

CC    43-MK134                      CHRISTIAN HOSP NE                     * * *    CS     20

CC    43-MK154                      ST MARYS ST LOUIS MO                  * * *    CS     10

CC    43-MK188                      UNIV OF TENNESSEE-PEDIATRIC           * * *    CS     10

CC    43-MK209                      METHODIST HOSPITAL-SINGLE ART         * * *    CS     20

CC    43-MK238                      "SWAN KIT" SPECIAL ORDER              * * *    CS     20

CC    43-MK256                      43-2X2 60" DPT KIT UNIFLOW            * * *    CS     20

CC    43-MK292                      CATH LAB DPT SPECIAL ORDER KIT        * * *    CS     20
</TABLE>

                                   31 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                              EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                      13-Aug-96

===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM    QPC
===============================================================================================
<S>   <C>                   <C>     <C>                                <C>         <C>    <C>
CC    43-MK298                      60" TRIFURCATED UNIFLOW               * * *    CS     10

CC    43-MK312                      108" SINGLE LINE CUSTOMER             * * *    CS     20

CC    43-MK343                      24" PED KIT FOR LITTLE CO OF          * * *    CS     10

CC    43-MK377                      VA BUFFALO CDP KIT                    * * *    CS     10

CC    43-MK9121                     ST ELIZABETHS KIT                     * * *    CS     20

CC    43-MK9239                     ST MARYS-MADISON                      * * *    CS     20

CC    43-MK9626                     WATERBURY HOSP.                       * * *    CS     20

CC    43-MK9829                     CHILDRENS IN FRESNO                   * * *    CS     20

CC    43-CMK280                     BIFURCATED 43 SERIES 72IN LINE        * * *    CS     20

CC    43-MK037                      DONALD SHARP                          * * *    CS     20

CC    43-MK297                      TRIFURCTED 2X# UNIFLOW KIT            * * *    CS     10

CC    43-MK309                      2X2 CUSTOMER DEFINED PRODUCT          * * *    CS     20

CC    43-MK345                      2X2 TRI CUST. DEFNED KIT FOR          * * *    CS     10

CC    43-MK9209                     METHODIST HOSP                        * * *    CS     20

CC    43-VK220                      UNIFLOW 2X2 VAMP COMBO                * * *    CS     20

CC    43-CMK202                     3X3 MACRO PM KIT FOR BRITISH          * * *    CS     10

CC    43-MK049                      BRISTOL MEM HSP                       * * *    CS     10

CC    43-MK125                      ROCHESTER GEN. HOSP.                  * * *    CS     20

CC    43-MK183                      ST ANTHONY'S                          * * *    CS     20

CC    43-MK189                      JEWISH HOSPITAL - 3X3 REVERSED        * * *    CS     20

CC    43-MK214                      UNIFLOW-DISPOSABLE TRANSDUCER         * * *    CS     20

CC    43-MK229                      ELLIS HOSP                            * * *    CS     10

CC    43-MK239                      TRIFURCATED DPT KIT                   * * *    CS     10

CC    43-MK306                      UNIFLOW TRIPLE LINE KIT               * * *    CS     20

CC    43-MK311                      UNIFLOW TRIPLE LINE KIT               * * *    CS     20

CC    43-MK9208                     METHODIST HOSP                        * * *    CS     20

CC    43-MK9317                     ST JOSEPH BURBANK                     * * *    CS     10

CC    43-VK293                      ST PETERS 3X3 VAMP COMBO              * * *    CS     10

CC    43-AMK063                     SPECIAL ORDER DISPOSABLE TRANS        * * *    CS     20
</TABLE>

                                   32 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                              EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                      13-Aug-96

===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM    QPC
===============================================================================================
<S>   <C>             <C>           <C>                                <C>         <C>    <C>
CC    43-CMK071                     HOSPITAL FOR SICK CHILDREN            * * *    CS     20

CC    43-MK031                      LUTHERN HOSP                          * * *    CS     20

CC    43-MK322                      30CC LIPID RESISTANT 36N              * * *    CS     10

CC    43-MK9493                     ST JOSEPH BURBANK                     * * *    CS     20

CC    43-MK9625                     WATERBURY HOSP.                       * * *    CS     20

CC    43-MK357                      CDP KIT FOR PENROSE                   * * *    CS     10

CC    48-VJ244                      CDP VAMP JR FOR UNIV OF KANSAS        * * *    CS     20

CC    49-VK233                      UC DAVIS                              * * *    CS     20

CC    VJ259                         CHILDRENS HOSP-DALLAS                 * * *    CS     20

CC    VK298                         BALL MEMORIAL VENOUS VAMP KIT         * * *    CS     20

CC    59PXCT                        6" ADAPTOR CABLE FOR PX SERIES        * * *    EA      1

CC    PX-1800         896021-001    PX DPT SYSTEM INTERFACE CABLE         * * *    EA      1

CC    PX-1800         896040-001    PX DPT SYSTEM INTERFACE CABLE         * * *    EA      1

CC    PX-1800         896033-011    PX DPT SYSTEM INTERFACE CABLE         * * *    EA      1

CC    PX-1800         896032-001    PX DPT SYSTEM INTERFACE CABLE         * * *    EA      1

CC    PX-1800         896031-011    PX DPT SYSTEM INTERFACE CABLE         * * *    EA      1

CC    PX-1800         896031-001    PX DPT SYSTEM INTERFACE CABLE         * * *    EA      1

CC    PX-1800         896029-011    INTERFACE CALE FOR TRUWAVE DPT        * * *    EA      1

CC    PX-1800         896028-001    PX DPT SYSTEM INTERFACE CABLE         * * *    EA      1

CC    PX-1800         896025-001    PX DFT SYSTEM INTERFACE CABLE         * * *    EA      1

CC    PX-1800         896507-011    TRUWAVE INTERFACE CABLE               * * *    EA      1

CC    PX-1800         896019-011    PX DPT SYSTEM INTERFACE CABLE         * * *    EA      1

CC    PX-1800         896019-001    PX DFT SYSTEM INTERFACE CABLE         * * *    EA      1

CC    PX-1800         896012-016    PHOENIX INTERFACE CABLE FOR           * * *    EA      1

CC    PX-1800         896012-013    TRUWAVE INTERFACE CABLE               * * *    EA      1

CC    PX-1800         896008-011    PX DPT SYSTEM INTERFACE CABLE         * * *    EA      1

CC    PX-1800         896007-011    PX DPT SYSTEM INTERFACE CABLE         * * *    EA      1

CC    PX-1800         896004-011    PX DPT SYSTEM INTERFACE CABLE         * * *    EA      1

CC    PX-1800         896004-001    PX DPT SYSTEM INTERFACE CABLE         * * *    EA      1
</TABLE>

                                   33 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                              EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                      13-Aug-96

===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM    QPC
===============================================================================================
<S>   <C>             <C>           <C>                                <C>         <C>    <C>
CC    PX-1800         896003-001    PX DPT SYSTEM INTERFACE CABLE         * * *    EA      1

CC    PX-1800         896025-011    PX DPT SYSTEM INTERFACE CABLE         * * *    EA      1

CC    PX-1800         896090-011    PX DPT SYSTEM INTERFACE CABLE         * * *    EA      1

CC    PX-1800         896494-011    PX DPT SYSTEM INTERFACE CABLE         * * *    EA      1

CC    PX-1800         896137-011    PHOENIX INTERFACE CABLE FOR           * * *    EA      1

CC    PX-1800         896125-011    PX DPT SYSTEM INTERFACE CABLE         * * *    EA      1

CC    PX-1800         896115-011    TRUWAVE DPT INTERFACE CABLE           * * *    EA      1

CC    PX-1800         896106-011    PX DPT SYSTEM INTERFACE CABLE         * * *    EA      1

CC    PX-1800         896089-001    PX DPT SYSTEM INTERFACE CABLE         * * *    EA      1

CC    PX-1800         896088-011    PX DPT SYSTEM INTERFACE CABLE         * * *    EA      1

CC    PX-1800         896083-013    TRUWAVE DPT CONNECTING CABLE          * * *    EA      1

CC    PX-1800         896038-001    PX DPT SYSTEM INTERFACE CABLE         * * *    EA      1

CC    PX-1800         896083-001    INTERFACE CABLE FOR PHOENIX           * * *    EA      1

CC    PX-1800         896033-001    PX DPT SYSTEM INTERFACE CABLE         * * *    EA      1

CC    PX-1800         896080-001    PX DPT SYSTEM INTERFACE CABLE         * * *    EA      1

CC    PX-1800         896079-011    PX DPT SYSTEM INTERFACE CABLE         * * *    EA      1

CC    PX-1800         896056-001    PX DPT SYSTEM INTERFACE CABLE         * * *    EA      1

CC    PX-1800         896056-011    PX DPT SYSTEM INTERFACE CABLE         * * *    EA      1

CC    PX-1800         896036-001    PX DPT SYSTEM INTERFACE CABLE         * * *    EA      1

CC    PX-1800         896053-001    PX DPT SYSTEM INTERFACE CABLE         * * *    EA      1

CC    PX-1800         896049-011    PX DPT SYSTEM INTERFACE CABLE         * * *    EA      1

CC    PX-1800         896047-001    PX DPT SYSTEM INTERFACE CABLE         * * *    EA      1

CC    PX-1800         896044-001    INTERFACE CABLE FOR PHOENIX           * * *    EA      1

CC    PX-1800         896042-001    PX DPT SYSTEM INTERFACE CABLE         * * *    EA      1

CC    PX-I800         896083-011    INTERFACE CABLE FOR PHOENIX           * * *    EA      1

CC    PX-1800         896034-011    PX DPT SYSTEM INTERFACE CABLE         * * *    EA      1

CC    PX-1800         896507-001    PX DPT SYSTEM INTERFACE CABLE         * * *    EA      1

CC    PX-1800         896508-011    PX DPT SYSTEM INTERFACE CABLE         * * *    EA      1

CC    PX12N                         PX 12 INCH NEONATE KIT                * * *    CS     10
</TABLE>

                                   34 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                              EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                      13-Aug-96

===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM    QPC
===============================================================================================
<S>   <C>                   <C>     <C>                                <C>         <C>    <C>
CC    PXIX2                         PX 1 DPT STANDARD KIT                 * * *    CS     10

CC    PX200                         PX VAMP READY KIT                     * * *    CS     10

CC    PX-L                          PX SINGLE LINE DPT 12"                * * *    CS     10

CC    PX24N                         PX 24 INCH NEONATE KIT                * * *    CS     10

CC    PX260                         PX SINGLE LINE DPT KIT 60"            * * *    CS     10

CC    PX260R                        PX 60" POLE MOUNT OR KIT              * * *    CS     10

CC    PX272                         PX SINGLE LINE DPT 72"                * * *    CS     10

CC    PX284                         PX SINGLE LINE DPT 84"                * * *    CS     10

CC    PX36N                         PX 36 INCH NEONATE KIT                * * *    CS     10

CC    PX600                         PX STANDALONE TRANSDUCER              * * *    CS     20

CC    PX600F                        PX STANDALONE TRANSDUCER 3CC          * * *    CS     20

CC    PX600F30                      PX STANDALONE TRANSDUCER 30CC         * * *    CS     20

CC    PX6001                        PX STANDALONE TRANSDUCER              * * *    CS     20

CC    PX601                         PX STANDALONE TRANSDUCER              * * *    CS     20

CC    PX604                         PX STANDALONE TRANSDUCER              * * *    CS     20

CC    PXSIM                         PHOENIX DPT TESTER                    * * *    EA      1

CC    PX2X2                         PX 2 DPT STANDARD KIT                 * * *    CS     10

CC    PX2X3                         PX 2 DPT STANDARD KIT                 * * *    CS     10

CC    PX3X3                         PX 3 DPT STANDARD KIT                 * * *    CS     10

CC    PX3X3272                      PX 3 DPT ANESTH PM KIT 72"            * * *    CS     10

CC    PXAVMP                        PX VAMP SINGLE DPT ANESTH             * * *    CS     10

CC    PXAVMP3                       PX 3X3 VAMP DPT ANESTHESIA            * * *    CS     10

CC    PXVMP120                      PX VAMP/TRANSDCER 120 CMBO KIT        * * *    CS     10

CC    PXVMP160                      PX VAMP/TRANSDCER 160 CMBO KIT        * * *    CS     10

CC    PXVMP172                      PX VAMP/TRANSDCER 172 CMBO KIT        * * *    CS     10

CC    PXVMP184                      PX VAMP/TRANSDCER 184 CMBO KIT        * * *    CS     10

CC    PXVMP260                      PX POLE MOUNT VAMP/DPT CMBO           * * *    CS     10

CC    PXVMP272                      PX POLE MOUNT VAMP/DPT KIT            * * *    CS     10

CC    PXMP284                       PX POLE MOUNT VAMP/DPT KIT            * * *    CS     10
</TABLE>

                                   35 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                              EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                      13-Aug-96

===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM    QPC
===============================================================================================
<S>   <C>                   <C>     <C>                                <C>         <C>    <C>
CC    PXVMP2X21                     PX ARM MOUNT VAMP DPT 160 2X2         * * *    CS     10

CC    PXVMP2X22                     PX POLE MOUNT VAMP/DPT 260 2X2        * * *    CS     10

CC    PXVMP2X31                     PX ARM MOUNT VAMP/DPT 160 2X3         * * *    CS     10

CC    PXVMP3X31                     PX ARM MOUNT VAMP/DPT 160 3X3         * * *    CS     10

CC    PXVMP3X32                     PX POLE MOUNT VAMP/DPT 272 3X3        * * *    CS     10

CC    VMP306PX                      VAMP JR "PX" DPT COMBO KIT            * * *    CS     10

CC    VMP406PX                      VAMP JR "PX" DPT COMBO KIT            * * *    CS     10

CC    VMP448PX                      VAMP JR "PX" DPT COMBO KIT            * * *    CS     10

CC    43-AVMP                       SINGLE UNIFLOW VAMP ANESTH            * * *    CS     10

CC    43-AVMP3                      3X3 UNIFLOW VAMP ANESTHESIA           * * *    CS     10

CC    49-VMP120UF                   VAMP 120 KIT, TRANSDUCER READY        * * *    CS     10

CC    48-VW160UF                    VAMP 160 KIT, TRANSDUCER READY        * * *    CS     10

CC    48-VMP172UF                   VAMP 172 KIT, TRANSDUCER READY        * * *    CS     10

CC    48-VMP184UF                   VAMP 184 KIT, TRANSDUCER READY        * * *    CS     10

CC    48-VMP260UF                   VAMP POLE MOUNT DPT COMBO KIT         * * *    CS     10

CC    48-VMP272UF                   VAMP POLE MOUNT DFT COMBO KIT         * * *    CS     10

CC    48-VMP2X2UF1                  VAMP/UNIFLOW 160 2X2 ARM MOUNT        * * *    CS     10

CC    49-VMP2X3UF1                  VAMP/UNIFLOW 160 2X2 ARM MOUNT        * * *    CS     10

CC    48-VMP3X3160UF                60" VAMP W/ ARM MOUNT /3 DTS          * * *    CS     10

CC    48-VMP3X3272UF                UNIFLOW VAMP COMBO 3X3 POLE           * * *    CS     10

CC    VWP306UF                      VAMP JR DPT COMBO KIT                 * * *    CS     10

CC    VMP426UF                      VAMP JR/UNIFLOW DPT COMBO KIT         * * *    CS     10

CC    33-AVMP                       SINGLE SUMMIT VAMP ANES               * * *    CS     10

CC    33-AVMP3                      3X3 SUMMIT VAMP ANESTHESIA            * * *    CS     10

CC    49-VMP120S                    VAMP/TRANSDUCER 120 COMBO KIT         * * *    CS     10

CC    48-VMP160S                    VAMP/TRANSDUCER 160 COMBO KIT         * * *    CS     10

CC    48-VMP172S                    VAMP AND SUMMIT TRANSDUCER            * * *    CS     10

CC    48-VMP184S                    VAMP AND SUMMIT TRANSDUCER            * * *    CS     10

CC    48-VMP260S                    VAMP POLE MOUNT COMBO DPT KIT         * * *    CS     10
</TABLE>

                                   36 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                              EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                      13-Aug-96

===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM    QPC
===============================================================================================
<S>   <C>                   <C>     <C>                                <C>         <C>    <C>
CC    48-VMP272S                    VAMP POLE MOUNT DPT COMBO KIT         * * *    CS     10

CC    49-VMP2X2S1                   VAMP/SUMMIT 160 2X2 ARM MOUNT         * * *    CS     10

CC    48-VMP2X2S2                   VAMP/SUMMIT 260 2X2 POLE MOUNT        * * *    CS     10

CC    48-VMP2X3S1                   VAMP/SUMMIT 160 2X3 ARM MOUNT         * * *    CS     10

CC    48-VMP2X3S2                   VAMP/SUMMIT 260 2X3 POLE MOUNT        * * *    CS     10

CC    48-VMP3X3160S                 60" VAMP W/ ARM MOUNT /3 DPTS         * * *    CS     10

CC    48-VMP3X3272S                 VAMP COMBO 3X3 POLE MOUNT 72"         * * *    CS     10

CC    VMP306                        VAMP JR                               * * *    CS     20

CC    VMP406                        VAMP JR                               * * *    CS     20

CC    VMP426                        VAMP JR                               * * *    CS     20

CC    VMP448                        VAMP JR                               * * *    CS     20

CC    CC-02-80                      80 CM SHIELD HEMO                     * * *    CS     40

CC    CC-03-80.5F                   8.5F POLYURETANE SHEATHS              * * *    CS     40

CC    CC-52-80                      80 CM SHIELD, TUOHY                   * * *    CS     40

CC    CC-300 8.5F                   INTRODUCER TRAY W/ AUTOMATIC          * * *    CS     10

CC    CC-350B-8.5F                  TUOHY-BORST VALVE, BONDED             * * *    CS     10

CC    CC-500-8.5F                   INTRODUCER TRAY W/ AUTOMATIC          * * *    CS     10

CC    CC-500B-8.5F                  INTRO SHEATH BONDED HEMO VALVE        * * *    CS     10

CC    CC-507-8.5F                   INTRO SHEATH W/DETACHABLE             * * *    CS     10

CC    CC-507B-8.5F                  INTRO SHEATH W/BONDED HEMO            * * *    CS     10

CC    CC-550-8.5F                   INTRODUCER TRAY; 8.5F                 * * *    CS     10

CC    CC-550B-8.5F                  INTRODUCER TRAY; 8.5 F                * * *    CS     10

CC    CC-A301B-8.5F                 INTRO KIT W / AMC STD                 * * *    CS     10

CC    CC-A351B-8.5F                 INTRO KIT W / AMC STD                 * * *    CS     10

CC    CC-A502-8.5F                  INTRO TRAY / AMC STD                  * * *    CS     10

CC    CC-A502B-8.5F                 INTRO TRAY / AMC STD                  * * *    CS     10

CC    CC-A551-8.5F                  INTRO TRAY / TD                       * * *    CS     10

CC    CC-A551B-8.5F                 INTRO TRAY / AMC STD                  * * *    CS     10

CC    GW-25-35                      GUIDEWIRE.025X35 CM                   * * *    CS     20
</TABLE>

                                   37 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                              EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                      13-Aug-96

===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM    QPC
===============================================================================================
<S>   <C>                   <C>     <C>                                <C>         <C>   <C>
CC    GW-25-45HS                    GUIDEWIRE.025 X 45CM                  * * *    CS     20

CC    GW-35-45                      GUIDEWIRE.035X45 CM                   * * *    CS     20

CC    GW-35-70                      GUIDEWIRE.035X70 CM                   * * *    CS     20

CC    48-AVMP                       ANESTHESIA VAMP                       * * *    CS     20

CC    48-VMP106                     6* SAMPLING KIT FOR BODY MOUNT        * * *    CS     20

CC    489-VWP120                    ARM MOUNT RES. FOR BODY MOUNT         * * *    CS     20

CC    48-VMP160                     PKG. ASSY. 48-VMP160                  * * *    CS     20

CC    48-VMP172                     PKG. ASSY. 48-VMP172                  * * *    CS     20

CC    49-VMP184                     PKG ASSY.48-VMP184                    * * *    CS     20

CC    48-VMP260                     PKG. ASSY 48-VMP260                   * * *    CS     20

CC    48-VMP2.72                    PKG. ASSY. 49-VMP272                  * * *    CS     20

CC    48-VMP503H                    PKG ASSY .3 CC SYRINGE                * * *    CS     50

CC    48-VMP600                     PKG. ASSY., 48-VMP600                 * * *    CS     50

CC    VMP400                        PKG. ASSY. - VAMP CANNULA             * * *    CS    200

CC    VMP700                        VAMP DIRECT DRAW                      * * *    CS     50

CC    CC-07-7F                      COMPONENT OBTURATOR                   * * *    CS     40

CC    CC-301-5F                     INTRODUCER TRAY 5F W/AUTOMATIC        * * *    CS     10

CC    CC-301-6F                     INTRODUCER TRAY-6F                    * * *    CS     10

CC    CC-301-7F                     INTRODUCER TRAY-7F                    * * *    CS     10

CC    CC-301-8F                     INTRODUCER TRAY -8F                   * * *    CS     10

C     CC-351B-6F                    INTRODUCER TRAY 6F                    * * *    CS     10

CC    CC-351B-7F                    INTRODUCER TRAY-7F                    * * *    CS     10

CC    CC-351B-8F                    INT0RDUCER TRAY OF                    * * *    CS     10

CC    CC-500-5F                     INTRODUCER TRAY 5F                    * * *    CS     10

CC    CC-500-6F                     INTRODUCER TRAY-6F                    * * *    CS     10

CC    CC-500-7F                     INTRODUCER TRAY-7F                    * * *    CS     10

CC    CC-500-F                      INTRODUCER TRAY - 8F                  * * *    CS     10

CC    CC-550B-5F                    INTRODUCER TRAY 5F                    * * *    CS     10

CC    CC-550B-6F                    INTRODUCER TRAY - 6F                  * * *    CS     10
</TABLE>

                                   38 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                              EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                      13-Aug-96

===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM    QPC
===============================================================================================
<S>   <C>                   <C>     <C>                                <C>         <C>    <C>
CC    CC-550B-7F                    INTRODUCER TRAY-7F                    * * *    CS     10

CC    CC-550B-8F                    INTRODUCER TRAY 8F                    * * *    CS     10

CC    33-12N                        12 INCH NEONATE KIT                   * * *    CS     10

CC    33-1X2                        SUMMIT 1DPT STANDARD KIT              * * *    CS     10

CC    33-200                        VAMP READY KIT- SUMMIT                * * *    CS     10

CC    33-212                        SUMMIT 1 DPT STANDARD KIT             * * *    CS     10

CC    33-24N                        24 INCH NEONATE KIT                   * * *    CS     10

CC    33-260                        SUMMIT 1 DTP STANDARD KIT             * * *    CS     10

CC    33-272                        SUMMIT 1 DPT STANDARD KIT             * * *    CS     10

CC    33-284                        SUMMIT 1 DPT STANDARD KIT             * * *    CS     10

CC    33-36N                        36 INCH NEONATE KIT                   * * *    CS     10

CC    33-600                        SUMMIT STANDALONE TRANSDUCER          * * *    CS     20

CC    33-600F                       SUMMIT STANDALONE TRANSDUCER          * * *    CS     20

CC    33-600F30                     SUMMIT STANDALONE TRANSDUCER          * * *    CS     20

CC    33-6001                       SUMMIT STANDALONE TRANSDUCER          * * *    CS     20

CC    33-2X2                        SUMMIT 2DPT STANDARD KIT              * * *    CS     10

CC    33-2X3                        SUMMIT 2DPT STANDARD KIT              * * *    CS     10

CC    33-3X3                        SUMMIT 3DPT STANDARD KIT              * * *    CS     10

CC    33-3X3.272                    SUMMIT 3 DPT ANESTH PM KIT            * * *    CS     10

CC    57-BD240                      I LINDEN FITTINGS FOR USE WITH        * * *    CS     20

CC    57-BD241                      I LUER-LOCK FITTINGS.FOR USE          * * *    CS     20

CC    57-BH271                      I DISPOSABLE DOME FOR                 * * *    CS     20

CC    S7-GD261                      I LUER-LOCK FITTINGS.FOR USE          * * *    CS     20

CC    57-HPQ290                     I LINDEN FITTINGS,FOR USE WITH        * * *    CS     20

CC    54-IV1-2                      IV ADMINISTRATION SET. SINGLE,        * * *    CS     10

CC    54-IV2-2                      IV ADMINISTRATION SET,                * * *    CS     10

CC    54-IV3-2                      IV ADMINISTRATION SET.                * * *    CS     20

CC    58-1WV-06                     1 WAY VALVE/6INCH TUBING              * * *    CS     20
</TABLE>

                                   39 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                              EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                      13-Aug-96

===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM    QPC
===============================================================================================
<S>   <C>                   <C>     <C>                                <C>         <C>   <C>
CC    58-K169-06                    STOPCOCK WITH 6 INCH PRESSURE         * * *    CS     20

CC    58-K169-12                    STOPCOCK WITH 12 INCH PRESSURE        * * *    CS     20

CC    50-P20OR                      ROTATING M-M ADAIYTER                 * * *    CS     50

CC    59-1 WSC                      1 -WAY STOPCOCK L-L                   * * *    CS     50

CC    59-3WSC                       3-WAY STOPCOCK L/L                    * * *    CS     50

CC    59-4WSC                       4-WAY L-L STOPCOCK                    * * *    CS     50

CC    59-AM300                      ADHESIVE BODY MOUNT FOR               * * *    CS    100

CC    59-CL200                      HOLDER FOR MANIFOLD II                * * *    EA      1

CC    59-DTH4                       DISPOSABLE HOLDER FOR DPT             * * *    CS     10

CC    59-DTS-C                      CLAMP FOR DISPOSABLE PRESSURE         * * *    EA      1

CC    59-DTS-S                      PKG ASSY-AARM STRAP,59-DTS-S          * * *    CS     10

CC    59-MNVC                       MALE NONVNTD CAP 100 EA-2 PER         * * *    CS     5O

CC    59-UAS                        PKG ASSY-ARM STRAP 59-UAS             * * *    CS     10

CC    50-P106               20      PRESSURE TUBING, 6" M\F               * * *    CS     20

CC    50-P112               20      PRESSURE TUBING, 12", M\F             * * *    CS     20

CC    50-P124               20      PRESSURE TUBING, 24", M\F             * * *    CS     20

CC    50-P136               20      PRESSURE TUBING, 36", M\F             * * *    CS     20

CC    50-P148               20      PRESSURE TUBE, M\F, 48"               * * *    CS     20

CC    50-P160               20      PRESSURE TUBING. 60", M\F             * * *    CS     20

CC    50-P172               20      PRESSURE TUBING, 72",M\F              * * *    CS     20

CC    50-P184               20      PRESSURE TUBING, 84",  M\F            * * *    CS     20

CC    50-P206               20      PRESSURE TUBING, 6", M\M              * * *    CS     20

CC    50-P212               20      PRESSURE TUBING, 12", M\M             * * *    CS     20

CC    50-P224               20      PRESSURE TUBING, 24", M\M             * * *    CS     20

CC    50-P236               20      PRESSURE TUBING. 36", M\M             * * *    CS     20

CC    50-P248               20      PRESSURE TUBING, 48", M\M             * * *    CS     20

CC    50-P260               20      PRESSURE TUBING, 60", M\M             * * *    CS     20

CC    5O.P272               20      PRESSURE TUBING. 72", M\M             * * *    CS     20

CC    50-P284               20      PRESSURE TUBING, 84", M\M             * * *    CS     20
</TABLE>

                                   40 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                              EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                      13-Aug-96

===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM  QPC
===============================================================================================
<S>   <C>                   <C>     <C>                                <C>         <C>  <C>
CC    52-F211                       STD PRESSURE MONITORING KIT           * * *    CS   20

CC    52-F221                       STD PRESSURE MONITORING KIT           * * *    CS   20

CC    52-F231                       STD PRESSURE MONITORING KIT           * * *    CS   20

CC    52-F234                       STD PRESSURE MONITORING KIT           * * *    CS   20

CC    52-F235BE                     STD PRESSURE MONITORING KIT           * * *    CS   20

CC    52-F235G                      STD PRESSURE MONITORING KIT           * * *    CS   20

CC    52-F235HPQ                    KIT WITH DOME FOR USE W/HP            * * *    CS   20

CC    52-F248HPQ                    STD PRESSURE MONITORING KIT           * * *    CS   20

CC    52-F72HPQ                     KIT WITH DOME FOR USE W/HP            * * *    CS   20

CC    55-LTFIDO                     FLUSH DEVICE, 3CC/HOUR                * * *    CS   20

CC    55-UF130                      FLUSH DEVICE, 30CC/HR                 * * *    CS   20

CC    43-12N                        12 IN NEONATE KIT                     * * *    CS   10

CC    43-1X2                        POLE MOUNT 1DPT FOR 3 PRESSURE        * * *    CS   20

CC    43-200                        VAMP READY KIT-TRANSDUCER             * * *    CS   10

CC    43-212                        12 IN ARM MOUNT KIT                   * * *    CS   10

CC    43-24N                        24 IN NEONATE KIT                     * * *    CS   10

CC    43-260                        60 IN POLE MOUNT KIT                  * * *    CS   10

CC    43-26OR                       60 IN POLE MOUNT OR VJT               * * *    CS   10

CC    43-272                        72 IN POLE MOUNT KIT                  * * *    CS   10

CC    43-284                        84 IN POLE MOUNT KIT                  * * *    CS   10

CC    43-36N                        36 N NEONATE KIT                      * * *    CS   10

CC    43-600                        STAND ALONE DPT                       * * *    CS   20

CC    43-60OF                       STANDALONE WITH 3ML FLUSH             * * *    CS   20

CC    43-60OF30                     STANDALONE WITH 30ML FLUSH            * * *    CS   20

CC    43-6001                       1CP AND 1UP KIT                       * * *    CS   20

CC    43-604                        STANDALONE DPT WITH 4FT CABLE         * * *    CS   20

CC    43212F                        12 IN POLE MOUNT KIT W-FLUSH          * * *    CS   10

CC    43284F                        84 IN POLE MOUNT KIT W-FLUSH          * * *    CS   10

CC    43-2X                         POLE MOUNT 2DPT FOR 3 PRESSURE        * * *    CS   20
</TABLE>

                                   41 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                              EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                      13-Aug-96

===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM    QPC
===============================================================================================
<S>   <C>                   <C>     <C>                                <C>         <C>  <C>
CC    43-2X3                        POLE MOUNT 2DPT FOR 3 PRESSURE        * * *    CS   20

CC    43-3X3                        POLE MOUNT 3DPT FOR 3 PRESSURE        * * *    CS   20

CC    43-3X3-272                    UNIFLOW3DPT ANESTH PM KIT             * * *    CS   20

CC DIVISION                         TOTAL MODELS  873
</TABLE>

                                   42 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                             EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                      13-Aug-96

===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM    QPC
===============================================================================================
<S>   <C>                   <C>     <C>                                <C>         <C>   <C>
CVS   4700                          PERICARDIAL PATCH                     * * *    EA    1

CVS   4800                          JANKE-BARRON HEART SUPPORT            * * *    CS    6

CVS DIVISION                        TOTAL MODELS  2
</TABLE>

                                   43 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                              EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                     13-Aug-96

===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM    QPC
===============================================================================================
<S>   <C>                   <C>     <C>                                <C>         <C>   <C>
VS    830515F                       MILLER ATRIOSEPTOSTOMY CATH           * * *    EA    1

VS    830705F                       ATRIOSEPTOSTOMY DILATION CATH         * * *    EA    1

VS    620403F                       3F OCCLUSION CATHETER 40CM            * * *    EA    1

VS    620404F                       4F OCCLUSION CATHETER 40CM            * * *    EA    1

VS    620405F                       5F OCCLUSION CATHETER 40CM            * * *    EA    1

VS    62AO403F                      OCCLUSIN CATH 3F, 40CM                * * *    EA    1

VS    62AO404F                      OCCLUSIN CATH 4F, 40CM                * * *    EA    1

VS    62AO405F                      OCCLUSIN CATH 5F, 40CM                * * *    EA    1

VS    12TL0404F                     FOGARTY THRU-LUMEN ARTERIAL           * * *    EA    1

VS    12TLO904F                     FOGARTY THRU-LUMEN ARTERIAL           * * *    EA    1

VS    12TLO805F                     FOGARTY THRU-LUMEN ARTERIAL           * * *    EA    1

VS    12TLO806F                     FOGARTY THRU-LUMEN ARTERIAL           * * *    EA    1

VS    12TLO807F                     FOGARTY THRU-LUMEN ARTERIAL           * * *    EA    1

VS    12TLW403F                     FOGARTY THRU-LUMIN EMBO CATH          * * *    EA    1

VS    12TLW404F                     FOGARTY THRU-LUMIN EMBO CATH          * * *    EA    1

VS    12TLW803F                     FOGARTY THRU-LUMIN EMBO CATH          * * *    EA    1

VS    12TLW804F                     FOGARTY THRU-LUMIN EMBO CATH          * * *    EA    1

VS    12TLW805F                     FOGARTY THRU-LUMIN EMBO CATH          * * *    EA    1

VS    12TLW806F                     FOGARTY THRU-LUMIN EMBO CATH          * * *    EA    1

VS    CV6000                        FOGARTY CATHETER RACK                 * * *    EA    1

VS    420404F                       EDSLAB CHOLANGIOGRAPHY                * * *    EA    1

VS    420406F                       CHOLANGIOGILAPHY CATHETER             * * *    EA    1

VS    420804F                       LAPAROSCOPIC CHOLANGIOGRAM            * * *    EA    1

VS    42TL0804F                     LAPAROSCOPIC CHOLANGIOGRAPHY          * * *    EA    1

VS    CV8000                        CHOLANGIOGRAPHY KIT                   * * *    EA    1

VS    1408010                       FOGARTY ADHERANT CLOT CATH            * * *    EA    1

VS    140806                        FOGARTY ADHERENT CLOT 4F 6MM          * * *    EA    1

VS    140808                        ADHERENT CLOT CATHETER                * * *    EA    1

VS    160245F                       FOGARTY GRAFT THROMBECTOWY            * * *    EA    1
</TABLE>

                                   44 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                              EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                     13-Aug-96

===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM    QPC
===============================================================================================
<S>   <C>                   <C>     <C>                                <C>         <C>   <C>
VS    160246F                       FOGARTY GRAFT THROMBECTOMY            * * *    EA    1

VS    120403FS                      FOGARTY ART EMBO CATH W STYLET        * * *    EA    1

VS    120803FS                      FOGARTY ART EMBO CATH W STYLET        * * *    EA    1

VS    12A0403F                      FOGARTY EMBOLECTOMY (FLAT PKG)        * * *    EA    I

VS    12A0404F                      FOGARTY EMBOLECTOMY (FLAT PKG)        * * *    EA    1

VS    12A0602F                      FOGARTY EMBOLECTOMY (FLAT PKG)        * * *    EA    1

VS    12A0803F                      FOGARTY EMBOLECTOMY (FLAT PKG)        * * *    EA    1

VS    12A0804F                      FOGARTY EMBOLECTOMY (FLAT PKG)        * * *    EA    1

VS    12A0805F                      FOGARTY EMBOLECTOMY (FLAT PKG)        * * *    EA    1

VS    12A0806F                      FOGARTY EMBOLECTOMY (FLAT PKG)        * * *    EA    1

VS    12AO807F                      FOGARTY EMBOLECTOWY (FLAT PKG)        * * *    EA    1

VS    12A1004F                      FOGARTY EMBOLECTOMY (FLAT PKG)        * * *    EA    1

VS    320806F                       FOGARTY THROMBECTOMY CATHETER         * * *    EA    1

VS    32080810F                     FOGARTY THROMBECTOMY CATH             * * *    EA    1

VS    320909F                       FOGARTY THROMBECTOMY CATHETER         * * *    EA    1

VS    62080814F                     FOGARTY OCCLUSION CATHETER            * * *    EA    1

VS    62080822F                     FOGARTY OCCLUSION CATHETER            * * *    EA    1

VS    2202310F                      FOGARTY VENOUS IRRIGATION             * * *    EA    1

VS    220804F                       FOGARTY ARTEIUAL IMUGATION            * * *    EA    1

VS    220906F                       FOGARTY ARTERIAL IRRIGATION           * * *    EA    1

VS    410235F                       FOGARTY BILIARY PROBE                 * * *    EA    1

VS    410236F                       FOGARTY BILIARY PROBE                 * * *    EA    1

VS    410405F                       FOGARTY BILIARY PROBE                 * * *    EA    1

VS    120403F                       FOGARTY EMBOLECTOMY CATHETER          * * *    EA    1

VS    120404F                       FOGARTY EMBOLECTOMY CATHETER          * * *    EA    1

VS    120602F                       FOGARTY EMBOLECTOMY (TUBE PKG)        * * *    EA    1

VS    120803F                       FOGARTY EMBOLECTOMY (TUBE PKG)        * * *    EA    1

VS    120904F                       FOGARTY EMBOLECTOMY (TUBE PKG)        * * *    EA    1

VS    120805F                       FOGARTY EMBOLECTOMY (TUBE PKG)        * * *    EA    1
</TABLE>

                                   45 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                              EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                     13-Aug-96

===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM    QPC
===============================================================================================
<S>   <C>                   <C>     <C>                                <C>         <C>   <C>
VS    120806F                       FOGARTY EMBOLECTOMY (TUBE PKG)        * * *    EA    1

VS    120807F                       FOGARTY EMBOLECTOMY (TUBE PKG)        * * *    EA    1

VS    DHYDRA33                      FOGARTY DOUBLE HYDRAJAW               * * *    CS   10

VS    DHYDRA61                      FOGARTY DOUBLE HYDRAJAW               * * *    CS   10

VS    DHYDRA86                      FOGARTY DOUBLE HYDRAJAW               * * *    CS   10

VS    SAFEHY33                      FOGARTY SAFEJAW-HYDRAJAW              * * *    CS   10

VS    SAFEHY86                      FOGARTY SAFEJAW-HYDRAJAW              * * *    CS   10

VS    CDSAFE12                      FOGARTY DOUBLE SOFTJAW                * * *    CS   10

VS    CDSAFE6                       FOGART DOUBLE SOFTJAW                 * * *    CS   10

VS    CSAFE6                        FOGARTY SAFEJAW CLIP                  * * *    CS   10

VS    700014                        1.5 PASSIVE ANGIOSCOPE                * * *    EA    1

VS    700015                        0.7 PASSIVE ANGIOSCOPE                * * *    EA    1

VS    700046                        ANGIOSCOPIC VALVULOTOME               * * *    EA    1

VS    700047                        2.3 PASSIVE ANGIOSCOPE                * * *    EA    1

VS    700070                        1.9 PASSIVE ANGIOSCOPE                * * *    EA    1

VS    700071                        AV ANGIOSCOPE                         * * *    EA    1

VS    700072                        DEFLECTNG ANGIOSCOPE                  * * *    EA    1

VS    700073                        2.8 PASSIVE ANGIOSCOPE                * * *    EA    1

VS    700031                        IRRIGATION TUBING:5 PACK              * * *    EA    1

VS    700042                        TUBING EX7ENSION SET: 5 PACK          * * *    EA    1

VS    700081                        PULLING CATHETER                      * * *    CS    5

VS    700082                        LIGHT REDUCER                         * * *    EA    1

VS    700051                        CBD STONE BASKET                      * * *    EA    1

VS    704000                        BAX 2.5D70 CBD SCOPE                  * * *    EA    1

VS    700018                        CAMERA COUPLER                        * * *    EA    1

VS    700025                        STORZ ADAPTER                         * * *    EA    1

VS    700026                        WOLF ADAPTER                          * * *    EA    1

VS    700029                        V TO C ADAPTER                        * * *    EA    1

VS    700030                        EYEPIECE ADAPTER                      * * *    EA    1
</TABLE>

                                   46 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                              EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                     13-Aug-96

===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM    QPC
===============================================================================================
<S>   <C>                   <C>     <C>                                <C>         <C>   <C>
VS    700038                        OLYMPUS TO C ADAPTER                  * * *    EA    1

VS    700039                        STRYKER ADAPTER                       * * *    EA    1

VS    700041                        MAGNIFIER                             * * *    EA    1

VS    700043                        ENDOSCOPIC PUMP (110/115V)            * * *    EA    1

VS    700085                        LIGHT SOURCE ADAPTOR                  * * *    EA    1

VS    700086                        CAMERA COUPLER FIXED FOCUS            * * *    EA    1

VS    700087                        ENDOSCOPIC FOOT PEDAL 120/220         * * *    EA    1

VS    702010                        2.8 PASSIVE REUSABLE SHAFT            * * *    EA    1

VS    702018                        1.9 PASSIVE REUSABLE SHAFT            * * *    EA    1

VS    702023                        2.4 PASS REUSE ANGIOSCOPE SET         * * *    EA    1

VS    702025                        ANGIOSCOPE SHAFT. 2.4MM               * * *    EA    1

VS    702002                        STERILIZATION CONTAINER               * * *    EA    1

VS    702003                        LUS OLYMPUS ADAPTER                   * * *    EA    1

VS    702004                        LUS STORZ ADAPTER                     * * *    EA    1

VS    702005                        LUS WOLF ADAPTER                      * * *    EA    1

VS    702006                        LUS ACMI ADAPTER                      * * *    EA    1

VS    702007                        LEAK TESTER                           * * *    EA    1

VS    702011                        BAX OPTICS MODULE                     * * *    EA    1

VS    702012                        CLEANING BRUSH 1 MM: 5 PACK           * * *    EA    1

VS    702013                        LUS EYEPIECE                          * * *    EA    1

VS    702014                        CLEANING BRUSH 0.6MM: 5 PACK          * * *    EA    1

VS    702020                        BAX LIGHT REDUCER                     * * *    EA    1

VS    702021                        BAX LSA SOLOS                         * * *    EA    1

VS    702000                        2.8 PASSIVE REUSE SET                 * * *    EA    1

VS    702016                        1.9 PASSIVE REUSE SET                 * * *    EA    1

VS    DSOFT33                       FOGARTY DOUBLE SOFTJAW                * * *    CS   10

VS    DSOFT61                       FOGARTY DOUBLE SOFTJAW                * * *    CS   10

VS    DSOFT86                       FOGARTY DOUBLE SOFTJAW                * * *    CS   10

VS    SOFT33                        FOGARTY SOFTJAW                       * * *    CS   10
</TABLE>

                                   47 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                              EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                     13-Aug-96

===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM    QPC
===============================================================================================
<S>   <C>                   <C>     <C>                                <C>         <C>  <C>
VS    SOFT61                        FOGARTY SOFTJAW                       * * *    CS   10

VS    SOFT86                        FOGARTY SOFJTAW                       * * *    CS   10

VS    HYDRA33                       FOGARTY HYDRAJAW                      * * *    CS   10

VS    HYDRA61                       FOGARTY HYDRAJAW                      * * *    CS   10

VS    HYDRA86                       FOGARTY HYDRAJAW                      * * *    CS   10

VS    CCATH6                        CATHETER SPRING CLIP                  * * *    CS   10

VS    CPARAL12                      PARALLEL JAW CLIP                     * * *    CS   10

VS    CPARAL6                       PARALLEL JAW CLIP                     * * *    CS   10

VS    HCDSOFT8                      EDSLAB HANDLELESS CLAMP               * * *    CS   10

VS    HCSOFT10                      EDSLAB HANDLELESS CLAMP               * * *    CS   10

VS    DSAFE33                       FOGARTY DOUBLE SOFTJAW                * * *    CS   10

VS    DSAFE61                       FOGARTY DOUBLE SAFEJAW                * * *    CS   10

VS    DSAFE86                       FOGARTY DOUBLE SAFEJAW                * * *    CS   10

VS    SAFE33                        FOGARTY SAFEJAW                       * * *    CS   10

VS    SAFE61                        FOGARTY SAFEJAW                       * * *    CS   10

VS    SAFE86                        FOGARTY SAFEJAW                       * * *    CS   10

VS    SAFEHY61                      FOGARTY SAFEJAW-HYDRAJAW              * * *    CS   10

VS    CSOFT12                       FOGARTY SOFTJAW CLIP                  * * *    CS   10

VS    CSOFT6                        FOGARTY SOFTJAW CLIP                  * * *    CS   10

VS    CSAFE12                       FOGARTY SOFTJAW CLIP                  * * *    CS   10

VS    CV3200                        2F EMBOLECTOMY CATH/ACCESS SET        * * *    EA    1

VS Division                         Total Models  137
</TABLE>

                                   48 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                              EXHIBIT A - Products

<TABLE>
<CAPTION>
                                                                                     13-Aug-96

===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM    QPC
===============================================================================================
<S>   <C>                   <C>     <C>                                <C>         <C>   <C>
BPS   PERFUSION SERVICES            ALL PERFUSION AND RELATED SERVICES    * * *    N/A   N/A
                                    OFFERED BY BAXTER PERFUSION
                                    SERVICES AS OF SEPTEMBER 30, 1996

CVG                                 Total Models  1,326
</TABLE>

                                   49 OF 49
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                             Schedule 1 to Exhibit A

<TABLE>
<CAPTION>
                                                                                     13-Aug-96
===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM    QPC
===============================================================================================
<S>   <C>                           <C>                                   <C>      <C>  <C>
BEN   C0006A1D                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C0006K2C                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    4

BEN   C0006Z2D                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS   15

BEN   C0008Q3T                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    2

BEN   C0225A1F                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C03B0UIN                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    4

BEN   C0380U2L                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    4

BEN   C0380YIC                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C052012J                      CUSTOM DESIGNED PEPFUSION KITS        * * *    EA    1

BEN   C0520Z6A                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS   25

BEN   C0580K31                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C0580K61                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    2

BEN   C0580M3M                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    2

BEN   C0580Y1F                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    4

BEN   C0690L4C                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C0750M1W                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    2

BEN   C0750M3U                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    2

BEN   C0790X3C                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C0810E1J                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    2

BEN   C0810F2K                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    4

BEN   C0810H2A                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    4

BEN   C0810X1M                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C0830G6E                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    2

BEN   C0830X2T                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C0900A2B                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C0900A2Z                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C0900K2C                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C0900Z1A                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS   10

BEN   C0930P2F                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1
</TABLE>

                                    1 OF 10
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                            Schedule 1 to Exhibit A

<TABLE>
<CAPTION>
                                                                                     13-Aug-96
===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM    QPC
===============================================================================================
<S>   <C>                           <C>                                   <C>      <C>   <C>
BEN   C0930X3G                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C095OY1A                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    4

BEN   C0950Z1Y                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    2

BEN   C1010X1B                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C1090L2X                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    I

BEN   C1110W1D                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    I

BEN   C1620X7F                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    I

BEN   C1850H1A                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    2

BEN   C1860W1S                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS   24

BEN   C1860Z3D                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    5

BEN   C1860ZSC                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS   12

BEN   C2130M1E                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    2

BEN   C2130P1B                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    2

BEN   C2130S1A                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS   10

BEN   C2130X1G                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    I

BEN   C2170F1A                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    I

BEN   C2170G1D                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS   24

BEN   C2170G2A                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS   24

BEN   C2170H1A                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    2

SEN   C2170JIA                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS   50

BEN   C2170K2D                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    6

BEN   C2170K4A                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    6

BEN   C2170N1P                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C2170N2N                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C2170N3H                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    6

BEN   C2170N6D                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C2I70N9C                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C2170PIM                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    6

BEN   C2170P3C                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    2
</TABLE>

                                    2 OF 10
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                             Schedule 1 to Exhibit A

<TABLE>
<CAPTION>
                                                                                     13-Aug-96
===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM    QPC
===============================================================================================
<S>   <C>                           <C>                                   <C>      <C>  <C>
BEN   C2170P7B                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    6

BEN   C2170Z2B                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS   24

BEN   C2410D2B                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    6

BEN   C2410K4F                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    4

BEN   C2410KSB                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    4

BEN   C2410WIC                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    2

BEN   C241OX2Z                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C2410X3A                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C2410X4A                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C2560Y2E                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    5

BEN   C2570M2U                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C2570X4E                      CUSTOM DESIOWED PERFUSION KITS        * * *    EA    1

BEN   C2640K4L                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    2

BEN   C2640Z6A                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS   10

BEN   C2660K1D                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    2

BEN   C2820Z3A                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS   20

BEN   C2900A1D                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C2960Z1A                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS   15

BEN   C2960Z2A                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS   15

BEN   C3010A1F                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C3010X3E                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C3010Z1A                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    5

BEN   C3030X2J                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C3080A4E                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    I

BEN   C3080E3E                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    I

BEN   C308OF6D                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    2

BEN   C3080K2B                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    4

BEN   C3470A1E                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C3470F1B                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1
</TABLE>

                                    3 OF 10
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                             Schedule 1 to Exhibit A

<TABLE>
<CAPTION>
                                                                                      13-Aug-96
===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM    QPC
===============================================================================================
<S>   <C>                           <C>                                   <C>      <C>  <C>
BEN   C3470F2B                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C3650A1C                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C3790P1T                      CUSTOM DESIGWED PERFUSION KITS        * * *    CS    2

BEN   C3790T2J                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    6

BEN   C3820C41                      CUSTOM DESIGNED PERFUSION KIMS        * * *    CS    4

BEN   C3820P10                      CUSTOM DESIGNED PERFUSION KRTS        * * *    CS    5

BEN   C3820T2F                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    3

BEN   C3820X1C                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    I

BEN   C4020Z2R                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    I

BEN   C4030A1B                      CUSTOM DESIGWED PERFUSION KITS        * * *    EA    1

BEN   C4040Q4H                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    I

BEN   C4040Q5J                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    I

BEN   C4040Y1F                      CUSTOM DESIGNED PERFUSION KM          * * *    CS    5

BEN   C4310X1D                      CUSTOM DESIGNED PEKFUSION KITS        * * *    EA    1

BEN   C4380K1B                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C4380T1B                      CUSTOM DESIGNED PEILFUSION KITS       * * *    EA    1

BEN   C4400X6E                      CUSTOM DESIGNED PFIVUSION KITS        * * *    EA    1

BEN   C4400X7E                      CUSTOM DESIGNED PEIVUSION KITS        * * *    EA    1

BEN   C4420X4H                      CUSTOM DESIGNED PERFUSION KLTS        * * *    EA    1

BEN   C4420Y2C                      CUSTOM DESIGNED PEIVUSION KM          * * *    CS    4

BEN   C4470H2B                      CUSTOM DESIGNED PEIVUSION KM          * * *    CS    4

BEN   C4470X4O                      CUSTOM DESIGNED PEPFUSION XITS        * * *    EA    1

BEN   C4470X5D                      CUSTOM DESIGNED POLRUSION KJTS        * * *    EA    1

BEN   C4470X8B                      CUSTOM DESIGNED PERFUSION XRTS        * * *    EA    1

BEN   C4470Z5D                      CUSTOM DESMED PERFUSION KITS          * * *    CS    2

BEN   C4470Z6B                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    2

BEN   C4560X4J                      CUSTOM DESIGNED PERFUSION KM          * * *    EA    1

BEN   C4580M2R                      CUSTOM DESIGNED PEKFUSION KM          * * *    EA    1

BEN   C4580M3T                      CUSTOM DESIGNED PERYUSION WS          * * *    EA    1
</TABLE>

                                    4 OF 10
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                             Schedule 1 to Exhibit A

<TABLE>
<CAPTION>

                                                                                     13-Aug-96
===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM   QPC
===============================================================================================
<S>   <C>                           <C>                                   <C>      <C>   <C>
BEN   C4580Z6J                      CUSTOM DESIGNED PEIVUSION XM          * * *    EA     1

BEN   C4SA0Z7G                      CUSTOM DESIGNED PEKFUSION KITS        * * *    EA     1

BEN   C4580Z8G                      CUSTOM DESIGNED PERFUSION KRM         * * *    EA     1

BEN   C4690K1D                      CUSTOM DESIGNED PERFUSION XRM         * * *    EA     1

BEN   C4690X2G                      CUSTOM DESIGNED PEIVUSION KM          * * *    EA     1

BEN   C4830H1B                      CUSTOM DESIGNED PEIVUSION KJTS        * * *    EA     1

BEN   C50807A                       CUSTOM DESIGNED PEIVUSION KRM         * * *    CS     5

BEN   C5460X2B                      CUSTOM DESIGNED PERFUSION KRRS        * * *    EA     1

BEN   C5500X5G                      CUSTOM DESIGNED PERFUSION KRM         * * *    EA     1

BEN   C6030P2F                      CUSTOM DMGNED PEIVUSION KITS          * * *    EA     1

BEN   C6030P4B                      CUSTOM DESIGNED PERFUSION KJTS        * * *    EA     1

BEN   C6430X3B                      CUSTOM DESIGNED PEPLFUSION KITS       * * *    EA     1

BEN   C6500K5B                      CUSTOM DESIGNED PERFUSION KM          * * *    CS     2

BEN   C650OX4A                      CUSTOM DESIGNM PERFUSION KITS         * * *    CS     4

BEN   C6500Y1C                      CUSTOM DESIGNED PERFUSION XFFS        * * *    CS     6

BEN   C6700F1S                      CUSTOM DESIGNED PEKFUSION XRRS        * * *    CS     2

BEN   C6700X2D                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA     1

BEN   C6700X3F                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA     1

BEN   C6916A2C                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA     1

BEN   C6916A4K                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA     1

BEN   C6916C1D                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS     5

BEN   C6916G6F                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    24

BEN   C6916G7B                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    24

BEN   C6916J7E                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS     5

BEN   C6916K6F                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS     4

BEN   C6916K8C                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS     4

BEN   C6916S1A                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS     5

BEN   C6916T4C                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS     4

BEN   C6916T5F                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS     6
</TABLE>

                                    5 OF 10
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                             Schedule 1 to Exhibit A

<TABLE>
<CAPTION>
                                                                                     13-Aug-96
===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM    QPC
===============================================================================================
<S>   <C>                           <C>                                   <C>      <C>    <C>
BEN   C6916T6H                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS      6

BEN   C6916V5A                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS     20

BEN   C6916V6A                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS     24

BEN   C6916X3G                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA      1

BEN   C6916X5F                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA      1

BEN   C6916X6C                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA      1

BEN   C6916Y2B                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS      3

BEN   C7004X11                      CUSTOM DESIGNED PEIVUSION KITS        * * *    EA      1

BEN   C7006N10                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA      1

BEN   C7006P3G                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA      1

BEN   C9044Y1A                      CUSTOM DESIGNED PEIVUSION KITS        * * *    CS     12

BEN   C9046X1H                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA      1

BEN   C9D96X2C                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA      1

BEN   C9130A4H                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA      1

BEN   C9130X3B                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA      1

BEN   C9130Z3B                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS      6

BEN   C9132Q11                      CUSTOM DESIGNED PEPFUSION KITS        * * *    EA      1

BEN   C9138X3G                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA      1

BEN   C9166M1P                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS      2

BEN   C9166M6D                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA      1

BEN   C9166X4C                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA      1

BEN   C9198M11                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA      1

BEN   C9204X3E                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA      1

BEN   C9204X4H                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA      1

BEN   C9207A1B                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS      4

BEN   C9207E1B                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS      2

BEN   C9207K11                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS      2

BEN   C920711A                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS      2

BEN   C9208P7H                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA
</TABLE>

                                    6 OF 10
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                             Schedule 1 to Exhibit A

<TABLE>
<CAPTION>
                                                                                     13-Aug-96
===============================================================================================
  DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM    QPC
===============================================================================================
<S>   <C>                           <C>                                   <C>      <C>    <C>
BEN   C9214K4C                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS      4

BEN   C9214X3H                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA      1

BEN   C9214X4D                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA      1

BEN   C9214Y2B                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS      6

BEN   C9235C4K                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS      2

BEN   C9235P5B                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS      4

BEN   C9235V1D                      CUSTOM DESIGWED PERFUSION KITS        * * *    CS     24

BEN   C9235Z4C                      CUSTOM DESIGNED PEIVUSION KITS        * * *    CS      6

BEN   C9245A1U                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS      2

BEN   C9262A1N                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA      1

BEN   C9276T3K                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS      4

BEN   C9318A2D                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA      1

BEN   C9318C1C                      CUSTOM DESIGNED PERFBSION KITS        * * *    CS      2

BEN   C93I8W31                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA      1

BEN   C9336A1K                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS     3

BEN   C9358X2B                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA     1

BEN   C9369H1A                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS     4

BEN   C9369H2B                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS     4

BEN   C9404G1A                      CUSTOM DESIGWED PERFUSION KITS        * * *    CS     2

BEN   C9420L3O                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA     1

BEN   C9420X2D                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA      1

BEN   C9433Y1C                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS      6

BEN   C9444X1B                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA      1

BEN   C9475Q1Z                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA      1

BEN   C9525K11                      CUSTOM DESIGNED PERFUSION KRRS        * * *    CS      2

BEN   C9525X1M                      CUSTOM DESIGNED PERFUSION KRRS        * * *    EA      I

BEN   C9529CIC                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS      2

BEN   C9529T3C                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS      4

BEN   C9529X7C                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA      1
</TABLE>

                                    7 OF 10
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                             Schedule 1 to Exhibit A

<TABLE>
<CAPTION>
                                                                                     13-Aug-96
===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM    QPC
===============================================================================================
<S>   <C>                           <C>                                   <C>      <C>  <C>
BEN   C9533X1H                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C9536K1H                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    2

BEN   C9536X1L                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C9536X2G                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C9536Z5A                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS   10

BEN   C9541C5A                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS   10

BEN   C9541E2F                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C9541K2G                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    4

BEN   C9541K6C                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    4

BEN   C9541K7A                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS   10

BEN   C9541K8A                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS   10

BEN   C9541P3B                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C9541X6C                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C9541X9F                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C9541Y1F                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    2

BEN   C9541Z5A                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS   12

JEW   C9573A1F                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    2

BEN   C9582H1E                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C9587A1L                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    2

BEN   C9597D1D                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    2

BEN   C9597X2U                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C9603X4I                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C9626A1E                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    2

BEN   C9626H1K                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    2

BEN   C9626Y1H                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS   12

BEN   C9663C1A                      CUSTOM DESIGNED PERFUSION KIT         * * *    CS    2

BEN   C9663K1B                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    4

BEN   C9663M3E                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C9671A1A                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1
</TABLE>

                                    8 OF 10
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                             Schedule 1 to Exhibit A

<TABLE>
<CAPTION>
                                                                                     13-Aug-96
===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM    QPC
===============================================================================================
<S>   <C>                           <C>                                   <C>      <C>  <C>
BEN   C9671L2H                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C9685X2G                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C9704X2J                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C9783P1L                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    5

BEN   C9783T2D                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    5

BEN   C9799K2B                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    6

BEN   C9799N3C                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C9799N4C                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C9799P2D                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C9799Z4A                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    6

BEN   C9807K1B                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    2

BEN   C9807X3E                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C9810X8P                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C9819Q1X                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C9821A1A                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    5

BEN   C9821K1B                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    4

BEN   C9821T1B                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    3

BEN   C9821X2B                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C9827R2M                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C9850M1F                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C9850X1H                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C9851Y1D                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    5

BEN   C9854A1G                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C9854E1J                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C9854F2G                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C9854Z2B                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C9854Z3B                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C9862X2G                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C9867M1K                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1
</TABLE>

                                    9 OF 10
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                             Schedule 1 to Exhibit A

<TABLE>
<CAPTION>
                                                                                     13-Aug-96
===============================================================================================
 DIV        MODEL           SIZE               DESCRIPTION             PRICE/UOM   UOM    QPC
===============================================================================================
<S>   <C>                           <C>                                   <C>      <C>  <C>
BEN   C9867M2J                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C9889K2E                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    1

BEN   C9908X1O                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C9923G3D                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS   10

BEN   C9923H1C                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    2

BEN   C9927A1F                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C9927K1E                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    4

BEN   C9927X1D                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C9927X3F                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

BEN   C9927Y1B                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    4

BEN   C9934A1A                      CUSTOM DESIGNED PERFUSION KITS        * * *    CS    2

BEN   C9934X1C                      CUSTOM DESIGNED PERFUSION KITS        * * *    EA    1

                                    273 TOTAL MODELS
</TABLE>

                                   10 OF 10
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                      SERVICES AND DISTRIBUTION AGREEMENT

                                   EXHIBIT B

                              Allegiance's Duties
                              -------------------

1.   General Duties.

     1.1  Corporate Agreement Bonus Program.  Allegiance shall participate in
          ---------------------------------
the corporate agreement bonus program for the Products as follows:

          1.1.1     Existing Agreements.
                    -------------------

               1.1.1.1  The "Existing Corporate Agreements" shall mean Baxter's
     agreements with stand-alone hospitals and regional and national health
     systems with effective dates prior to September 30, 1996 which provide for
     annual bonus or discount payments based, inter alia, upon the quantity of
                                              ----------
     Baxter-manufactured products purchased by the customer.

               1.1.1.2  Allegiance will accept assignment of the Existing
     Corporate Agreements and will administer the Existing Corporate Agreements
     on behalf of itself and Baxter.

               1.1.1.3  Allegiance shall honor and administer each Existing
     Corporate Agreement through its expiration or earlier termination pursuant
     to its terms.

               1.1.1.4  The corporate agreement bonus funding process will be
     the same as prior to October 1, 1996, i.e., the corporate agreement bonuses
                                           ----
     will be funded by Baxter and Allegiance, the allocation will be made based
     on the estimated total year-end payout and actual May year-to-date sales
     and gross profit recognized from the applicable customers, the bonus
     allocation will be invoiced by Allegiance to Baxter on a monthly basis
     (terms of payment will be net 30 days), and on or before May 31 of each
     year, any over-accrual or under-accrual will be allocated to Allegiance or
     Baxter based upon the foregoing allocation for the applicable year.

               1.1.1.5  Allegiance shall prepare and present the corporate
     agreement bonus payments to the customers and Baxter has the right to have
     Baxter

                                      B-1
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

     representatives present.

          1.1.2     Future Agreements.  For any corporate bonus agreements
                    -----------------
entered into on or after the Effective Date with stand-alone hospitals and
regional and national health systems, Allegiance shall meet with each Baxter
business unit to determine whether such Baxter business unit desires to
participate in any such agreements.

     1.2  Sales Support.  Allegiance shall use commercially reasonable efforts
          -------------
to support sales of the Products and Perfusion Services in accordance with the
following and such efforts are in lieu of any standard of performance implied by
Section 2-306(2) of the U.C.C.:

          1.2.1     Allegiance field service representatives (customer service
representatives in the field) shall direct customer inquiries regarding the
Products and Perfusion Services to Baxter's customer service support
organization for resolution (the parties agree that field service
representatives will be resident in each region as of the Effective Date).

          1.2.2     Allegiance account managers shall:  (a) provide Baxter with
access to the customer decision-makers; (b) generate sales interest in the
Products and Perfusion Services; (c) actively support the joint customer
satisfaction strategy between Allegiance and Baxter; and (d) work with Baxter
(in a manner similar to that prior to the Effective Date) relative to account
segmentation rating of Baxter customers.

          1.2.3     Allegiance shall participate with Baxter in a semi-annual
review of regional account segmentation, performance to critical business
indicators, and regional sales to be conducted with Baxter's leaders of the
respective sales organizations and the Allegiance region president and the
Allegiance region president's steering team.

          1.2.4     Allegiance's sales generalist sales force shall continue to
promote sales of the Products and Perfusion Services in the same manner as prior
to the Effective Date.

          1.2.5     Upon termination or expiration of any pre-existing customer
contract with a third-party supplier for products that compete with any Product
or Products, Allegiance shall cause such customer contracts to encourage and
facilitate use of the Products (rather than any product competing with any
Product or Products) through appropriate means, including, but not limited to,
the Allegiance customer contract provisions and/or sales representative
incentives.

                                      B-2
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

          1.2.6     Allegiance shall use commercially reasonable efforts to
encourage its customers to convert BCS Kit components manufactured by third
parties to Baxter-manufactured components.

     1.3  Marketing Support.  Allegiance shall use commercially reasonable
          -----------------
efforts to support marketing of the Products and Perfusion Services in
accordance with the following and such efforts are in lieu of any standard of
performance implied by Section 2-306(2) of the Uniform Commercial Code:

          1.3.1     Allegiance shall provide marketing services (other than
product management services which will be provided by Baxter) to Surgery
Centers.

          1.3.2     Allegiance shall maintain its own communications resources
and shall coordinate the communications messages with Baxter when appropriate.

          1.3.3     Allegiance shall attempt whenever possible to share with
Baxter expenses for convention fees, industry organizations, and industry
databases when and where appropriate.

          1.3.4     Prior to publication, Allegiance shall submit to Baxter for
Baxter's approval all Allegiance promotional/communication endeavors
specifically referencing the Products, Perfusion Services or any Baxter
services.

          1.3.5     As part of a general promotion, Allegiance shall represent
the Products and Perfusion Services fully and prominently in Allegiance's
product and service literature or any other media, including field sales support
tools, except for non-Cost Management accounts, such promotions shall be
provided by Allegiance at a similar level as provided prior to the Effective
Date.

          1.3.6     Allegiance shall include Baxter sales volume by Product
category on Allegiance's sales reports in a similar format as provided by
Allegiance prior to the Effective Date.

          1.3.7     For a fee to be agreed upon from time to time, Allegiance
shall provide literature distribution services to Baxter.

     1.4  Materials Management.  Allegiance and Baxter shall use commercially
          --------------------
reasonable efforts to make the supply chain as efficient as possible.  Future
opportunities to improve efficiency could include, but are not limited to, EDI,
bar coding, custom palletization, network channels and the use of returnable
totes.  Both parties agree to work in good faith to

                                      B-3
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

achieve this goal.

          1.4.1     Finished Goods Requirements Planning.
                    ------------------------------------

               1.4.1.1  Allegiance will adhere to stocking, storage and delivery
     levels established by Baxter for all Products.

               1.4.1.2  Allegiance will assist Baxter in moving inventory
     between Allegiance-owned replenishment centers and all distribution centers
     for purposes of re-balancing excess stocks and/or managing back orders.

               1.4.1.3  Allegiance will not be required to carry more than 1995
     average Days Inventory On Hand.

          1.4.2     Tracing Reports.
                    ---------------

               1.4.2.1   Allegiance will electronically provide a daily sales
     tracing report to Baxter.  With respect to Products, this tracing report
     will show for all Products sold to customers, including Products sold as
     components of PBDS Kits, at a minimum (a) the product model, (b) quantity
     shipped, (c) lot number in accordance with Section 1.5.6 of Exhibit B, (d)
     oxygenator serial number, only when required, (e) customer name and
     address, (f) the Allegiance customer number, and (g) any Products shipped
     to customers directly by Baxter on behalf of Allegiance (drop/ship).

               1.4.2.2  Within 5 days of the end of each month, Allegiance shall
     transmit to Baxter trace sales information for BCS Kit components.

     1.5  Distribution.
          ------------

          1.5.1     Shipment From Plants to Replenishment Centers.  Allegiance
                    ---------------------------------------------
will be responsible for assisting Baxter in the resolution of all freight claims
for Products manufactured at any Allegiance manufacturing facility.

          1.5.2     Receiving (Notification and Planning).
                    -------------------------------------

               1.5.2.1  Product will be system received within one and one-half
     business days of arrival at an Allegiance distribution center or an
     Allegiance replenishment center.

                                      B-4
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

               1.5.2.2   Allegiance will work in coordination with Baxter to
     schedule receiving appointments for Products coming from Plants and
     Replenishment Centers.

               1.5.2.3   Allegiance will receive products at distribution
     centers using Baxter's and Allegiance's computer systems or an Allegiance
     warehouse management system that will upload to such computer system.

          1.5.3     Warehouse Management.
                    --------------------

               1.5.3.1  Allegiance will be responsible for the management of all
     Allegiance facilities.

               1.5.3.2  Allegiance will measure and report to Baxter on a
     monthly basis Product damage or loss that occurs subsequent to arrival at
     Allegiance distribution centers and prior to shipment to customers.  If any
     Products purchased by Allegiance under the Distributor Model or Kit Model
     are damaged, lost or stolen while in an Allegiance replenishment center or
     distribution center, (1) Baxter will issue a credit memo to Allegiance for
     such damaged, lost or stolen Products at Baxter's applicable Distributor
     List Price, and (2) Baxter will invoice Allegiance monthly for such
     damaged, lost or stolen Products (but not carton failure) at its applicable
     standard cost as stated in Baxter's inventory valuation reports.

               1.5.3.3  Allegiance shall have the right to any amounts recovered
     with respect to freight claims for Products shipped from Allegiance
     facilities to customers under the Distributor Model.

               1.5.3.4  Should Baxter redefine storage requirements, Allegiance
     and Baxter will mutually agree upon a new fee for service rate.

               1.5.3.5  Except as otherwise agreed to, Allegiance will adhere to
     existing storage, shipping and receiving practices, including practices
     regarding time-sensitive Products.

               1.5.3.6  Both parties agree that the echeloning of products based
     on line item usage generally makes sense. Assuming there are no significant
     customer contractual issues or financial impacts to Baxter, Baxter agrees
     to the parameters set forth by the rationalized supply chain.  If after the
     appropriate review there are significant customer contractual issues or
     financial impacts to Baxter, 1995 will be used as the baseline for where

                                      B-5
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

     products are stocked and the number of low velocity SKU's will not exceed
     1995 levels.

               1.5.3.7  Allegiance will measure and report to Baxter on a
     monthly basis Product damage that occurs prior to arrival at Allegiance
     distribution centers or its replenishment centers.

          1.5.4     Pipeline Visibility. Visibility to actual inventory levels
                    -------------------
for all segments of the Allegiance pipeline necessary to support Baxter
production planning will be provided through Allegiance systems as provided
prior to the Effective Date.

          1.5.5     Order Fulfillment.  When customer orders are released
                    -----------------
through Baxter's or Allegiance's computer systems, Allegiance personnel will
pick, pack, load and stage the customer order for delivery within the Allegiance
distribution center.

          1.5.6     Outbound Shipment.
                    -----------------

               1.5.6.1  Allegiance personnel shall be responsible for the
     selection and routing, private fleet or commercial carrier, of the Baxter
     customer order.

               1.5.6.2  Allegiance shall continue to provide the following
     services for all outbound shipments (i.e., shipments to customers), to the
     extent that such services were normally being provided by Baxter prior to
     the Effective Date:  (a) freight payment; (b) audit of freight payments,
     (c) transportation cost reporting, and (d) logistics analysis/distribution
     technology to include network planning and replenishment center sourcing.
     Allegiance's compensation for such services is included in the amounts
     provided in Section 7.2. For an additional fee to be agreed upon,
     Allegiance may agree to provide to Baxter additional outbound freight
     services beyond the scope of the services normally being furnished by
     Baxter prior to the Effective Date.

               1.5.6.3  Allegiance shipments will be based on bill of lading
     (BOL) instructions.  If no specific instruction appears in BOL, shipments
     will occur on the next scheduled delivery or within a maximum of two
     business days (if no scheduled delivery).

               1.5.6.4  Whenever Allegiance is responsible for shipping the
     Products to the customer, Allegiance will be responsible for filing freight
     claims with commercial

                                      B-6
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

     carriers/private fleet and will be responsible for resolving product
     shortages and overages, including proof of delivery.

               1.5.6.5   Allegiance will verify shipments of Products to
     customers by private fleet or commercial carriers within one business day.

          1.5.7     Lot Tracking.  Allegiance shall provide lot tracking
                    ------------
capabilities, if any, as provided by Allegiance for the Products prior to the
Effective Date.  As the Witron system lot tracking capabilities become available
at each Allegiance distribution center or replenishment center, Allegiance shall
make such capabilities available to Baxter under the existing fee structure.

          1.5.8     Returned Goods Management.
                    -------------------------

               1.5.8.1   Allegiance shall pick up, process and dispose of
     returned Products at Baxter's request. Allegiance will be compensated by
     Baxter for the actual out-of-pocket cost of such returned Product disposal
     services.

               1.5.8.2   Allegiance will continue practices existing immediately
     prior to the Effective Date regarding returned goods processing, including
     unloading, segregation, inspection, product disposition (restocking,
     disposal, or transport for restocking), documentation, and forwarding
     paperwork for Baxter to administer credit to Allegiance.

               1.5.8.3   Return goods processing time (receipt date at
     distribution center to paperwork receipt at Baxter) will not exceed 30
     days.

               1.5.8.4   Allegiance shall use commercially reasonable efforts to
     dispose of returned Products in a cost-effective manner, subject to
     Baxter's instructions.

     1.6  Product Field Corrective Actions.
          --------------------------------

          1.6.1     Allegiance shall perform field corrective action ("FCA")
services in a manner consistent with the quality systems, procedures and
specifications as of the Effective Date. Allegiance shall provide the following
FCA services for the fee stated in Section 6.7:

               a.   FCA notification processing;
               b.   FCA disposition processing;
               c.   storage of Products affected by an FCA inside an Allegiance
                    distribution center for up to

                                      B-7
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                    six months from the date of initiation of the FCA;
               d.   transportation of all Products affected by the FCA to
                    Baxter, freight collect;
               e.   rework or inspections of Products by Allegiance employees;
               f.   discard and destruction of Products utilizing nonhazardous
                    waste disposal methods by Allegiance employees;
               g.   delivery of recall report information to Baxter;
               h.   incoming inspection of all Baxter Products for open FCAs for
                    twelve months from the date of initiation of the FCA; and
               i.   third-party invoices for any of the services listed above.

     1.6.2     At Baxter's request and with Baxter's approval, Allegiance shall
perform FCA services not included in Section 1.6.1 for additional compensation
to be agreed upon.  Baxter will be invoiced separately for such additional
services pursuant to Section  of this Agreement.  Examples of additional FCA
services addressed by this Section 1.6.2 include:

               a.   all third-party invoices related to expenses incurred by
                    Allegiance that arise out of the need for Baxter to issue an
                    FCA for Products;
               b.   computer system upgrades requested by Baxter or Baxter for
                    Allegiance FCA systems;
               c.   storage of Products affected by an FCA for periods longer
                    than six months or storage of such Products in rented
                    trailers; and
               d.   incoming inspection of all Products for open FCAs for
                    periods longer than 12 months from the date of initiation of
                    the FCA.

          1.6.3  For purposes of the subsequent provisions of this Section 1.6,
Allegiance shall use commercially reasonable efforts to accomplish the FCA tasks
identified within the time periods indicated.  If extraordinary volume or other
circumstances make such time periods impracticable, Baxter and Allegiance will
make adjustments by extending time periods, setting priorities or otherwise.

          1.6.4     Allegiance shall perform FCA notification to Allegiance's
distribution centers and replenishment center based upon priorities.  Priority A
notification requires extraordinary and immediate action.  Priority B
notification requires

                                      B-8
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

notification to all Allegiance distribution centers and its replenishment center
within one business day. Priorities will be based on the urgency of the FCA as
determined primarily by Baxter.

          1.6.5     For FCAs involving Products sold under the Distributor
Model, Allegiance shall provide customer lists to Baxter the next business day
for requests received before 1:00 p.m. Central Standard Time.

          1.6.6     Allegiance shall perform stock checks based upon priorities.
Priority A requires extraordinary and immediate action.  Priority B requires
processing and reporting on the same day.  Priority C will be negotiated based
upon needs but generally requires processing and reporting in 2 to 5 business
days.  Priorities will be based on the urgency of the FCA as determined
primarily by Baxter.

          1.6.7     Initial inventory reports shall be issued in 5 business days
from initial FCA notification to Allegiance's distribution centers or
replenishment center unless otherwise requested.

          1.6.8     Subject to local restrictions regarding discard of the
products, routine dispositions (as designated by Baxter) shall be issued to
Allegiance's distribution centers and replenishment center in 5 business days.
Allegiance's distribution centers and replenishment center shall then have 5
business days to process the routine disposition.

          1.6.9     Subject to local restrictions regarding discard of the
Products, expedited dispositions (as designated by Baxter) shall be issued to
Allegiance's distribution centers and replenishment center within 1 business
day.  Allegiance's distribution centers and replenishment center shall then have
five business days to process the expedited disposition.

          1.6.10    Subject to local restrictions regarding discard of the
Products, extraordinary dispositions (as designated by Baxter) shall be issued
within 1 business day. Allegiance's distribution centers and replenishment
center shall then have one business day to process the extraordinary
disposition.

          1.6.11  Reconciled disposition reports for quantity variance shall be
negotiated between Allegiance and Baxter at the time of disposition.

          1.6.12  The necessity for and content of sampling plans

                                      B-9
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

and protocols shall be negotiated at the time of the FCA.

          1.6.13  Allegiance shall cooperate with Baxter in performing any FCA
by identifying affected Products and customers, developing an action-specific
management plan detailing specific responsibilities, and notifying customers of
any such action.  Allegiance shall encourage customers to follow instructions
related to any hold or recall situation.

     1.7  Special Allegiance Inbound Freight Services. Allegiance shall continue
          -------------------------------------------
to provide the following services for all inbound freight shipments (i.e.,
shipments of Products from manufacturing plants to replenishment centers or
distribution centers or from replenishment centers to distribution centers) to
the extent that such services were normally being provided by Baxter's US
Distribution business to Baxter prior to the Effective Date:  (a) freight
payment; (b) audit of freight payments, (c) transportation cost reporting, and
(d) logistics analysis/distribution technology to include network planning and
replenishment center sourcing.  Allegiance's compensation for such services will
be determined in accordance with the methodology used by Baxter prior to the
Effective Date. For an additional fee to be agreed upon, Allegiance may agree to
provide to Baxter additional inbound freight services beyond the scope of the
services normally being furnished by Baxter prior to the Effective Date.

2.   Distributor Model.

     2.1  Receipt of Products.  Allegiance system receives the Products into its
          -------------------
computer system.

     2.2  Customer Service.  Allegiance shall provide customer service support
          ----------------
and order entry as follows for all Products and Perfusion Services sold under
the Distributor Model:

          2.2.1     Product/Service Specifications - Allegiance shall forward to
                    ------------------------------
Baxter any requests for Product information not available on Allegiance systems.

          2.2.2     Pricing/Contracting Information - Allegiance shall develop
                    -------------------------------
and maintain contract information for all contracts, and such information shall
be accessible to Allegiance via its computer system.

          2.2.3     Product Availability - Allegiance shall provide fill rate
                    --------------------
and product availability information to all service personnel and regions, and
such information shall reside in Allegiance and Baxter systems.

                                     B-10
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

          2.2.4     Competitive Product Cross-Referencing - Allegiance shall
                    -------------------------------------
update Product cross-reference information on a consistent time frame and
provide it to the service personnel via Allegiance's system.

          2.2.5     Sales Representative Information - Allegiance shall provide
                    --------------------------------
Allegiance representative identification to the customer.  This information will
reside in the customer master file and be updated as needed by the sales
administration group.

          2.2.6     New Customer Set-Up - Allegiance customer service
                    -------------------
representatives will ensure effective and efficient coding of all new customers
into the customer master files.

          2.2.7     Order Fulfillment/Sales Process.
                    -------------------------------

               2.2.7.1  Order Placement - Allegiance customer service
                        ---------------
     representatives will be the initial access point for customer into
     Allegiance and will handle inquiries and order placement efficiently and
     effectively.  The order entry activity will function on the Allegiance's
     computer system (except for hardware ordered through sales support groups).

               2.2.7.2  Order Tracking - Allegiance shall maintain the ability
                        --------------
     to identify to customers the location of Products in the order process.

               2.2.7.3  Special Request Processing - Allegiance customer service
                        --------------------------
     representatives will process special handling requests by customer such as
     drop shipping, alternate shipping, special handling, lot holding, etc., and
     will work within contract guidelines and procedural boundaries to service
     the customer.

               2.2.7.4  Invoicing - Allegiance will perform billing for the
                        ---------
     Products and Perfusion Services where required via appropriate computer
     system.

               2.2.7.5  Customer Satisfaction - Allegiance service personnel are
                        ---------------------
     accountable for the customer's satisfaction regarding the service provided.
     Allegiance will use processes established to survey customer satisfaction
     levels and manage improvement plans.

          2.2.8     Post-Sales Service.
                    ------------------

               2.2.8.1  Discounts - Allegiance will pass all appropriate sales
                        ---------
     information to Baxter who will calculate all discounts and incentives for
     all customers.

                                     B-11
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

               2.2.8.2  Credit and Collection - Allegiance shall be responsible
                        ---------------------
     for all collection and credit approval processes for all invoices.
     Allegiance shall have the sole authority to issue credits.  Allegiance
     shall inform Baxter when a customer is placed on credit hold.

               2.2.8.3  Credits for Shortages, Damages, Misdeliveries -
                        ---------------------------------------------
     Allegiance shall issue credits and resolve customer issues and communicate
     with Baxter.

               2.2.8.4  Pricing Disputes - Allegiance will handle pricing
                        ----------------
     disputes.

               2.2.8.5  Back Order Status and Resolution - Allegiance will be
                        --------------------------------
     accountable for managing customer communication of back orders to provide
     accurate and timely information on resolution.  Appropriate product
     substitution information will be communicated to customer.  Allegiance will
     transmit back order details the same as they were transmitted immediately
     prior to the Effective Date.

               2.2.8.6  Product Complaint - Initial customer complaints will be
                        -----------------
     logged by Allegiance customer service and forwarded to the Vice President
     of Regulatory Affairs (or such person's designee) of Baxter (CVG) at a
     frequency to be agreed upon by the parties.  Such complaints may be
     escalated for resolution per FDA procedures.

               2.2.8.7  Technical Support - Basic technical support information
                        -----------------
     as resident on Baxter's computer system will be provided to Allegiance.
     Additional information including technical letters and clinical information
     will be provided by the Baxter Product Information Center.

     2.3  Pricing/Billing.
          ---------------

          2.3.1     Allegiance will negotiate the delivered price for the
Products and Perfusion Services sold through the Distributor Model and Kit
Model.

          2.3.2     Allegiance will quote the Allegiance price to the customer
in response to market conditions but may quote as its price the Suggested Sales
Price, plus any markup or less any markdown it feels is appropriate including
any markup for added services.

          2.3.3     Each customer will sign a bid or contract with Allegiance
and an addendum or new contract with Baxter that states that such customer has
reached agreement with Allegiance

                                     B-12
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

on the final price such customer will pay. The customer must comply with
purchase requirements of the bilateral contract with Baxter and the bilateral
contract shall continue to constitute a binding commitment of the customer to
Baxter. Shortfall charges and cancellation fees, if any, under such bilateral
contract will be calculated using the Sales Price and will be administered by
Baxter. If shipment to a customer occurs prior to execution of a bilateral
contract, Allegiance will be charged the List Price for the Products shipped
less the applicable percentage specified in Section 6.2.

          2.3.4     Allegiance shall process all billing to the customer on its
computer system.

                                     B-13
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                      SERVICES AND DISTRIBUTION AGREEMENT

                                   EXHIBIT C

                                Baxter's Duties
                                ---------------

1.   General Duties.

     1.1  Corporate Agreement Bonus Program.  Baxter shall participate in the
          ---------------------------------
corporate agreement bonus program as follows:

          1.1.1     Baxter shall assign the Existing Corporate Agreements to
Allegiance.

          1.1.2     Baxter shall provide to Allegiance comparable sales and
gross profit data as it provided prior to October 1, 1996, for each applicable
customer.

          1.1.3     Baxter shall pay to Allegiance Baxter's share of operations
and systems expenses required to support the administration of the Existing
Corporate Agreements and bonus plan based upon Baxter's share of the corporate
agreement bonus as a percentage of the total corporate agreement bonus.

          1.1.4     Baxter may have a representative(s) present when Allegiance
presents each bonus check to each customer.

     1.2  Sales.
          -----

          1.2.1     Baxter shall participate with Allegiance in a semi-annual
review of regional account segmentation, performance to critical business
indicators, and regional sales to be conducted with Baxter's leader of the
respective sales organizations and the Allegiance region president and the
Allegiance region president's steering team.

     1.3  Marketing.  Baxter shall market the Products and Perfusion Services in
          ---------
accordance with the following:

          1.3.1     Baxter's marketing organizations shall remain substantially
as they were prior to the Effective Date promoting the Products and Perfusion
Services.

          1.3.2     Baxter shall provide product and service development in a
comparable manner as provided by Baxter prior to the Effective Date.

          1.3.3     Baxter shall maintain its own communications

                                      C-1
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

resources and will coordinate communications messages with Allegiance where
appropriate.

          1.3.4     Baxter shall attempt whenever possible to share with
Allegiance expenses for convention fees, industry organizations, and industry
databases where appropriate, and convention assets originally purchased by
Baxter shall remain Baxter's.

          1.3.5     Baxter shall maintain a convention and planning
organization.

          1.3.6     Baxter shall provide sales volumes by Product category for
inclusion on Allegiance sales reports as provided by Baxter prior to the
Effective Date.

     1.4  Materials Management.  Allegiance and Baxter shall use commercially
          --------------------
reasonable efforts to make the supply chain as efficient as possible.  Future
opportunities to improve efficiency could include, but are not limited to, EDI,
bar coding, custom palletization, network channels and the use of returnable
totes.  Both parties shall work in good faith to achieve this goal.  A
Baxter/Allegiance transportation council (the "Transportation Council") will be
formed to provide joint input on management of freight costs and to be the forum
for problem resolution and to establish and review performance standards.
Performance standards will be set annually including, but not limited to,
receiving turn time, picking accuracy, freight claims management, and inventory
accuracy.

          1.4.1     Finished Goods Requirements Planning.
                    ------------------------------------

               1.4.1.1  Baxter and Allegiance will establish appropriate
     stocking levels for all product codes to meet required customer service
     commitments.

               1.4.1.2  Allegiance will not be required to carry more than 1995
     average Days Inventory On Hand.

               1.4.1.3  Both parties agree that the echeloning of products based
     on line item usage generally makes sense. Assuming there are no significant
     customer contractual issues or financial impacts to Baxter, Baxter agrees
     to the parameters set forth by the rationalized supply chain. If after the
     appropriate review there are significant customer contractual issues or
     financial impacts to Baxter, 1995 will be used as the baseline for where
     products are stocked and the number of low velocity SKU's will not exceed
     1995 levels.

                                      C-2
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

          1.4.2     Pipeline Visibility.  Visibility to actual in transit
                    -------------------
inventory levels for all segments of the Baxter pipeline will be provided upon
request by Allegiance.

          1.4.3     Shipments from Plants to Replenishment Centers.
                    ----------------------------------------------

               1.4.3.1  Baxter will ship all products to appropriate
     replenishment centers as directed by the replenishment center sourcing
     model.

               1.4.3.2  Product will move on carriers agreed upon by the
     Council.

               1.4.3.3  Baxter will be responsible for paying freight charges
     for shipments of Products to appropriate Baxter or Allegiance replenishment
     centers.

               1.4.3.4  Baxter will be responsible for filing freight claims
     with commercial carriers and will be responsible for resolving product
     shortages and overages including proof of delivery.

               1.4.3.5  Baxter will work in coordination with Allegiance to
     schedule receiving appointments for Products coming from Plants and
     Replenishment Centers.

          1.4.4     Shipments from Replenishment Center to Distribution Center.
                    ----------------------------------------------------------

               1.4.4.1  Baxter shall be responsible for the physical
          replenishment of Baxter product from replenishment center to
          distribution center, except where specifically ordered by Allegiance,
          using the following process: (a) variable review, (b) load build, and
          (c) pick, pack, schedule delivery, load and ship.

               1.4.4.2  Shipping terms are FOB destination, freight to be paid
          by Baxter at cost.

               1.4.4.3  Baxter will be responsible for filing freight claims
          with commercial carriers and will be responsible for resolving product
          shortages and overages including proof of delivery.

          1.4.5     Packaging Quality and Load Build Configuration.  Quality of
                    ----------------------------------------------
packaging and load build configuration will conform to uniform distribution
standards (e.g., palletized, etc.) as agreed by the parties in the Council.
           ----

                                      C-3
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

          1.4.6  Warehouse Management.
                 --------------------

               1.4.6.1   Except as otherwise agreed to, existing storage
     requirements will be adhered to by Baxter.

               1.4.6.2   Should Baxter redefine storage requirements, Baxter and
     Allegiance will mutually agree upon a new fee for service rate.

     1.5  Product FCAs.
          ------------

          1.5.1  Baxter shall provide to Allegiance in a format to be agreed
upon by the parties all information reasonably required by Allegiance to perform
Allegiance's duties in connection with Product FCAs.  Such information shall
include, without limitation, product identifiers, reason priority, and any
information related to disposition plans.

          1.5.2  Baxter shall have sole authority to initiate any FCA.  If
Baxter is required to initiate an FCA for any Product, Baxter's Vice President
of Quality Management (or such person's designee) shall notify Allegiance's Vice
President of Quality Management (or such person's designee).

          1.5.3  Baxter shall cooperate with Allegiance in performing any FCA by
identifying affected Products and customers, developing an action-specific
management plan detailing specific responsibilities, and notifying customers of
any such action.  Baxter and Allegiance shall encourage customers to follow
instructions related to any FCA situation.

          1.5.4  Baxter shall be solely responsible for all communications with
the U.S. Food and Drug Administration in connection with the Products.

     1.6  Perfusion Services Sales Information.  Baxter will provide to
          ------------------------------------
Allegiance quarterly sales information for Perfusion Services.

2.   Distributor Model.

     2.1  Pricing/Billing.
          ---------------

          2.1.1  If a customer approaches Baxter rather than Allegiance in
connection with a Distributor Model transaction, Baxter will advise the customer
that the customer must obtain the delivered price from Allegiance, and Baxter
will advise Allegiance of the Suggested Sales Price. Baxter may inform the
customer that it will provide a Suggested Sales Price to

                                      C-4
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

Allegiance, and Allegiance could use the Suggested Sales Price as a starting
point. Nevertheless, Allegiance shall have the sole right to set the delivered
price.

          2.1.2     New Customer Set-Up - Allegiance and Baxter customer service
representatives will ensure effective and efficient coding of all new customers
into their respective customer master files.

          2.1.3     Baxter will administer customer contracts on its computer
system including, without limitation, account number set-up, ship-to/sold-to
information, licensing information and ongoing customer contract maintenance.

          2.1.4     Baxter will provide to Allegiance the Suggested Sales Price
related to the Products and Perfusion Services.

          2.1.5     Baxter will use commercially reasonable efforts to provide
Product-related technical support to Allegiance, including the basic technical
information resident on Baxter's computer system, technical letters and clinical
information. Baxter will respond to Product-related technical questions from
Allegiance's Distributor Model customers.

          2.1.6     Dealer Management Group

               2.1.6.1  Terms and Fees.  For a period not to exceed six months
     from the Effective Date, Baxter may continue to use the Dealer Management
     Group (DMG) services. For any and all sales of Products that occur after
     the Effective Date through DMG, a service fee of * * * of the net sales of
     such Products will apply.  Such services fee will be invoiced to Baxter on
     a monthly basis and will be due 30 days from date of invoice.  For purposes
     of this section, "net sales" shall be defined as gross sales of Products
     sold through DMG at dealer price less any applicable rebates, cash
     discounts and allowances.

               2.1.6.2  Obligations.  For any DMG transactions, Baxter shall
     bear final responsibility, accountability and liability for sales, sales
     revenue, dealer rebates and account receivables in connection with the
     dealer and inventory carrying costs for inventory held by Allegiance.
     Carrying costs shall be calculated at * * * per month of the cost of
     Products sold at Distributor List Price.  DMG transactions shall not be
     included in calculating Gross Profit Growth or in calculating any fees or
     refunds set forth in Section 6.

                                      C-5
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

               2.1.6.3  Transition.  Upon transition of DMG transactions to
     Baxter, DMG shall continue for a period of 90 days from the date of such
     transition to provide dealer rebate data to Baxter and to reconcile the
     accrued rebate and actual dealer trace sales as performed prior to the
     Effective Date.  Upon expiration of such 90 day period, Baxter shall be
     responsible for such reconciliation.

                                      C-6
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                                   Exhibit D
                                   ---------

<TABLE>
<CAPTION>
                                                                -------------------------------
                                                                             1996
                         Critical Care                                    Post Split
                                                                            Price*
                                                                -------------------------------
Model Name
----------
<S>                                                             <C>
201708001 - Stopcock-3-Way, Blue Fixed Nut                                               * * *
33-260 - Summit 1dtp Standard Kit                                                        * * *
33-600F - Summit Standalone Transducer                                                   * * *
33-600I - Summit Standalone Transducer                                                   * * *
33-MK9313 - Va-Omaha                                                                     * * *
33-MK9851 - Northershore Cdp Kit                                                         * * *
43-600I - Icp And Iup Kit                                                                * * *
50-P106 - Pressure Tubing, 6", M/F                                                       * * *
50-P112 - Pressure Tubing, 12", M/F                                                      * * *
50-P124 - Pressure Tubing, 24", M/F                                                      * * *
50-P136 - Pressure Tubing, 36", M/F                                                      * * *
50-P148 - Pressure Tube, M/F, 48"                                                        * * *
50-P160 - Pressure Tubing, 60", M/F                                                      * * *
50-P172 - Pressure Tubing, 72", M/F                                                      * * *
50-P184 - Pressure Tubing, 84", M/F                                                      * * *
50-P248 - Pressure Tubing, 48", M/M                                                      * * *
50-P260 - Pressure Tubing, 60", M/M                                                      * * *
50-P272 - Pressure Tubing, 72", M/M                                                      * * *
50-P284 - Pressure Tubing, 84", M/M                                                      * * *
57-BD240 -  Disposable Dome For Trantec                                                  * * *
58-K169-06 - Stopcock With 6 Inch Pressure                                               * * *
59-DTH4 - Disposable Holder For Dpt                                                      * * *
CC-02-80 - 80 Cm Shield Hemo                                                             * * *
CC-55OB-8.5F - Introducer Tray; 8.5f                                                     * * *
CC-A301B-8.5F - Intro Kit W/Amc Std                                                      * * *
PX200 - Px Vamp Ready Kit                                                                * * *
PX600I - Px Standalone Transducer                                                        * * *
                                                                -------------------------------
</TABLE>

*These prices are effective through 12/21/97. Thereafter prices are to be
negotiated annually.
<PAGE>

CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION IN ACCORDANCE WITH
SECTION 24(B) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, AND RULE 24b-2
PROMULGATED THEREUNDER. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS.

                                   Exhibit D
                                   ---------

<TABLE>
<CAPTION>
                                                                -------------------------------
                                                                             1996
                            Bentley                                       Post Split
Model Name                                                                  Price*
-----------------------------------------------------------------------------------------------
<S>                                                             <C>
10510303 - Noz Cov 1/4 Vented Blue                                                       * * *
10510311 - Noz Cov 1/4 Vented Green                                                      * * *
20079819 - Tubing-Pvc 1/4xl/16 (G)                                                       * * *
200870 - Adapter Male-Male Luer                                                          * * *
C110B - Connector, Non-Sterile                                                           * * *
C120B - Connector, Non-Sterile                                                           * * *
C125B - Connector, Non-Sterile                                                           * * *
C130B - Connector, Non-Sterile                                                           * * *
C130S - Connector, Sterile                                                               * * *
C135B - Connector, Non-Sterile                                                           * * *
C140B - Connector, Non-Sterile                                                           * * *
C140S - Connector, Sterile                                                               * * *
C145B - Connector, Non-Sterile                                                           * * *
C220B - Connector, Non-Sterile                                                           * * *
C230B - Connector, Non-Sterile                                                           * * *
C240B - Connector, Non-Sterile                                                           * * *
C245B - Connector, Non-Sterile                                                           * * *
C320B - Connector, Non-Sterile                                                           * * *
C330B - Connector, Non-Sterile                                                           * * *
C330S - Connector, Sterile                                                               * * *
C335B - Connector, Non-Sterile                                                           * * *
C340B - Connector, Non-Sterile                                                           * * *
C430B - Connector, Non-sterile                                                           * * *
C430S - Connector, Sterile                                                               * * *
C435B - Connector, Non-Sterile                                                           * * *
C440B - Connector, Non-Sterile                                                           * * *
C521B - Disposable Locknuts                                                              * * *
C532B - Disopsable Locknuts                                                              * * *
C5570Z7B - Custompac,                                                                    * * *
C9772G2A - Custompac,                                                                    * * *
CSP20 - Cell Saver Suction Assembly                                                      * * *
CSP208 - Assembly, Basic A & A                                                           * * *
SDB08 - Tubing, Ster 1/4xl/16x8                                                          * * *
SFB06 - Tubing, Ster 3/8xl/16x6                                                          * * *
                                                                -------------------------------
</TABLE>

*These  prices  are  effective  through  12/21/97.  Thereafter  prices are to be
negotiated annually.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00002-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00002-of-00352.parquet"}]]